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ABSTRACT  
   
Biological fluids, in particular blood plasma, provide a vital source of information 
on the state of human health. While specific detection of biomarker species can aid in 
disease diagnostics, the complexity of plasma makes analysis challenging. Despite the 
challenge of complex sample analysis, biomarker quantification has become a primary 
interest in biomedical analysis. Due to the extremely specific interaction between 
antibody and analyte, immunoassays are attractive for the analysis of these samples and 
have gained popularity since their initial introduction several decades ago. Current 
limitations to diagnostics through blood testing include long incubation times, 
interference from non-specific binding, and the requirement for specialized 
instrumentation and personnel. Optimizing the features of immunoassay for diagnostic 
testing and biomarker quantification would enable early and accurate detection of disease 
and afford rapid intervention, potentially improving patient outcomes. Improving the 
limit of quantitation for immunoassay has been the primary goal of many diverse 
experimental platforms. While the ability to accurately quantify low abundance species in 
a complex biological sample is of the utmost importance in diagnostic testing, models 
illustrating experimental limitations have relied on mathematical fittings, which cannot 
be directly related to finite analytical limits or fundamental relationships. By creating 
models based on the law of mass action, it is demonstrated that fundamental limitations 
are imposed by molecular shot noise, creating a finite statistical limitation to quantitative 
abilities. Regardless of sample volume, 131 molecules are necessary for quantitation to 
take place with acceptable levels of uncertainty. Understanding the fundamental 
limitations of the technique can aid in the design of immunoassay platforms, and assess 
  ii 
progress toward the development of optimal diagnostic testing. A sandwich-type 
immunoassay was developed and tested on three separate human protein targets: 
myoglobin, heart-type fatty acid binding protein, and cardiac troponin I, achieving 
superior limits of quantitation approaching ultimate limitations. Furthermore, this 
approach is compatible with upstream sample separation methods, enabling the isolation 
of target molecules from a complex biological sample. Isolation of target species prior to 
analysis allows for the multiplex detection of biomarker panels in a microscale device, 
making the full optimization of immunoassay techniques possible for clinical diagnostics. 
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CHAPTER 1 
INTRODUCTION 
1.1 Disease, and the Role of Biological Species 
 
It is unlikely that one can ever know the origins of medicine exactly, as the 
practice of treating the sick seems as old as mankind. However, the concept of illness 
has evolved throughout time, and the foundations of our modern understanding of 
disease are easier to trace. Historic cultures throughout the world attributed illness to 
witchcraft, demons, hubris, or the will of gods [1-3]. In these cultures a physician 
was closely associated with religion and functioned primarily to gather herbs or 
perform rites believed able to reverse the misfortune of the sick [1-4].  
The foundation of modern medical beliefs can be attributed to the ancient Greeks. 
While Greece still maintained one school of thought based on spiritual beliefs, a 
second emerged, founded by Hippocrates, stating that treatment should be based on 
observations of the condition of the human body [1,2]. The emergence of diagnostics 
based on observation lead to a new belief about the origins of disease. The body was 
understood to consist of four humors (blood, phlegm, yellow bile and black bile) that 
must be in balance to maintain physical health [2,3]. While this medicine was more 
grounded in observation than that practiced in earlier cultures, its treatments 
functioned only to restore this balance, and disease was primarily attributed to 
changes in season, climate, or the habits of an individual [3].  
For several centuries the humoral theory of medicine persisted, until the 1880s 
with the emergence of Germ Theory developed by Robert Koch and Louis Pasteur 
[5-7]. With the evolution to a belief that disease states are produced by molecular 
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entities foreign to the body, or from a physical event occurring internally, technology 
has had to evolve to improve the ability to recognize and diagnose disease states. A 
clear and direct line could be drawn between the Germ Theory philosophy and the 
development modern diagnostic techniques, including histology and the testing of 
biological fluids.  
1.2 Current Disease Diagnostics 
When testing biological fluids, the monitoring of minute changes in disease-
indicating species is needed in order to make effective healthcare decisions and allow 
early disease intervention. In many cases, such as that of myocardial infarction (MI) 
where early intervention leads to a much better prognosis, the rapid serial monitoring of 
target species may be required for the positive identification of a disease state so 
appropriate courses of treatment can be administered [8].  
Initial clinical evaluations in the diagnosis of MI have a two-fold objective: to assess 
the likelihood that observed cardiac symptoms relate to an acute coronary event, and to 
determine an individual’s risk of a experiencing subsequent cardiac event [8]. While it is 
necessary to consider factors such as a patient’s medical history, visible physical 
symptoms, and results of the electrocardiogram (ECG), cardiac biomarkers are also 
valuable in achieving the diagnostic objectives.  
Optimal sensitivity of blood testing is expected to coincide with the time at which 
cardiac protein marker concentrations reach a maximum in the blood, which may occur 
several hours after the initial onset of symptoms [8]. However, by utilizing high sensitive 
assay approaches and a multimarker strategy for the diagnosis of MI, earlier diagnosis 
and intervention may be possible. Early diagnosis would require more rapid and, where 
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necessary, serial monitoring and quantification of specific disease targets. Since blood 
testing currently takes place in centralized laboratories requiring several milliliters of 
blood and long assay times for quantitative monitoring [9],
  
achieving these goals 
compels a change in the way blood samples are treated for testing, shifting away from 
single-analyte assay requiring long analysis times to those allowing the simultaneous 
quantitation of multiple targets.  Truly optimized diagnostic testing should satisfy several 
criteria:
 
high sensitivity, low sample volumes, the ability for multiplex quantification, 
rapid analysis times, and operational simplicity while maintaining a low cost per analysis 
[10]. Rapid testing in the emergency room for the diagnosis of myocardial infarction 
should meet the following metrics to be considered truly optimized: sensitivity allowing 
quantification of samples below the pM range using fingerprick blood and the ability to 
quantify 3 targets simultaneously in under 30 minutes without the requirement for 
expensive, complicated or bulky instrumentation. 
1.3 Analysis of Complex Biomedical Samples 
While there are many approaches to the diagnosis of disease, when analyzing 
physical samples they can often be too complex for direct analysis, necessitating the rapid 
isolation and analysis of target species. The study of these complex samples is of primary 
interest in biomedical analysis where current clinical approaches to diagnosis include 
both imaging [11-13]
 
and biological recognition techniques [14-16].
 
 Immunoassays have 
gained in popularity since their initial introduction in 1959 [17] and are attractive for the 
analysis of complex samples because of the extremely specific interaction between 
analyte and antibody. While the applications of immunoassay are highly diverse, ranging 
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from detecting pesticides in soil [18] to the detection of small molecules [19,20], a 
primary clinical sample of interest is blood [21-23].
 
 
Blood is generally considered to be the most important fluid used for clinical 
diagnostics because it is the most reflective of the physiologic condition of the body and 
provides a relatively easy source of specific health information [22,23].
 
 Not only does 
this include classical plasma proteins, but also proteins present through tissue leakage, 
and many immunoglobulin sequences [22].
 
While the density of information that can be 
attained by monitoring the concentration of a biomarker, or set of biomarkers, offers 
great diagnostic potential, these species are often present in very low concentrations 
while the protein content is dominated by only a handful of species [24].
 
These species 
may interfere with the quantitation of low abundance species, therefore it is necessary to 
fractionate samples prior to detection [24,25].
 
Cross-reactivity can be mitigated to some 
extent through the use of highly specific monoclonal antibodies [25].
  
Among 
immunoassay techniques, non-competitive sandwich immunoassays have been generally 
recognized to allow the most sensitive detection [26]. This has made them an attractive 
option for both commercial and experimental applications geared towards clinical 
diagnostics.
 
1.4 Advantages and Limitations of Traditional Non-Competitive Immunoassays 
 
Non-competitive immunoassays utilize a sandwich-type format and involve the 
binding of two antibodies to different target sites [27]. This may be accomplished through 
the use of the same polyclonal antibody for both capture and detection, but is frequently 
performed with multiple monoclonal antibodies. Compared with competitive 
immunoassays, this two-site binding allows for better specificity in the assay.  
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Traditional non-competitive immunoassays have been used experimentally for many 
years and are available commercially. These techniques have been successful in 
achieving sensitive limits of detection. Duhau et al. describe a sandwich-type 
immunoassay utilizing a 96-well microtiter plate for the detection of rat prolactin [28].
 
In 
this work, the detection threshold was found to be 0.5 ng/mL (2.2 pM). However, to 
achieve high sensitivity, incubation times of up to five days were used in a total reaction 
volume of 150 μL for the quantitation of a single analyte.  
Similar immunoassay techniques were used by Boever et al. [29] and by Kratzsch et 
al. [30]
 
for the detection of samples from biological fluids. Both methods achieved 
detection limits in the pM range. However, analogous to the work performed by Duhau et 
al., incubation times were long and sample volumes on the order of 100 μL per target 
were required to achieve these results. The long reaction times necessary for these 
techniques can be explained in part by their use of a static solid substrate for the 
immobilization of capture antibody. 
While reactions taking place in solution or on a cell surface are limited by their 
equilibrium coefficient, those taking place on static solid surfaces have been 
experimentally shown to differ [31,32].
  
After the initial stage of a reaction at an artificial 
surface there is a local decrease in analyte concentration which forces reactants to travel 
further to participate in binding events [32,33]. This depletion, along with strong antigen-
antibody interactions and  the high capture antibody concentrations used in reagent-
excess assays, produces a diffusion-limited reaction over long incubation times arising 
from the distribution of analyte in solution becoming less random as more antigen binds 
to the surface-immobilized antibodies in a reaction considered to be practically 
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irreversible [31,34,35].
 
Since separation of the unbound phase from the solid surface 
takes place before quantification, in a diffusion-controlled reaction setting incubation 
times must be unrealistically long to produce a quantifiable signal for low-concentration 
samples [36].  
These drawbacks have led to the development of miniature assays and use of forced 
convection during incubations to alleviate diffusion related limitations and help 
homogenize the reaction volume near the capture surface [37]. The evolution of the solid 
phase from microtiter wells to microparticles as a solid surface has also proven to be 
useful in the elimination of diffusion dependence. Microparticles have a very high 
surface area relative to a microtiter well and have been demonstrated to achieve solution-
phase performance due to their colloidal nature [27].
 
 
1.5 Miniaturization in Immunoassay 
Miniaturization in immunoassay has resulted in the development of highly diverse 
platforms, ranging from straightforward downscaling of traditional concepts [38,39], to 
flow-based techniques [40,41], and those utilizing microparticles as a solid surface [42-
45]. These varied methods have improved upon the limitations noted in traditional 
clinical tests in several ways: lowered analysis time [40,43-45], portability [44], and 
lowered sample size [40,41,45], while maintaining clinically-relevant limits of detection 
[38-45]. Miniaturized immunoassays employing a static solid surface, while useful in 
maintaining high levels of sensitivity, continue to suffer from long analysis times on a 
microscale [46-48]. 
To combat long analysis times, alterations in the solid support used for target 
immobilization have been explored in several ways. Flow-based techniques are capable 
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of very rapid analysis, ranging from 30 seconds to 10 minutes [40,41].
 
These rapid assays 
have maintained clinically relevant limits of detection (pM range) while utilizing small 
sample volumes (0.5 – 20 μL). However, at present these systems are only able to 
quantify a single target analyte per assay. In particular, the reverse displacement 
immunoassay described by Schiel et al. relies on the use of columns containing 
immobilized analog for the specific target being examined [41].
 
Label displaced by 
analyte is eluted from the column past a detector to determine the extent of analyte in a 
sample (Figure 1.1). While it is possible to redesign a system using a portable analysis 
device, the redesign would present significant challenges before parallel or multiplexed 
detection could be possible. 
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Figure 1.1 Scheme for the reverse displacement immunoassay, where (—●) represents 
the immobilized drug analog; (shaded □) indicates the labeled monoclonal antibody or 
Fab fragments; (○) depicts the drug or target analyte; and (half circle), indicates the 
serum protein or binding agent. 
 
An alternative method to flow-based systems is the use of microparticle-based 
immunoassays.
 
By incorporating particles as a solid support for immunoassay techniques, 
several advantages are realized, including both the ease of surface manipulation during 
wash steps as well as the potential for convective mixing to shorten incubation times. 
Along with the ability for rapid analyte capture, these techniques are compatible with 
traditional detection methods, maintaining sensitive limits of quantitation. Microparticles 
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have been incorporated into assays in a variety of ways, and a subset of this work that is 
of particular interest involves the use of magnetic microparticles as the solid support.  
 Magnetic microparticles have been used by the Gijs group for both on- and off-
chip incubation methods employing fluorescence detection (Figure 1.2) [49,50].
 
While 
incubation off-chip enabled easy manipulation of the capture surface and maintained 
similar limits of detection to commercial methods, results show that performing on-chip 
incubations was able to both lower the detection limit and reduce the overall assay time.  
 
Figure 1.2 Image of self-assembled magnetic chains and chain intensity profile formed 
on chip [50]. A) Image of the self-assembled chains B) Intensity profile derived from an 
image as shown in part A. 
 
 Beyond exploiting their unique ability to easily be captured during wash steps or 
stabilized in the presence of sample flow, an assay based on the incorporation of a period 
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fluctuation in the applied field was originally developed to improve the detectability of 
low concentration samples in the presence of a relatively high background signal (Figure 
1.3) [51,52].
 
In addition to utilizing a magnetic field to improve the ease of wash steps, 
incorporating a periodic fluctuation in the magnetic field during data capture enables this 
technique to take advantage of coupling signal processing and amplification strategies 
that allow greater signal power to be extracted from the data [53].
 
 The advantage of 
extracting a greater signal power from collected video is that it enables improved limits 
of quantitation for the technique and enables sensitive detection from a small original 
sample volume. 
A methodical optimization of data collection and processing was employed to 
achieve extremely sensitive quantitation and directly address many of the metrics of an 
optimized immunoassay stated above. Changes to both optics and acquisition settings 
allowed improvements to the signal-to-noise ratio (S/N), while data analysis was altered 
to maximize the signal power obtained from each sample. This enabled the extremely 
sensitive quantification of cardiac biomarkers myoglobin, cardiac troponin I (cTnI), and 
heart-type fatty acid binding protein (H-FABP) while maintaining a simple batch 
incubation approach [54]. While these improvements satisfy the sensitivity needs of 
clinical assays while utilizing a minimal sample volume, there still exists a need for this 
sensitive and selective quantitation ability to be applied to the simultaneous detection of 
biomarker panels. Parallel detection is of particular importance because no single marker 
has proven to have sufficient diagnostic accuracy for AMI, or a variety of other 
conditions in which early detection would improve prognosis [8,55,60].
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Figure 1.3 Schematic showing method utilized for immunoassay. In the presence of a 
magnetic field, self-assembled supraparticle structures form and may be manipulated 
through the alteration of the field producing a periodic change in fluorescence intensity. 
 
1.6 Parallel Detection in Immunoassay 
There are many potential advantages to the use of a parallel detection immunoassay 
system, including increased throughput, simplification of the work performed, reduced 
overall cost per analyte, and increased sensitivity for disease detection through use of a 
biomarker panel as compared to a single species [27]. Multianalyte testing has been 
investigated in two primary ways: through batch incubation with specific antibodies to 
different target analytes (e.g. Luminex systems or microarray printing) and differentiation 
during detection, and through separation prior to target capture [57-60]. While 
multianalyte testing hold the potential to improve diagnostic testing capabilities, it has 
not yet commercially replaced the singleplexed analyte testing frequently used both 
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clinically and in point-of-care testing. One of the drawbacks of batch incubation, 
particularly when utilizing a complex sample such as plasma, is the potential for cross-
reactivity [24,25].
 
Reducing or eliminating the potential for cross-reactivity brings about interest in 
sample pre-treatment steps to separate components. On a microscale, several options 
exist for the treatment of blood prior to target quantification. These range from the use of 
physical barriers to filter sample components [61,62], to differentiation through the use of 
lateral flow, and the incorporation of electrophoretic separation methods [63-67]. While 
there are many potential methods for plasma separation, the use of electrophoretic 
exclusion to separate proteins is particularly attractive because it allows samples to be 
separated in bulk solution based on their native properties without the need for 
differentiation based on binding. Differentiation using this method requires the presence 
of three factors: hydrodynamic flow, the presence of an electric field, and species having 
an electrophoretic mobility in the buffer conditions used [67]. Electrophoretic exclusion 
achieves resolution of species based on differences in their electrophoretic mobilities 
(Figure 1.4) [68]. With the assumption that flow and buffer conditions remain constant 
during an experiment electric field strengths may be manipulated to separate species. 
Exclusion is achieved by maintaining a constant electric field across reservoirs in a 
channel or array, and introducing a sharp gradient to the electric field at channels 
connecting these reservoirs. When the electrophoretic velocity of an analyte (𝑣𝑎), based 
on the relationship: 
𝑣𝑎 =  𝜇𝑎𝐸                   1.1 
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where μa is the electrophoretic mobility of an analyte and E is the local electric field 
strength, is equal and opposite (or greater than) the hydrodynamic flow. Under these 
conditions a species is prevented from entering a channel whereas species with a smaller 
μa (and therefore smaller 𝑣𝑎 ) will be able to enter and flow through the channel. 
 
Figure 1.4 Schematic demonstrating the principles of electrophoretic exclusion. When no 
electric field is applied both samples are allowed to flow through the channel (left), but 
when the electric field is applied and electrophoretic velocity of one species is equal and 
opposite to (or greater) than hydrodynamic flow it is excluded from the channel while the 
analyte with a smaller electrophoretic mobility is still able to enter and flow through the 
channel (right). 
 
Creation of a microscale analysis system consisting of one primary separation 
channel (consisting of reservoirs connected by microchannels) connected to many 
parallel cross-channels with individual compartments for specific target detection makes 
electrophoretic exclusion ideal for the separation of complex samples prior to the 
simultaneous quantitation by immunoassay of many isolated species since it not only 
isolates species, but serves to concentrate individual targets prior to detection. Because 
separation of components based on other native physical properties takes place prior to 
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identification based on a binding interaction between the target species and its respective 
antibodies, there is a reduction in potential NSB from competing species as the sample 
has been greatly simplified compared to batch incubation approaches. This allows the 
simultaneous quantitation of species that is theoretically limited only by the size of the 
analysis system and number of individual compartments as opposed to increasing 
uncertainty as additional analytes are quantified using batch incubation methods. 
1.7 Dissertation Objectives 
This dissertation is dedicated to describing the optimization of an immunoassay 
platform for disease diagnostics and its incorporation into a microscale analysis system 
envisioned as an accurate, rapid tool for plasma analysis. The novel non-competitive 
immunoassay platform was initially used to quantify myoglobin concentrations to a limit 
of 50 pM using a benchtop incubation format and lock-in amplification [52]. However, 
the bulk of the work presented herein discusses the optimization of data collection and 
signal processing to achieve superior detection sensitivities for myoglobin, cTnI and H-
FABP. A discussion of its applicability as a quantification scheme incorporated into a 
microscale total analysis system and the limitations of immunoassay quantification are 
also addressed, focusing on the importance of developing a fully-optimized platform for 
clinical immunoassay applications. 
1.8 Dissertation Summary 
To first introduce the field of biomedical analysis, analyte detection carried out both 
in laboratory settings and utilizing point-of-care devices a review of novel techniques is 
included as Chapter 2. This chapter covers detection platforms utilizing both imaging and 
biological recognition and evaluates the capacity of techniques to be used both in clinical 
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and remote disease diagnostics and monitoring. Articles that are reviewed in this chapter 
are from January 2010 to January 2014. 
To further explore emerging microimmunoassay techniques, a critical evaluation 
based on their ability to achieve the capabilities of a fully optimized quantification 
platform is included as Chapter 3. This chapter covers diverse immunoassay platforms 
including the use of microparticles as an assay surface, flow-based techniques, and the 
incorporation of a static solid support. Articles that are reviewed in this chapter are from 
January 2008 to April 2012. 
Chapters 4 – 7 present experiments using a novel immunoassay platform and 
evaluating its utility for incorporation into a microscale total analysis system (μTAS). 
Chapter 4 presents individual detection and quantification utilizing benchtop sample 
preparation for three target species: myoglobin, cTnI, and H-FABP. Chapter 5 develops 
the theory for the limitations of quantitation possible for a non-competitive immunoassay 
and includes a brief analysis of the results obtained from individual targets. Chapter 6 
demonstrates the ability of insulator-based dielectrophoresiss (i-DEP) to act as an initial 
sample preparation step for the evaluation of whole blood samples on a microscale. 
Chapter 7 evaluates the capability a current microdevice to manipulate and separate the 
target species using electrophoretic exclusion. A discussion for adaptation of the assay to 
a more complete microscale analysis system is also included. Chapter 8 details the 
development of a prototype total analysis system and includes the preliminary results 
achieved as well as a discussion of modifications that could improve its ability to process 
a whole blood sample completely on-chip. 
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CHAPTER 2 
EMERGING TECHNOLOGIES FOR BIOMEDICAL ANALYSIS 
2.1 Introduction 
 
Early disease diagnosis is vital so that more effective intervention strategies may 
be employed. Because early intervention is essential for improving disease prognosis, in 
recent years there has been an emphasis on increasing the sensitivity of biomedical 
analysis methods [1-6]. Stemming from this quest for superior sensitivity, several new 
technologies for biomedical analysis have emerged on both experimental and commercial 
platforms. These technologies, in general, take place in one of two formats; biological 
recognition or imaging.  
The area of biological recognition is focused on specifically and sensitively 
quantifying low-abundance species that are indicators of disease pathways. The platforms 
are highly diverse, ranging from the immobilization of antibodies on hydrogels
1
 or 
unmodified plastics [7,8], to CD disks for microarray printing [2,9-11], and assays taking 
place in the traditional microwell format [3]. While some of these assays focus on 
reducing the non-specific binding associated with long incubation times in traditional 
assays [3], the primary trends over the last few years have been toward the development 
of multiplex assays or rapid point-of-care devices [8,11,12]. 
Work also continues towards improving traditional imaging methods used in 
disease diagnosis. Imaging approaches analyze the information-rich spectra obtained 
from tissues to identify characteristic absorptions revealing the underlying chemical 
composition of the sample and identifying cellular biomarkers [13]. Using these methods 
both labeled and label-free detection methods have been utilized [13-20]. A main 
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contribution in this area has been the improvement of resolution in infrared spectroscopy 
(IR) to overcome the usual limitations imposed by diffraction [13-17]. 
Although methods that can be used for biomedical analysis in a traditional lab 
setting continue to be investigated, a primary focus over the last several years has been 
the development of mobile health (mHealth) platforms that could be used in telemedicine 
applications or resource-poor settings where access to quality healthcare is limited [21-
26]. Mobile health devices have largely been created on one of two platforms: CD discs 
that have been used as the solid phase for immunorecognition assays and can be read 
using an unmodified CD player [8,27], and those that take place via a smartphone 
attachment [9,12,21-23,25,26]. In both cases an emphasis is placed on using simple 
fabrication procedures, as well as reusable materials, to keep costs low.  There is also an 
emphasis on  producing user-friendly applications that allow patients to perform tests 
independently and upload the results for experts to interpret and determine the best 
course of treatment [21-23,26]. Advances in this capacity are vital to rapidly identify and 
address emerging public health threats, as well as to treat chronic diseases that require 
persistent monitoring [26].
 
While both imaging techniques and biological recognition assays have been the 
subject of recent reviews [28-31], the focus of this review will be the application of those 
new techniques to biomedical analysis and the improvement of early disease intervention 
published during the time span from January 2010 to January 2014, initiated with 
literature keyword searches associated with biomedical analysis as well as their 
references and the later citations of found works. Articles were chosen based on their 
contribution to new technologies in the area of biomedical analysis and offering 
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improvements both in terms of shorter test duration and higher sensitivity, as well as 
improving the mobility of testing platforms to reach resource poor areas. While many 
tests were described in the context of identifying a particular molecule or disease pattern, 
they could easily be adapted for the testing of many biological species. The topics 
addressed are divided into techniques used for biological recognition [Section 2.2] and 
those used for imaging analysis [Section 2.3]. These sections are further subdivided into 
laboratory or clinic-based testing and platforms intended for point-of-care diagnostics. 
2.2 Biological Recognition 
 
Techniques utilizing biological recognition may further be divided into two main 
subcategories: (i) biorecognition assays that take place within a laboratory or clinical 
setting and (ii) portable microarrays allowing point-of-care diagnostic testing. Some of 
the techniques discussed in this section include magnetic bead-based assays, assays 
taking place on unmodified plastic substrates (Figure 2.1), and those utilizing a compact 
disc (CD) as a solid support. CD-based assays have gained popularity for a variety of 
reasons including the ease of fabrication and established detection methods. The use of 
computer drives/disc players adapted as a precise optical reading mechanism and 
employed as a detection instrument allows the assays to be accomplished at low-cost and 
away from specialized laboratories. Users are able to fabricate high-density microarrays 
on a CD disc and perform tests for a variety of different targets including DNAzyme 
assays, antibody-antigen binding, and microorganisms. The recent expansion of this 
technique to Blu-ray technology has allowed a reduction in feature sizes and a subsequent 
improvement in assay sensitivity. 
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2.2.1 Laboratory-Based Bio-recognition Assays 
Traditional biological recognition assays employing a static solid support 
continue to have widespread use both on commercial and experimental platforms 
[1,3,7,32-36]. Their high sensitivity, versatility in detection methods, and adaptability for 
the quantification of a myriad of targets continue to make their replacement by other 
testing platforms a challenge (summary of techniques shown in Table 2.1). While these 
methods employ diverse tactics, a primary focus over the last several years has been to 
address a common pitfall of these assays: non-specific binding (NSB) and its limitation 
of the assays’ potential sensitivity [1,3]. Efforts continue to be made toward increasing 
sensitivity and reducing the characteristically long incubations associated with these 
techniques so they may eventually be adapted to portable care diagnostics. 
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Technique Applications Sensiti
-vity 
Analysis 
Time 
Fabrication/Equipm
ent Requirements 
Reference(s) 
Microwell 
ELISA 
Serum 
antibody 
immunoassay
s, protein 
detection 
- 10 min  Micro-well plate pre-
incubation procedure, 
optical density 
detection 
3 
Microarray 
Assays 
Protein 
detection, 
diagnostics 
1 pM 3+ hours Protein printing, UV-
exposure crosslinking; 
Biodetect 645
®
 read-
out system 
1,7 
Colorimetric 
Detection 
Sandwich 
bioassays, 
DNA and 
protein 
detection 
0.67 - 
10 nM 
2+ hours UV/ozone activation 
of plastic sheet, 1-
ethyl-3-(3’-
dimethylaminopropyl)
-cabodiimide/N-
hydroxy-succinimide 
coupling; fluorescent 
microscope 
8 
Rolling circle 
amplification 
Assay 
Low-
abundance 
protein 
monitoring 
38 fM 5+ hours Overnight microplate 
preparation; 
electrochemical 
workstation 
37 
pH and 
metabolic 
monitoring of 
live cells  
Personalized 
medicine 
applications 
50 
cells 
Real-time 
monitorin
g 
Chemical 
modification of 
nanowires; 
extracellular pH probe 
38 
Amperometric 
Biosensor 
Simultaneous 
drug detection 
1.2- 
5.5 fM 
35 
minutes 
Fabrication of 
biosensor probe; 
electrochemical 
detector 
39 
Magnetic 
Bead 
Separation 
Assay 
Biomolecule 
detection 
7.1 nM 15 min Soft lithography 
fabrication; 
hemocytometer and 
microscope apparatus 
40 
Optically 
switched 
dielectrophore
tic force  
Tissue 
engineering 
- Days Photolithography 
using SU-8 
photoresist; CCD 
equipped microscope 
41 
Table 2.1 Summary of laboratory-based biological recognition assays. 
 
The reduction in non-specific binding for assays having long incubations was 
investigated by Farajollah et al [3]. They describe that the most common problem in 
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microwell assays is the detection antibody binding directly to the solid phase. This can 
occur if undiluted serum is applied even when using a well that has been chemically or 
biochemically blocked. To minimize the signal arising from NSB while continuing to 
provide sufficient signal for the detection of low-abundance species, this work introduces 
a pre-incubation procedure. Using this technique, a biotinylated capture reagent is first 
incubated with the serum sample and introduced in a secondary step to a streptavidin-
coated well. Detection is enabled with labeled anti-species antibodies. The utility of this 
technique was investigated and findings show that NSB is time-dependent and both 
serum as well as purified IgG would bind non-specifically to plastic wells. Blocking 
provided a slight reduction in NSB, but the blocking agents could be displaced after 
lengthy incubations. Utilizing the pre-incubation method, along with rapid capture times 
have allowed for improved sensitivities compared with traditional ELISA (enzyme-linked 
immunosorbent assay) testing and could potentially help to solve the background noise 
issue associated with those tests. However, because pre-incubation takes place prior to 
antibody fixation this technique would be difficult to adapt to the parallel detection of 
analytes since signals could not be spatially isolated. 
 The issue of NSB was also addressed by the Ruhe group [1]. In earlier work the 
single step production of protein microarrays on unmodified plastic substrates is 
presented [7]. Proteins, along with a terpolymer, were printed at high concentration in 
surface-attached hydrogels. A single UV-exposure step both covalently immobilizes the 
protein and modifies the surface, inducing swelling to a 3D surface and increasing its 
binding capacity. The swelling strongly influences the accessibility of the proteins in the 
hydrogel. Analyzing this method over a series of analyte standards, it was discovered that 
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analyte capture increases linearly with antibody concentration up to an asymptotic limit 
of ~10
8
 antibodies/spot while achieving a signal-to-noise value of more than 200 at a 
concentration of 9 x 10
7
 antigens/spot. This technique, through employing more 
complicated fabrication procedures than assays achieving detection through use of a 
microwell plate, enables parallel detection of analytes due to the pre-printing of capture 
proteins prior to analyte incubation and detection. If the fabrication and swelling of the 
3D surfaces in the device could be achieved at low cost and with a reasonable shelf life 
this technique could transition from use in the lab to a portable device. 
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Figure 2.1. Illustration of the process for printing microarrays with mixed polymer 
protein solutions and immobilization through UV-crosslinking both in the macroscopic 
(A) and microscopic (B) views.
7
 Macroscopic view images show (1) a solution is mixed 
of buffer and polymer (2) a microarray of the solution is printed onto the provided plastic 
slide and (3) the chip is irradiated using UV light to crosslink the polymers and 
immobilize them on the surface. On a microscopic level (B) it is observed that (1) 
epoxide side groups of the polymer react with primary amino acids, (2) droplets 
containing these formed complexes form on the surface, and (3) the UV photoreaction 
crosslinks the polymer, attaching it to the surface and immobilizing the proteins in the 
network of polymers. 
 
 In later work the Ruhe group evaluated assay sensitivity and the extent of NSB 
observed using these hydrogels [1]. Compared to traditional methods of preventing NSB 
through blocking procedures the hydrogel has an intrinsically weak binding capacity for 
proteins. While purified capture antibody is covalently linked to the structure during the 
UV-exposure step, NSB is essentially eliminated on these surfaces. This method proved 
effective for the quantification of bovine serum albumin (BSA) between 1 and 500 nM. It 
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was detected to a limit of 1 pM using this technique. However, at this level the 
concentration dependence of the signal is too low for quantification. While this limitation 
is sufficient for the detection of BSA, for adaptation to the detection of other species 
more sensitive quantitation to the low pM range would be necessary. 
 Work has also been done on the development of highly sensitive assays by Zhang 
et al. using alpha-fetoprotein (AFP) as a model protein [37]. This was accomplished by 
coupling metal surface nanolabels to a silver nanocluster (AgNC)-based rolling circle 
amplification strategy. Under optimal assay conditions results show a dynamic range of 
0.14 fM – 2.9 nM with a detection limit of 0.11 fM and a limit of quantification found at 
38 fM. These levels are able to completely meet the clinical diagnostic requirements for 
AFP. However, the long duration of incubations and specialized detection methods 
required for the assay prevents its easy adaptation for use outside the clinic. 
 In an effort to move biochip technology away from labs and hospitals and enable 
its use as a point-of-care device, Wen et al. describe the development of a novel plastic 
biochip [8]. The work shows its utility for the sensitive colorimetric detection of both 
human IgG and DNA. After UV/ozone activation of the plastic substrate probe 
biomolecules are covalently attached. Signal reporting units are introduced to complete a 
sandwich-style assay and achieve sensitive detection. Using this label-free recognition 
system detection limits of 67 pM and 10 nM were achieved for IgG and DNA, 
respectively. These limits are dependent on staining time and could be adjusted according 
to assay needs, providing an easy and flexible approach to a portable biochip. 
 Beyond assays employing a static support, several unique laboratory-based 
approaches have been developed [38]. Quantitative bioanalysis was accomplished using a 
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sensitive pH sensor by the Patolsky group. This detection method was performed by 
evaluating the ratio of electrical signals in ground and excited states to determine the 
concentration of target species. The device was applied to the real-time monitoring of 
both intra- and extracellular metabolic activity, with sensitivities down to the signal 
produced by less than 50 cells, or in the vicinity of single-cell metabolic measurements. 
Although the assay is not currently carried out on a mobile platform, its ability to provide 
sensitive and rapid monitoring gives this approach potential for the expansion to 
detecting specific biological species and its utilization in personalized medicine-oriented 
diagnostics. However, since detection is based on ratios of electrical signals, 
modifications to allow the parallel detection of biomarker panels represent a significant 
hurdle for this technique.  
 Amperometric biosensors were used in a microfluidic device by Chandra et al. for 
the sensitive detection of several anticancer drugs [39]. Sensing was accomplished 
through the integration of preconcentration and separation steps prior to detection. 
Results show that the detection limit for all four drugs tested was between 1.2 – 5.5 fM 
with a linear response over the 2 – 60 pM range. This work represents a rapid and 
sensitive microscale total analysis system whose adaptation to the detection of 
biomarkers would be beneficial in diagnostics as well as disease monitoring. 
 Detection on the microscale was also accomplished by Wang et al. who 
demonstrated the capture and separation of biomolecules using magnetic beads [40]. 
Taking place on a microchip consisting of two reservoirs connected by a tapered channel, 
assays were performed in one well using the beads as a solid surface and separated for 
detection in the second well by an external permanent magnet. Results show the transfer 
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could be accomplished within two minutes and that carryover was less than 0.002%. This 
separation was achieved without the use of a pump, giving it potential as a point-of-care 
device. While this method allows for rapid detection and in the absence of excess 
detection antibody, the current setup only allows for the quantification of one target 
molecule at a time. Alterations of the assay to detect markers in parallel would require 
drastic changes to the chip design as species would need to be separated prior to capture 
and detection to avoid cross reactivity and allow differentiation of signals. 
 Microbeads were also utilized alongside and optically switched dielectrophoretic 
(ODEP) force in bottom-up tissue engineering [41]. Cell-encapsulating alginate 
microbeads with three different densities were assembled and manipulated using an 
ODEP force-based mechanism. Manipulations allowed for the formation of a sheet-like 
cell structure imitating the cell distribution of articular cartilage. Cells encapsulated 
remained viable to a rate of 96 ± 2%. This system holds promise for the engineering of 
tissue with a tunable cell distribution and may aid in efforts for developing biological 
substitutes for the repair of damaged or diseased tissues. 
 Many commercial methods for bio-recognition assays employing a solid support 
are available. These include Whatman’s FAST® slides, Oncyte-Avid slides, and Unisart 
slides [6,32-36].
 
FAST
®
 slides can be used to perform reverse phase protein arrays, 
traditional protein arrays and antibody arrays utilizing less sample than a traditional 
ELISA test. They also allow for the parallel quantitation of many samples to a limit of 1 
pg/mL [6]. This platform has recently been utilized as a point of reference for new 
experimental techniques as well as tested in comparison to other commercially available 
slides [32-34]. The ONCYTE®
 
nitrocellulose slides provide a three dimensional 
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microporous film designed in three formulations to diversify its use for higher binding 
capacities, low-fluorescence intensity, or both [35]. This diversity allows for the use of 
ONCYTE slides in biomarker discovery as well as studies of protein function. The 
Unisart membranes are utilized in lateral flow immunoassays (LFIAs) by binding the 
antibodies or capture molecules while preserving their reactivity [36]. These membranes 
currently enable the analysis of over 60 markers. 
2.2.2 Point-of-Care Assays 
 
The compact disc assay is a diagnostic platform that functions without the use of 
sophisticated laboratory equipment. Utilizing this technique, a microfluidic device is 
created by modifying a CD so that quantitative biological assays can be performed and 
detection can take place using a standard (or modified) disc reader or the CD drive in a 
personal computer (Figure 2.2, Table 2.2). Typically, CDs are prepared by activating the 
polycarbonate surface with UV/ozone treatment followed by the use of a PDMS stamp to 
apply surface patterning [2,9,27]. Following CD disc preparation, samples are applied 
and allowed to incubate for extended periods of time. Once assays are complete, the disc 
is loaded into a CD-drive where the extent and location of errors in disc reading directly 
detect and quantify compounds of interest. In addition to their high sensitivity and 
relatively simplistic fabrication processes, assays using this platform have become 
increasingly popular due to their low-cost and portability. This makes them an attractive 
diagnostic option for remote settings as well as use in areas with limited resources. 
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Technique Applications Sensiti
-vity 
Analysis 
Time 
Fabrication/Equip
-ment 
Requirements 
Reference(s
) 
CD disc 
bioassay 
Lead 
detection, 
streptavidin 
binding, DNA 
detection, 
antibody-
antigen 
detection 
10 nM 
– 25 
nM 
45 – 65 
min 
Soft lithography 
fabrications; 
unmodified disc 
reader/computer 
drive and error 
analysis software 
2, 9, 27 
CD disc 
micro-
immunoassa
y 
Agrochemical 
residue 
quantification 
37 pM 
– 0.28 
nM 
30 min Direct attachment 
of binding groups 
to disc; silver 
enhancement/optica
l disc drive 
detection 
11 
CD disc 
microparticl
e counting 
Measure 
biomolecules/
cells 
1 x 10
6
 
cells/m
L 
2.5 
hours 
Soft lithography 
fabrication; 
unmodified disc 
drive 
10 
Blu-ray 
microarray 
Competitive 
microcystin 
array 
0.4 nM 1 hour Blu-ray disc drive 
and Nero Disc 
speed software 
42 
Table 2.2 Experimental biological recognition techniques that can be used as point-of-
care devices for medical diagnostics. 
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Figure 2.2 is an illustration showing the overall process for performing a DVD-based 
assay. On the polycarbonate surface of the DVD, activation with oxygen plasma 
generates carboxylic acid groups which are covalently attached to amino-modified 
oligionucleotide probes. The use of an unmodified disc reader on a laptop allows for the 
visualization of spots where binding events occurred and the quantitation of species being 
investigated. Reproduced from Reference 11 with permission from The Royal Society of 
Chemistry. 
 
 In one experimental incarnation of this technique, Wang et al. have demonstrated 
the detection of lead at the parts-per-billion (ppb)-level [2]. Lead detection was quantified 
using a DNAzyme assay where a DNAzyme strand was hybridized to a substrate strand 
and immobilized on CD. In the presence of lead the substrate strand was cleaved 
preventing reporter strand binding and reducing CD reading-error rates. The results of 
this work demonstrate a direct correlation between lead concentrations and error reading 
signals in the range of 10 nM to 1 mM, with a lead detection limit of 10 nM (2 ppb). This 
high sensitivity for lead is more than is required for the routine monitoring of its presence 
in environmental samples. However, while the disc-based assay is adaptable for other 
targets the detection setup reflects the approach used in a competitive assay, where signal 
decreases as concentrations of target analyte increase. This method may therefore not 
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prove to be as sensitive as those for non-competitive immunoassay where signal is 
directly proportional to sample concentration and could result in an assay with 
insufficient sensitivity for other low-abundance species. Additionally, the method 
requires long assay times in excess of two hours, which should ideally be reduced for its 
application as a point-of-care device. 
 A similar example of a reading errordetection-based disc assay is demonstrated by 
Pallapa et al. in the development of a quantitative biotin-streptavidin binding assay 
utilizing IsoBuster software for the more specific detection of erroneous bits in a frame as 
opposed to total error number alone [27]. Identifying where errors took place on disc 
allows the most direct approach for the modification of a CD to biomedical diagnostics 
and allows various data formats to be used. Using the IsoBuster analysis software, the 
results depict a clear dependence of reading error on streptavidin concentration. This 
allowed for a quantitative assay over the tested range of 5.8 nM – 29 nM with high spatial 
accuracy. Detection was accomplished using an unmodified conventional optical drive, 
increasing its potential in point-of-care applications. While quantitation was achieved for 
the tested samples, to adaptto other targets the dynamic range should be expanded and 
fully evaluated, allowing clinically relevant concentrations of various biomarkers to be 
detected. 
 This same approach was used to analyze three trial systems: DNA hybridization, 
antibody-antigen binding, and ultrasensitive lead detection [9]. The CD-quality 
diagnostic program is used for detection, which allows a relationship to be generated 
displaying the reading error on disc as a function of CD playtime. This enables the 
specific position of the error on disc to be identified, corresponding to the position of the 
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binding event. The results show that this method is sensitive for all systems tested 
achieving a 25 nM detection limit of DNA from a sample volume of 2.0 µL (50 fmol of 
DNA), a 0.17 nM detection limit for IgG, and a 10 nM (2 ppb) detection limit for lead. 
This platform has been shown to be highly diverse in terms of applicable target molecules 
and portable for on-site applications due to its use of an unmodified disc reader for 
detection. 
 Error reading detection was also employed in microparticle and cell counting 
[10], providing  development of a health diagnostic compact disc (HDCD) aimed at 
providing rapid and affordable point-of-care diagnostics. While the detection methods 
employed are simplistic and accessible, the device fabrication is more complicated than 
that used in similar assays. First, a trench was machined in the polycarbonate surface of 
the CD and transparency was restored through wet sanding. A PDMS microfluidic layer 
was fabricated via soft lithography, embedded into the CD trench, and bonded to the CD 
through an additional PDMS adhesive layer. After sample application, a focused laser 
beam reflected on the CD data layer is interfaced by the sample suspension. Because the 
sample is placed directly above the CD data layer, the original digital information is 
changed through optical interference. The alteration of interaction between the laser and 
data layer directly relates to the shape, concentration, and optical density of the sample 
being analyzed. Results show a clear trend with increasing error rates as sample 
concentration increases. However, incubations of two hours were required between 
sample introduction and detection. This represents an obstacle to be overcome in the 
development of a truly mobile device, which would benefit from rapid assay times to 
increase end user ease of operation. 
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 An alternative CD assay approach was presented by Tamarit-Lopez et al [11]. 
Haptens were attached to the polycarbonate surface of the CD by direct covalent 
attachment. Assays were based on an indirect competitive format and utilized silver 
enhancement solution to display the immunoreaction. Compared to related methods, this 
assay occurs rapidly, lasting about 30 minutes from sample application to detection. The 
detection limits for the tested compounds chloropyrifos, atrazine, and 2-(2,4,5-
trichlorophenoxy)propionic acid were found to be 0.1nM, 37 pM and 0.28 nM, 
respectively,  an order of magnitude better than classical methods. Along with the use of 
a conventional optical detector, this illustrates the potential of this assay to be a useful 
point-of-care diagnostic tool even though it is demonstrated on non-biological samples. 
 The disc-based assay platform was expanded by this group through its extension 
to the use of the underlying physicality of DVD technology as the solid support [4]. The 
disc was activated with oxygen plasma and used to detect the PCR products of 
Salmonella spp. through attenuated analog signal detection. Similar to their previous 
work the assay time was short, with an 18 minute amplification time to achieve a 
detection limit of 2 nM with unmodified DVD drive detection. 
 A further evolution of this technique is illustrated by the introduction of Blu-ray 
technology in the recent work by Arnandis-Chouer et al [42]. The use of Blu-ray discs 
presents several advantages over a DVD-based assay: 1) blue laser light is used, so the 
range of optical detection is expanded and 2) a higher numerical aperture lens is used for 
greater focusing precision allowing for smaller spot sizes and more information to be 
stored on disc. As a proof-of-concept experiment Blu-ray discs were compared to DVDs 
for the same assay, Blu-ray assays were detected by a drive attached to a personal 
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computer through a USB and analyzed using Biodisk software. Results show the Blu-ray 
disc has a 6.2 fold improved detection limit versus DVD assays, achieving levels of 0.4 
nM for microcystin LR and 10
0
 and 10
1
 cfu/mL for Salmonella typhimurium and 
Cronobacter sakazakii respectively. While these assays have achieved clinically relevant 
detection limits for the targets investigated, to become a versatile point-of-care device 
increased sensitivity should be achieved for the detection of varied proteins. 
 Several commercial methods utilizing mobile platforms are also available through 
IMTEK, GenePOC, and Gyros [43-45]. These products have been utilized extensively for 
biomedical analysis investigations. IMTEK is working to develop an automated, user-
friendly platform that can integrate micro, nano, and bio components into a 
multifunctional point-of-care device [43]. The core of this lab-on-a-chip device is its foil-
based centrifugal cartridge that can assist in the integration of all operations allowing raw 
sample to be injected, purified and analyzed at low cost. Although use of this device has 
not been widespread to date, it’s continued investigation and fine-tuning promises to 
result in a valuable tool for point-of-care diagnostics and personalized medicine. 
 The Gyros lab has developed a range of Gyrolab Bioaffy
TM
 CD’s that are used for 
nanoliter-scale immunoassays that allowresults to be read in under an hour [44]. This 
technique was recently validated for the quantification of rituximab in human serum by 
Liu et. Al [46]. Here, the Gyrolab
TM
 technology was tested and results show validation of 
the quantification of rituximab between concentrations of0.62 nM – 0.41 µM.. This 
platform allows for fully automated assays to take place utilizing small reagent and 
sample volumes. While there are limited examples of fully validated Gyrolab assays, this 
method holds many advantages that make it an attractive option for point-of-care 
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diagnostics. While it also lacks significant examples of test validation in literature, the 
platform developed by GenePOC diagnostics was designed to be user-friendly with only 
four steps required for performance [45]. This fully automated system generates results in 
less than an hour with minimal hands-on time. 
2.3 Imaging 
 
Imaging-based techniques can be similarly divided into subcategories: (i) those 
utilizing modified traditional instrumentation and taking place in the laboratory or clinic 
and (ii) portable platforms allowing remote diagnostics. Some of the techniques discussed 
in this section include modified Fourier-Transform Infrared Spectroscopy (FTIR) 
detection, the development of multimodal optical probes, and mHealth  monitoring 
applications. The mHealth platform and others similar to it have gained interest over the 
last several years because they allow for rapid, sensitive and affordable testing to be 
accessible in remote settings. It also allows quality healthcare to be possible through 
telemedicine in regions where access is limited.  
2.3.1 Laboratory-based Imaging Technologies 
 
 Infrared (IR) spectroscopy has been used extensively for imaging-based 
biomedical analysis. A major focus in this area has been the improvement of FTIR for 
high definition imaging [13-20]. Conventional FTIR microscopy has been limited by 
trade-offs between signal-to-noise ratios (SNRs) and data acquisition times, as well as 
spatial resolution [17,18]. While IR spectroscopy has long been recognized as a 
potentially valuable diagnostic tool due to its coverage of regions encompassing 
characteristic biomolecule absorptions [13], its utility has been limited by these trade-offs 
and the lower size boundary imposed by the diffraction limit for the relatively long 
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wavelengths. New experimental techniques have worked over the past several years to 
overcome those limitations so its full diagnostic potential may be realized (Table 2.3). 
Technique Applications Resolution Duration Fabrication/ 
Equipment 
Requirements 
Reference(s) 
ATR-FTIR Endometriosi
s detection 
4 cm
-1 – 8 
cm
-1
 
32-45 
scans/sam
ple 
ATR-FTIR, Bruker 
Vector 22 FTIR 
spectrometer, 
Thermo Nicolet 
Continuum FTIR 
microscope 
13 
Synchrotron 
FTIR 
Lipid 
detection, 
label-free 
imaging 
Diffraction 
limited – 
0.54 x 0.54 
µm
2
 
From < 1 
min for 
30 x 30 
µm 
Mid-infrared 
beamline IRENI; 
multiple synchrotron 
beam source and 
wide field detection 
FTIR 
16, 17 
Nanoscale 
Imaging 
FTIR, AFM-
IR 
100 – 200 
nm 
From 10 
min for 
100 x 100 
pixel 
image 
AFM-IR, novel 
FTIR system based 
on s-SNOM 
15, 19 
Phototherma
lly induced 
resonance 
Organometall
ic conjugate 
detection 
20 – 50 
nm; 10 µM 
1 hour AFM and tunable 
pulsed laser 
20 
Multifunctio
nal probes 
Detection of 
cancer cells, 
estrogen 
From 10 
cells/mL; 
25 µM 
2 hours – 
overnight 
TEM, UV-Vis-near 
infrared laser; 
synchrotron UV 
spectromicroscope, 
FTIR 
47, 48 
Table 2.3 Laboratory-based imaging techniques that have been modified to improve 
resolution in biomedical analysis applications. 
 
 Work by Nasse et al. introduces the use of multiple synchrotron beams into FTIR 
[17]. This was able to extend the IR abilities to truly diffraction-limited imaging over the 
whole mid-infrared spectrum by combining the multiple beams with wide-field detection. 
This approach was based on the strategy of wide-field imaging with the use of 
multichannel focal plane array detectors. Results show the successful measurement of ~1 
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µm polystyrene beads to a limit of 6 ± 1 fmol in a single pixel (0.54 µm
2
). In addition to 
vast improvement in acquisition time (30 minutes to scan a 280 µm x 310 µm area 
compared to over 11 days using diffraction-limited resolution raster-scanning), this 
modification to IR holds great promise as a diagnostic imaging technique. 
 Synchrotron FTIR (sFTIR) was further used to examine lipids in and around 
amyloid plaques associated with Alzheimer’s disease [16]. The primary motivation was 
to test for elevated lipid presence near recently formed plaques using sFTIR in 
transmission mode. To archive acceptable SNR ratios, between 64 and 256 scans were 
co-added. From this analysis a lipid membrane-like signature was found in and around 
dense core plaques in both advanced and early stage plaque. While analysis suggests that 
lipid is a common feature of the plaque structure, there are several potential explanations 
for its origin, which remains unknown.  
 In addition to the analysis of Alzheimer’s disease-related tissue FTIR was 
recently used by Cheung et al. to discriminate spectral signatures of endometriosis [13]. 
In this work, both transmission FTIR and attenuated total reflection Fourier-transform IR 
(ATR-FTIR) were coupled with subsequent computational analysis in an attempt to 
discern endometrial tissue-specific biochemical-cell fingerprints. Through detailed 
spectral analysis biochemical differences were identified between healthy tissue and 
tissue with endometriosis present. While spectral signatures have been observed, this 
technique requires highly specialized analysis which may limit its utility as a widespread 
clinical diagnostic tool. 
 Beyond diffraction-limited resolution lies an interest in the application of FTIR to 
nanoimaging [15]. As recently discussed by Huth et al., an approach has been developed 
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based on the superfocusing of thermal radiation with an infrared antenna, detection of the 
scattered light and signal enhancement using an asymmetric FTIR spectrometer. A 
semiconductor device was used as the sample and imaging was accomplished within a 
few minutes. Results show that 10 nm spatial resolution can be achieved. For even more 
rapid applications spectra with 25 cm
-1
 resolution and an SNR of 10:1 were captured in 
only 2 minutes. While demonstrated here for the mapping of a semiconductor, imaging of 
this resolution could become a powerful tool for chemical/biochemical sample analysis. 
However, as with many imaging techniques, results must be interpreted by an expert 
adding to overall analysis time. Additionally, the use of highly specialized lab equipment 
prevents adaptation of this method to a point-of-care device. 
 Pita et al. also demonstrated simulations aimed at improving the spatial resolution 
of IR techniques [14]. Results of these simulations suggest that the difference in 
transmitted and reflected IR energy between a Gaussian reference and a vortex-shaped 
beam using a confocal microscope could be mapped. This would result in vibrational 
absorption images with a spatial resolution better than λ/10. This resolution would enable 
detection sensitivities great enough for the imaging of organic nanoparticles and would 
indicate great improvement over classical IR for diagnostic imaging. 
 In related work toward nanoscale IR spectroscopy, Marcott et al. have coupled an 
atomic force microscope (AFM) and a tunable IR laser source [19]. Using samples of 
stratum corneum (SC), results show a spatial resolution of ~200 nm. This technique 
enables the SC to be spectroscopically characterized in more detail than ever before. 
These studies may prove useful in diagnostic testing as they are enabling use of this 
technique for the understanding of penetration pathways for topically applied drugs. 
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However, data capture requires sophisticated laboratory equipment and data 
interpretation is performed by specialized personnel limiting its capability for widespread 
use in diagnostics or disease monitoring.  
 Another technique for the coupling of AFM to IR to improve near-field resolution 
is described by Policar et al [20]. It focusses on the development of photothermally 
induced resonance (PTIR), where AFM is coupled with a tunable pulsed IR laser. IR is 
attractive for bioimaging because IR probes are stable in biological environments, they 
are small, and have intense absorption in the 1800-2200 cm
-1
 region where biological 
samples are transparent. Using PTIR the spatial resolution is improved to 20-50 nm, 
which is sensitive enough for subcellular mapping. This was demonstrated using an 
organometallic conjugate whose uptake by breast cancer cells could be monitored. While 
not currently used in diagnostic biomedical analysis, imaging at this sensitive level 
illustrates a powerful improvement to traditional IR imaging and could provide valuable 
diagnostic data in a sophisticated laboratory setting. 
 Recent work by Guo et al. describes the development of an optical probe used for 
cancer cell detection [47]. Localized surface plasmon resonance (LSPR) absorption, as 
well as the fluorescence properties of folic acid-conjugated gold nanorods (F-GNRs) 
were used as detection systems for the multifunctional probe. The absorption capabilities 
were explored through the quantification of human cervical carcinoma (HeLa) cells 
versus African green monkey (Vero) control cells. Results indicate a detection limit using 
fluorescence detection of 70 cells/mL for HeLa cells with a quantitative range covering 
100 – 5000 cells/mL. Using the absorption mode, the probe reduced the detection limit to 
10 cells/mL while maintaining the quantitative range for the technique. While this 
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technique achieves low detection limits for whole cells, the same approach could not be 
used for the detection of proteins without alteration of the assay procedures prior to 
detection. Additionally, major adjustments would need to be made to the assay platform 
in order to achieve parallel target detection. 
 Another unique multimodal probe was investigated by Clède et al [48]. This 
probe, called SCoMPI (single core multimodal probe for imaging), was used for the 
detection of two breast cancer cell lines. Resolution at the subcellular level was achieved, 
allowing information about the location of the metal conjugated probe within the cell. 
This capability allows reliable information to be gathered using many imaging 
techniques. The diverse and sensitive, rapid imaging platform may prove to be a valuable 
tool for the biomedical analysis of tissues used in diagnostics.  
 Experimental adaptations to traditional imaging equipment have also been 
pursued by Neaspec [49]. The NeaSNOM microscope utilized a new technology allowing 
imaging in the visible, infrared and terahertz spectral regions to a spatial resolution of 10 
nm. This technology has been utilized to map insulin fibrils [50]
 
, as well as determine 
the local dielectric permittivity of a PMMA film [51], among other applications. With a 
scan speed of up to 20 µm/s and capability for the analysis of sample up to 40 x 50 x 15 
mm, this technique offers a desirable balance of sensitivity and speed for the imaging of 
biological tissues. 
2.3.2 Point-of-Care and mHealth Platforms 
 
 While improvements to traditional imaging techniques have garnered attention 
over the past several years, mHealth imaging efforts are growing just as quickly (Table 
2.4). This technique takes place with a variety of imaging detection formats attached to 
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the camera lens of a smartphone. By using the camera to capture data, results can be sent 
to a central hub in a clinic or hospital so care providers can make treatment decisions 
without patients having to commute from remote locations. This is also valuable for 
monitoring health in resource-poor settings where access to healthcare is limited and 
telemedicine is the only real viable option. 
Technique Applications Resolution Duration Fabrication/ 
Equipment 
Requirements 
Reference(s) 
mHealth Fluorescein 
detection 
1 – 10 nM 10 – 15 sec 
data 
capture 
(~85 min 
sample 
prep) 
Capillary array, 
fluorescence 
detector, multiple 
wavelength LED, 
computational 
image stacking 
program 
12, 25 
Cell-phone 
microscope 
Detection of 
micro-
particles, red 
blood cells, 
white blood 
cells, 
parasites 
~1 – 2 µm 5 minutes Specially 
designed 
microscope 
attachment 
21 
Fluorescent 
imaging 
cytometry 
on 
cellphone 
White blood 
cell density 
measurement 
2 µm 
resolution 
6 minutes Specialized 
optofluidic 
cellphone 
attachment 
23 
Label-free 
smartphone 
biosensor 
Protein 
detection 
4.25 nM 20 minutes Photonic crystal 
biosensor, 
application for 
automated data 
interpretation 
24 
Rapid 
diagnostic 
test reader 
on 
cellphone 
Immune-
chromatograp
hic assays 
4x dilution 
of whole 
blood 
< 1 minute, 
(0.2 
seconds 
per image) 
Specialty rapid 
diagnostic test 
reader attachment 
26 
Table 2.4 Summary of imaging techniques utilized as point-of-care devices for 
diagnostics. 
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 The Rasooly group has contributed a several studies in the area of mHealth over 
the last few years. In a first example a capillary tube array was developed to improve the 
sensitivity of smart phones [25]. An increase in sensitivity was needed since common 
cellphone cameras are generally not able quantify the weak fluorescent signals present in 
many mHealth applications. An array using 36 capillaries was developed and illuminated 
using a multi-wavelength LED directed horizontally to the capillary axis. Fluorescein 
dilutions were tested between 0-10,000 nM, and a limit of detection was found to be ~10 
nM in water. This represents roughly a 100-fold increase in sensitivity over the 
unmodified phone as well as a vast increase in sensitivity compared to 36 well plates 
whose LOD was 1000 nM. 
 In a secondary work from this group, mHealth diagnostic sensitivity was further 
improved using computational image stacking [12]. This was accomplished by capturing 
data in video mode, stacking the collected images and averaging the intensity of each 
pixel to reduce or eliminate random noise. To demonstrate the ability of this system to 
quantify disease-related biomarkers, adenovirus DNA was labeled with SYBR green or 
fluorescein. Using computational image stacking signal sensitivity was improved, 
reducing the LOD to 1 nM. While this technique currently demonstrates sensitivity 
similar to a standard well-plate reader, its portability, ease of use, and the potential for 
further increasing the sensitivity while utilizing minute sample volumes makes it an 
attractive and promising mHealth platform. However, before this technique could be used 
in diagnostic applications the platform would need to be evaluated for signal arising from 
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cross-reactivity or non-specific binding in samples which are not present in the current 
model system and have not been considered in its limit of detection. 
 Cost-effective microscopy for telemedicine has also been studied extensively by 
the Ozcan group. The primary focus of this group has been the development of lens-free 
microscopy (Figure 2.3) [21-23,26]. A microscope-based on digital in-line holography 
was developed using an light-emitting-diode (LED) and compact opto-electric sensor-
array, which allows imaging without the need for lenses or bulky optical equipment [21]. 
The microscope was tested for imaging performance using a variety of cells and particles. 
Results show that, in addition to making the platform robust and cost-effective, lens-free 
imaging was able to achieve subcellular resolution. This work was extended by the 
imaging of micro-particles, red-blood cells, white blood cells, platelets and a waterborne 
parasite [22]. The spatial resolution in this application was limited by the pixel size of the 
sensor. 
 
 
Figure 2.3 is reproduced from Reference 21 with permission from The Royal Society of 
Chemistry. The figure shows the platform for the attachment of a lens-free microscopy 
application to an existing cellphone camera. (A) shows an image of the actual device 
used. Shown in (B) is a schematic of the microscope shown in (A). 
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 Further expansion of these efforts was observed by the integration of imaging 
cytometery and fluorescent microscopy as an optofluidic attachment [23,26]. This is 
achieved by inserting a disposable microfluidic channel above the existing cellphone 
camera to deliver targets of interest to the imaging volume. The captured images are then 
processed through a smart application that both validates the test and automatically 
presents the diagnostic results. This provided an imaging resolution of ~2 µm, which 
highlights this technique’s potential as a valuable rapid imaging test for the routine 
remote monitoring of chronic conditions as well as disease screening in resource-poor 
areas. 
 The rapid-diagnostic-test platform was expanded to work with various lateral flow 
immuno-chromatographic assays to sense a target analyte [26]. In order to accomplish 
high-contrast imaging, diffused LED arrays were incorporated prior to data processing. 
The platform was experimentally tested using malaria, tuberculosis (TB) and HIV 
through detection with gold-labeled antibody-antigen complexes. This technique is 
capable of rapid, high-resolution screening while providing instant testing results. 
However, because its format only allows for the analysis of one target species at a time, 
its use as a diagnostic point-of-care device would require the transport of a library of 
microfluidic channel inserts which could decrease its ease of use, leaving it better suited 
to the monitoring of chronic diseases in remote locations as opposed to a diagnostic tool. 
 Label-free detection on a smart phone was recently demonstrated by Gallegos et 
al [24]. Broadband light entered through a pinhole and was collimated prior to passing 
through a photonic crystal biosensor fabricated on a plastic substrate. A custom software 
application was able to convert the resulting images to transmission spectra and perform 
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curve-fitting analysis. Results show peak wavelength value shifts could be measured with 
0.009 nm spectral accuracy, allowing the detection of an immobilized protein monolayer 
as well as selective, concentration-dependent antibody binding to a limitof 4.25 nM. The 
measurement of wavelength shifts above the sensor-specific background noise suggests 
the LOD is controlled by variations within the assay as opposed to the detector 
resolution. The development of label-free biodetection on an affordable, sensitive, and 
mobile platform represents a valuable potential tool for point-of-care diagnsotics, but 
similar to many cellphone-based techniques is hampered by its limitation to the detection 
of a single analyte. 
The concept of a rapid, affordable point-of-care device has also been explored 
commercially [52-55]. The most common commercial platform thus far is that 
traditionally used in glucose monitoring [52,53]. One recent study compares the StatStrip 
(SS) and SureStrep Flexx (SF) for glucose testing [52]. Results of this show the that the 
sensitivity of SS was 94.7%, compared to 100% for SF and negative predictive values 
were found to be 86.1% in both cases. These results were achieved using venous blood 
samples compared to plasma glucose traditionally monitored, and it was determined that 
they were of limited use compared to the reading of plasma samples. 
The development of point-of-care testing for diverse disease biomarkers has also 
been explored through a partnership between Texas Instruments and Cnoga Medical 
[54,55]. Together they have investigated the use of video cameras to measure vital signs 
like blood oxygen, carbon dioxide levels, blood pressure and pulse rate through skin 
analysis. Current research by these companies aims to expand this technology toward 
having capabilities to noninvasively identify biopatterns for diverse diseases.  
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2.4 Concluding Remarks 
 
In examining the publications over this time span, there was a large emphasis on 
the development of mobile diagnostic devices both utilizing imaging and biological 
recognition detection platforms. This focus has evolved from the need to monitor global 
health issues, as well as treat patients in remote or resource limited locations. While 
platforms in this arena range from microarrays printed on CD or DVD discs, to the use of 
a cellular phone camera to image or count cells and interface with applications that allow 
data to be analyzed centrally through telemedicine, importance has been placed on the 
need to perform tests rapidly, at low cost, with sensitivity comparable to technologies 
used in a permanent laboratory, and with user-friendly interfaces. While mHealth and 
related cellphone applications do not currently share the advantage of parallel biomarker 
analysis, alterations in the design of the microfluidic cartridges used for testing prior to 
detection through the cell phone camera should not detract from the sensitivity of 
detection.  
 Another broad area of research is modifying traditional infrared spectroscopy 
equipment to overcome the traditional diffraction-limited resolution capabilities while 
maintaining reasonable analysis times. These approaches are valuable as they allow for 
subcellular imaging, pinpointing label locations within a cell, and determination of 
characteristic spectral signatures for related tissues that may help in the evolution of 
imaging biomarkers for disease. However, the ultimate limitation to these techniques is 
the singleplex analysis format they are confined to. While improvements in resolution 
and reduction in analysis time make these valuable testing platforms, often a great deal of 
post image-capture analysis is required for the interpretation of results, and only one 
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tissue may be imaged at a time, presenting a bottleneck to diagnosis of conditions 
compared to techniques that allow many tests to be performed in parallel in a similar time 
frame. 
 Finally, laboratory or clinic-based biorecognition assays have continued to evolve 
in terms of their sensitivity and capability for the analysis of many compounds 
simultaneously. While these techniques are diverse, they often require moderate sample 
volumes and longer incubation times than many of the point-of-care testing devices. In 
terms of these testing devices, the greatest potential for providing an optimized 
biomedical analysis device comes from those assays being developed as part of a 
microfluidic analysis system, where traditional incubation methods are forgone in lieu of 
convective mixing, as well as sample pre-concentration and purification prior to detection 
which both reduces cross-reactivity and allows for relatively complete capture of analyte 
from a sample volume enabling low sample volumes and reduced analysis times. 
 While many of the biomedical analysis techniques described here have been 
successful in improving upon on diagnostic capabilities or disease monitoring, there does 
not currently exist one definitive optimal technique. Progress has been made in the ability 
of various platforms to be user-friendly, rapid, and sensitive while achieving high 
resolution and using low sample sizes. However, challenges still remain in adapting many 
laboratory-based biological recognition assays to a point-of-care format without 
compromising sensitivity or requiring specialists to interpret results. Future techniques, in 
addition to being adaptable for the testing of a variety of diseases, should require minimal 
sample and be capable of quantifying multiple targets in parallel.  
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While various analysis approaches have specific advantages, combining the rapid 
analysis capabilities and user-friendly data presentation of the cellphone-based platforms 
with the high sensitivities and parallel analyte analysis achieved in laboratory-based 
biological recognition assays appears to present the most realistic path toward optimizing 
diagnostic and disease monitoring capabilities. Although more work needs to be done 
toward optimizing microfluidic attachments that may be used in remote locations for 
multi-analyte detection, developments in this arena over the next few years hold promise 
in providing optimize tests for disease monitoring tailored to the needs of their specific 
targets, as well as versatile platforms that may be adapted to the early detection and 
diagnosis of varied diseases. 
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CHAPTER 3 
RECENT DEVELOPMENTS IN EMERGING MICROIMMUNOASSAYS 
3.1 Introduction 
 
 Over the last several years micro-immunoassay development has focused on 
replacing existing immunometric assays based on a micro-titer plate format. Notable 
among these currently existing methods is the enzyme-linked immunosorbent assay, or 
ELISA. Since its introduction in 1971, ELISA has remained a core, widely accepted 
practice and remains a common focal point to differentiate and discuss current 
experimental techniques [1]. Its success stems from the enzyme-based amplification 
mode and ease of use, along with the specificity and sensitivity of the antibody-antigen 
interactions common to all immunoassays. Despite the long incubation times and 
relatively high sample volumes and reagent costs, experimental assays aimed at the 
replacement of ELISA have universally failed to displace it and few have been 
implemented commercially. While much of the following discussion is centered on 
comparisons to ELISA, all immunoassay platforms are included. Over the last five years, 
efforts to improve upon clinically used sandwich immunoassays have targeted one (or 
more) of six metrics: increased sensitivity [2-5], reduced analysis time [6-9], reduced cost 
[10], lower sample volumes [6-11], ability to multiplex [2,6,12-15], or operational 
simplicity [3]. While many studies improved various aspects of immunoassays, a so-
called optimized immunoassay capable of displacing existing tests and significantly 
improving capabilities for clinical or diagnostic purposes has not been produced. A 
platform capable of doing so would need to not only meet the critera defined above, but 
possess high reproducibility and show selectivity for the condition or disease being 
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investigated. Many of the methods discussed herein have been addressed only in single 
publications, therefore reproducility of immunoassay results needs to be improved before 
one may be considered optimal for diagnostics. However, several studies noted here may 
lay the foundation for a successor to ELISA.  
 Several groups continue to develop variations on standard immunoassay 
protocols, notably those of Ko, Gijs, Yang, and Hage. The current article will focus on 
the ability of these systems (and others) to create sensitive, robust, rapid and cost-
effective diagnostic tools with high throughput on a multiplex format. While many of the 
assays discussed currently take place using singleplex analysis, their ability to be adapted 
to a high-throughput format will be assessed relative to other formats. 
 For any assay platform, the ultimate level of sensitivity will depend on the 
reaction kinetics (Keq) resulting from reagent quality [16]. However, reagent specificity 
will have differing impacts on the assay outcome depending on the platform in which 
they are used.  An optimized clinical immunoassay format should meet several criteria to 
be applicable to a comprehensive range of diagnostic tests. First, a sensitivity down to the 
low pg/mL range is optimal so any plasma protein may be monitored, which allows for 
ultra-sensitive detection in medical diagnostics [17]. An analysis time should be no more 
than 1 hour (if samples may be evaluated simultaneously) to permit changes over time to 
be tracked with ease [18], and sample volumes in the range of 10 µL per analyte 
interrogated to minimize reagent consumption. Finally, an assay should be able to 
multiplex for the evaluation of five proteins simultaneously, representing quantification 
of a group of biomarkers for a specific disease [15], and should take place with minimal 
transfer/pipetting steps to lessen variation between tests/testing sites [18]. These criteria 
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represent the desired capabilities of an immunoassay platform such that it may be easily 
adapted for the detection of a complete range of targets in a clinical setting. The 
individual assays discussed have been optimized for a particular target (or set of targets), 
which in some cases have requirements deviating from the desired qualities described 
above for an optimized clinical assay. While these criteria are not inclusive to all tests, 
they have been established to provide an organized framework in which to discuss the 
diverse experimental immunoassay platforms available. 
While immunoassays have been the subject of several recent reviews [19,20], the 
focus of this review is immunoassay platforms aimed at improving diagnostic abilities 
published during the time span from January 2008 to April 2012, initiated with literature 
keyword searches associated with micro-immunoassays along with the references and 
later citations of found works. These articles contributed new techniques to the field by 
improving limits of detection, decreasing sample analysis time, and refining the ability of 
assays to accommodate multiple samples in parallel. Many of the designs represent 
relatively simple fabrication processes and, while demonstrated for specific analytes, 
could be easily adapted for any number of target compounds. The topics addressed are 
categorized into three classes: (i) use of micro- or nanoparticles (both magnetic and non-
magnetic) as a solid support or to generate signal [Section 3.2], (ii) generation of signal 
using flow conditions [Section 3.3], and (iii) use of a static solid support to trap antigen 
and generate signal [Section 3.4]. A summary of these techniques is provided for 
reference (Table 3.1, Appendix B). Although articles have been divided into these 
categories for clarity, they are not mutually exclusive and many studies could have been 
placed in more than one class.   
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3.2 Assays using micro- or nanoparticles  
 
Assays employing micro- or nanoparticles may be further divided into two 
categories: (i) those using magnetized particles and (ii) those which use non-magnetic 
particles. Some of the techniques described here include the fluorescent microsphere 
immunoassay (FMIA) and its variations, magnetic bead-based immunoassays occurring 
fully on-chip where beads are manipulated to afford contact with successive reagents and 
samples, and magnetic bead-based assays which employ batch incubation off-chip prior 
to on-chip detection. The use of micro- or nanoparticles has gained popularity for a 
variety of reasons. Chief among these are the ease of manipulation during sample 
preparations and the ability to tailor the number of beads employed to suit the specific 
needs of an assay. This allows the solid surface area to be altered and optimized for 
various targets. Users are able to trap lesser sample concentrations on a small surface area 
(by employing low bead numbers) which provides signal concentration, allowing 
sensitive detection. Assays utilizing magnetic particles, in particular, also lend 
themselves well to coupling with varied signal processing approaches which have 
improved sensitivities and lowered limits of detection [4,5,21].
 
3.2.1 FMIA 
FMIA is a technique that uses numerous sets of spectroscopically-coded 
fluorescent microspheres, where each microsphere set is conjugated to a unique antibody 
or antigen, forming a solid phase for analyte detection [12]. This format was developed 
with a focus on multiplex analyses and has been used to successfully quantify ten 
compounds in parallel with detection limits in a clinically relevant range. Antigen-
antibody reactions are simply performed in the well of a micro-titer plate. Analysis 
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follows, on a flow cytometer using Luminex X-Map
TM
 technology, in which separate 
wavelengths of light excite the microsphere sets and surface-bound reporter dyes [22,23]. 
The microspheres are labeled with a combination of red and orange fluorescent dyes. The 
ratio of these dyes acts as an identifier of the target analyte immobilized on the 
microsphere surface [18]. A separate detector, measuring green fluorescent response 
proportional to the amount of target, is able to quantify the total analyte present (Figure 
3.1) [24]. This technique has been tailored to quantify groups of compounds relevant to a 
particular disease and possesses the obvious advantage observed in its ability to 
interrogate up to ten analytes from a single sample. However, in order to achieve 
clinically relevant levels of sensitivity, this format requires long incubation times and the 
use of specialized equipment. While verified assays are powerful in the information 
content they are able to provide, validation studies to ensure specificity represent a time-
consuming hurdle for adaptations to limitless biological applications. 
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Figure 3.1. Overall process of a Luminex
®
 multiplex immunoassay. Following the 
immunoreaction shown in (A) fluorescence signals from both the reporter-molecule and 
color-coding dyes are read simultaneously (B) and processed digitally to translate signals 
to quantitative data (C). 
 
 The labor-intensive development process for FMIA was demonstrated in one 
instance by the validation of assays detecting the porcine reproductive and respiratory 
virus (PRRSV) in both serum and oral-fluid based samples [12,13].This work, done at 
South Dakota State University, produced an 8-plex FMIA for cytokine detection and 
requires a single 50 μL sample to quantify the analytes simultaneously [13]. Using the 
same volume typically required for one ELISA sample, the FMIA assay was able to 
achieve sensitivities in the pg/mL range. For seven out of the eight analytes studied this 
detection limit represents between 1.2 – 8.2 fold improvements to sensitivity compared 
with the analogous ELISA. Follow-up work aimed at replacing serum samples with oral-
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fluid resulted in decreased diagnostic capabilities [12]. However, the assay did maintain a 
clinically-acceptable level of sensitivity and was able to detect the multiple target 
compounds in a single sample. While this work was successful in producing an assay 
based around the use of a non-invasive sample (allowing widespread testing), expansion 
to theoretical capabilities is limited by the quality, in terms of selectivity, of the 
antibodies employed. Additionally, since the possibility of shorter incubation times was 
not fully explored, leading to assay times comparable to a traditional commercial ELISA 
format [24], along with the requirement for sophisticated equipment, this assay carries 
significant costs both in terms of analysis time and labor for development.  
Nonetheless, this technology has been used for various applications including the 
detection of sera infectious agents [25], matrix metalloproteinases [26], and small 
molecule drugs [27]. These uniquely optimized assays share the advantage of using a 
single sample for multiple analytes equivalent to the volume used for one ELISA target. 
Moreover, owing to reduced sample handling, the multiplexed estimates are less 
impacted by operator error as compared to ELISAs performed on multiple analytes 
requiring several trials [26]. These studies were able to achieve sensitivities of 1 µg/mL 
for sera infectious agents, 17 pg/mL for matrix metalloproteinases and below 1 ng/mL for 
small molecule drugs. However, like the studies discussed above, antibody cross-
reactivity presents a practical limit to the number of analytes that may be interrogated 
from a single sample and may limit sensitivity.  
 Using a similar format, but with the added advantage of reduced analysis time, 
Kuriakose et al. described the use of FMIA for the development of a multiplex assay for 
avian influenza viruses [28].
 
The reactions were analyzed on a Bioplex instrument using a 
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minimum of 100 microspheres in each set. Mean fluorescence intensity calculations for 
each bead set were used to quantify influenza viruses M, H5, H7, N1 and N2 to 0.04, 
0.15, 0.17, 1.56, and 1.15 ng in a 50µl sample, respectively. This represents an average 
detection limit of 12.3 ng/mL, where the assay can be accomplished within 70 minutes. 
While the detection capabilities of FMIA are not fully exploited in this effort, the study 
represents a subset of work where reduced analysis times hold greater importance. 
A comparable emphasis on reduced analysis time is observed in the work on 
glycopolymer quantification by Pochechueva et al, where analysis time totaled 90 
minutes [29]. Here, glycoproteins Atri, Btri, Le
x
, and Hd were analyzed in both singleplex 
and multiplex formats to assess antibody cross-reactivity. The mono- and multiplex assay 
data correlated well, having Pearson’s r values ranging from 0.95 to 0.99 for the different 
analytes, indicating that the six target compounds investigated could be detected 
independently from a single sample. The lowest concentration tested was detected at 15 
µg/mL. While successful under these circumstances, where target compounds have a 
relatively high relevant range, the full detection capabilities of FMIA were not 
maximized. Application to other biological targets, where physiological concentrations 
may be significantly lower, could require longer incubations and negate the time 
advantage observed here.  
In a unique twist on work related to FMIA, Ji et al. reported on the production of 
quantum dot (QD)-doped microparticles for use in immunoassays [30]. A flow-focusing 
microchannel with a double T-junction was designed to merge a sodium alginate solution 
into a hydrogel matrix for trapping QDs. The system affords a series of QD-encoded 
microparticles to be developed in one step. When tested in an immunoassay on IgG 
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(immunoglobulin G), FITC-labeled (fluorescein isothiocyanate) IgG could be detected to 
a minimum concentration of 2.2 µg/mL. Further investigations are needed to separate 
target and encoding signals and optimize other assay conditions to improve detection 
sensitivities. Once optimized, this process provides an attractive alternative to the need to 
purchase fluorescent microparticles commercially for small-scale operations focused on 
minimizing cost. However, the low cap on bead diversity, as well as the time required to 
produce the QDs, limit the utility of this platform for large-scale clinical use. 
The assays developed using FMIA have, to this point, achieved success in 
measuring up to ten analytes from a single sample [25]. They require low sample 
volumes (typically 50 µL), which has permitted the thorough investigation of limited 
samples by allowing quantification of anywhere from one to ten antigens. Each of the 
investigations discussed have successfully adapted FMIA to suit their individualized 
needs. However, they are relatively expensive to perform due to the requirement for 
specialized analysis equipment and depend completely on antibody specificity for a 
reliable response. This reliance on antibody quality restricts the flexibility of FMIA in 
terms adaptation to new target compounds since adjustments require extensive testing to 
assure minimal cross-reactivity within the assay. This immunoassay format also requires 
long incubation times, totaling two or more hours, to achieve levels of sensitivity in the 
pg/mL range. The requirement for these long incubations arises from sample preparation. 
Samples are incubated in in the absence of convective mixing or sample flow employed 
by other methods to increase the speed of antibody-antigen recognition events. 
Other companies have developed similar commercial products to FMIA, 
including the cytometric bead array (CBA) from BD Biosciences and the Amplified 
  66 
Luminescent Proximity Homogeneous Assay (AlphaLISA) [31-33]. Like FMIA, CBA 
uses small sample volumes (50 µL) and has achieved clinically acceptable limits of 
detection (3 pg/mL) while operating in the same time frame as FMIA [31]. AlphaLISA 
has been able to quantify target compounds in a shorter time span using a competitive 
assay format [32,33]. While AlphaLISA has also attained sensitive detection (0.007 
ng/mL) in a shorter time frame using a competitive assay format, signal production 
depends on an energy transfer between donor and acceptor beads in close proximity to 
produce a chemiluminescent signal which subsequently activates a fluorophore in the 
same bead. This method of signal production has resulted in studies that focus on assay 
development in a singleplex format. Adaptation to a multiplex format would require the 
ability to distinguish between signals from different acceptor beads. Additionally, 
because AlphaLISA operates in a competitive assay format, where increases in analyte 
represent decreases in observed signal, the limits of detection for this platform are not as 
sensitive as those operating in a noncompetitive sandwich assay design. 
3.2.2 Off-chip preparation of magnetic bead-based assay 
The use of magnetic particles as a solid support is an attractive alternative to 
fluorescent microspheres because it allows for easy manipulations and separations both 
on and off-chip. Off-chip incubation is often employed because it allows sample 
preparations to be performed in advance of the assay. The initial incubations are simple 
to perform and can be accomplished using common lab equipment, such as an Eppendorf 
tube [21], or the well of a micro-titer plate [34].
 
Magnetic particles may be easily 
detained by the introduction of a permanent magnet during wash steps, and high 
sensitivities have been achieved with small sample volumes. In addition to the ease of 
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manipulations and high sensitivity, use of magnetic particles has gained in popularity 
because of their compatibility with diverse detection and signal processing systems 
including, but not limited to, chemiluminescent [34,35], fluorescent [21,36-38], or 
electrochemical detection [39].
 
 Fluorescence continues to be one of the most popular detection methods, and 
several protocols used in fluorescence immunoassays (FIA) were described during this 
time period by the Gijs group from Switzerland [36,37]. In one article, a channel was 
constructed having periodically enlarged cross-sections used to trap magnetic chains in a 
homogeneous field [36]. The results showed that off-chip incubation of capture antibody 
with target analyte under agitation produced uniform fluorescence throughout the channel 
(Figure 3.2). This approach provided a detection limit of 50 ng/mL, which is similar to 
classical ELISA. However, the off-chip incubation resulted in the linking of beads via 
capture antibody interactions creating chain irregularities on-chip. By implementing a full 
on-chip procedure the issue of chain irregularities was resolved [36,40]. This gave an 
improved detection limit of a few ng/mL and afforded a reduction in assay time from 2 
hours to 25 minutes. 
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Figure 3.2. Images of the self-assembled chains formed using off-chip incubation, 
on-chip detection and the full on-chip immunoassay formats. (A) shows an optical 
image of the self-assembled chains following off-chip incubation. (B & C) compare 
the fluorescence images of the chains after the off-chip incubation and full on-chip 
assay, respectively. 
 
 Building from their work on FIA protocols, an integrated silicon chip was 
developed by Dupont et al. based on the measurement of photon-induced electrical 
current pulses in single photon avalanche diodes (SPADs) [37].
 
This allows for 
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fluorescence measurements of microparticles without the requirement of a microscope. 
Here, manipulation on-chip after off-chip incubation of sample is achieved by applying 
current through microcoils which positions single beads over a SPAD. Once oriented, the 
fluorescence signal of a single bead could be measured for the detection of  monoclonal 
antibodies down to 1 ng/mL in only 25 minutes using a sample volume of 100 µl. While 
this assay achieves a comparable sensitivity in the same time frame to the fully on-chip 
assay described by the group, the sample volume required is much greater (100 μL as 
compared to 4.1 nL) [36,40]. Additionally, the speed of this assay is an improvement 
over the 2.5 -3 hours typically required of a commercial ELISA using an identical sample 
volume. However, the limit of detection is slightly higher than the 0.03 ng/mL limit 
typically observed commercially for monoclonal antibodies used in analyte capture [101].
 
 A different approach to signal generation in FIA protocols is described by the 
Hayes group from Arizona State University [4,21]. In these articles, during data 
acquisition on an inverted fluorescent microscope coupled to a CCD camera, a magnetic 
field is introduced. By incorporating a periodicity into this field, lock-in amplification 
was used to selectively quantify surface-localized myoglobin, even in the presence of 
background noise. Using lock-in amplification, a detection limit of 1 ng/mL was 
afforded, which is comparable to the methods previously described [21]. By introducing a 
novel image processing system capable of estimating and eliminating background noise, 
only the pixels corresponding to the solid surface are used in concentration 
determinations [4]. Coupling this signal processing to the previously described 
immunoassay protocol improved sensitivity to a 11.5 pg/mL detection limit for 
myoglobin using a sample volume of 30 µl. This detection limit represents roughly 100-
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fold improvement over previous results and is 2.3-fold more sensitive than the 
corresponding ELISA. 
Off-chip incubation protocols have also been described for methods using varied 
detection methods. Electrochemical detection was employed both by Proczek et al. [33], 
and by Piao et al [41].
 
In the work by Proczek et al. analyte quantification was performed 
using GRAVI
TM
-chips from DiagnoSwiss [39].
 
These chips contain eight independent 
microchannels, which allows parallel testing. Following off-chip incubation, IgE 
(immunoglobulin E) could be quantified to a detection limit of 17.5 ng/mL in less than an 
hour.  
Piao et al. used a novel approach to develop an electrochemical immunosensor 
based on carbon nanotubes coated with enzyme and magnetic particles in combination 
with an electrically-driven reversible reaction allowing substrate recycling to amplify 
signal [41]. After off-chip conjugation of magnetic particles and capture antibody to the 
carbon nanotubes and the binding of target analyte on-chip, the sensing assembly is 
magnetically guided to a gold electrode. Here, the amperometric responses of the 
enzymatic reaction were recorded using cyclic voltammetry. Results show a detection 
limit of 0.19 ng/mL of hIgG after a 30 minute enzymatic reaction. While both methods 
were able to quantify target compounds with a similar limit of detection to FIA and do 
not require the use of a fluorescent microscope, sensitivity is afforded through long 
enzymatic reactions relative to assays boasting the completion of entire protocols within 
25 minutes [36,40].  
An alternative method employing batch incubation was described by Li et al [34]. 
Here, the development of a micro-plate magnetic chemiluminescence immunoassay 
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(MMCLIA) was discussed. This assay uses magnetic particles as the solid support and 
micro-plate wells as the reactor. The full procedure takes just under two hours to perform. 
With incubation times similar to conventional ELISA, a detection limit of 0.61 ng/mL for 
carcinoembryonic antigen was afforded using a sample volume of 35 µl. Although not 
offering advantages in terms of rapid analysis, and with a format that would be reliant on 
antibody quality to preserve sensitivity if multiplexing were to take place, this assay 
affords a competitive detection limit while requiring roughly 1/3 the sample used by 
current commercial protocols. 
 This group of assay methods shares the advantage of sensitive detection limits 
using affordable methods and, in general, low to moderate levels of complexity. They 
also offer the ability to limit sample use (generally between 30-50 µl is consumed) and 
reagent consumption. This is afforded by the ability of the magnetic particles comprising 
the solid support to remain free-flowing during incubations, as well as through 
convective mixing, which allows the entire sample to be interrogated for antigen capture 
affording quantifiable signal of low-concentration targets from small sample volumes. 
Additionally, while many have been evaluated only in a singleplex format, the alteration 
to these assays allowing the ability to multiplex is straightforward and should not affect 
assay quality. However, while many of these assays require only simple lab equipment 
for the initial incubation steps, the chips employed during detection (as well as the 
detection methods themselves) vary greatly. So, while many methods can be performed 
with the use of a common fluorescent microscope, there may be initial instrumentation 
costs depending on the assay platform selected.  Furthermore, with off-chip preparation 
of samples, long incubation times on the order of hours are required. This limits the 
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capability of these assays to make serial measurements and track concentration 
fluctuations with time. In addition, some studies have observed issues in the manipulation 
or non-uniform aggregation, of beads on-chip, following off-chip pelleting protocols 
during wash steps [36].
 
Many of these issues can be eliminated through the adaptation of 
batch incubation procedures to those that take place fully on-chip. The advantages, and 
limitations, of the on-chip immunoassay format are discussed in the following section. 
3.2.3 On-chip assay with sequential introduction to reagents/samples 
When immunoassays take place entirely on-chip the magnetic beads employed as 
the solid support may be manipulated in a variety of ways. Beads can be injected onto the 
chip at the outset of the experiment, immobilized by permanent magnets, and introduced 
to reagents and sample by sequential injection [11,36,40,42,43]. They may also be 
injected onto the chip and manipulated through static plugs of sequential reagents [44], or 
forced through laminar streams of flowing reagents [8,9].
 
Relative to their batch-
incubation counterparts, these assays are relatively simple to perform, requiring minimal 
pipetting steps and no transfer of the assay between containers. This minimizes the 
aggregation issues that have been observed in some off-chip immunoassay applications 
[36]. Additionally, through the flow of sample and reagents the duration of the assays is 
minimized. While this is sometimes accompanied by a decrease in sensitivity, some 
optimized procedures are able to remain competitive with those using longer incubation 
steps. 
  The manipulation of magnetic particles through streams or static plugs of sample 
and reagent was explored by multiple groups [8,9,44]. In the first study, performed by 
Sasso et al., magnets are placed on both sides of a microchannel [9]. The field is strong 
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enough to pull magnetic beads to the wall of the channel, but not strong enough to 
overcome the shear stress from fluid flow required to trap the particles. This allows 
incubations to occur along the channel walls, and the beads are able to traverse the 
channel to enter or exit reactant streams. This format allows rapid assay times and 
requires minimal handling of the sample or reagent. Using an epifluorescence microscopy 
detection platform a 625 ng/mL limit of detection was realized for biotin-FITC with 
incubation times of less than five minutes and a sample volume of 90 µL. Despite 
requiring a relatively larger sample volume compared with other magnetic particle-based 
assays, this study allows for rapid serial measurements. This could easily be used to track 
changes in analyte concentration with time, but only for target compounds with a high 
concentration in plasma. Alterations to the method would have to be made to afford more 
sensitive detection, and allow this method to be readily ported to additional applications. 
A second example of the rapid analysis afforded by fully on-chip immunoassay 
applications was described by Peyman et al. where IgG quantification was achieved in 
about ten minutes consuming only 7.5 µl of reagents [8].
 
In this study several 
independent laminar flow streams are produced across a rectangular reaction chamber. 
The functionalized magnetic particles are deflected across these streams, passing through 
sample, wash, and detection reagents. Once the chip is set up there is only one required 
pipetting step to perform the assay, minimizing variations between runs. This, in addition 
to speed, represents a secondary advantage over batch incubation processes. Results show 
that negative controls used on chip produce little to no nonspecific binding or transfer of 
reagents between boundaries, evidenced by the lack of fluorescence for these samples. 
Using this system the detection limit for IgG was 0.1 µg/mL. This high limit of detection 
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could potentially be improved by increasing the sample volume, or through longer 
interaction times of the magnetic particles with sample.  
 A final example of particle manipulation through reagents and sample was 
developed by Chen et al. from the University of Rhode Island who describe a platform 
for a microfluidic inverse phase enzyme-linked immunosorbent assay (µIPELISA) [44].
 
In this format magnetic beads are loaded into a microchannel and transferred sequentially 
through plugs of sample and reagents separated by oil. This design allows the assay to be 
set up completely ahead of time and allows the process to be limited to one pipetting step, 
making operation simple. The oil plugs also prevents the mixing of reagents before, and 
during, the assay. The beads are allowed to incubate in each plug for 30-45 minutes and 
fluorescence data are collected for 180 seconds after being moved into the final buffer 
plug containing a fluorescein diphosphate (FDP) solution. Using this platform 
digoxigenin-labeled double-stranded DNA (Dig-dsDNA) was detected to a limit of 259 
ng/mL. However, at higher sample concentrations the µIPELSIA was less capable of 
detecting analyte compared to traditional methods. This was proposed to be a product of 
carry-on water between plugs bringing free detection antibody into the exposure plug. 
Although slightly more sensitive than similar on-chip methods, this assay loses the 
advantage of rapid analysis and does not compare to the sensitivities achieved with 
similar incubation times off-chip. Additionally, adaptation of the current assay to a 
multiplex format would involve use of all four parallel channels available in the current 
chip design. This would allow analytes to be quantified simultaneously but would 
quadruple the consumption of sample and reagents compared to the current system. 
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The other predominant assay structure for on-chip protocols involves maintaining 
magnetic beads in a single position by employing a homogeneous magnetic field and 
sequentially introducing reactants by flow, which has been explored extensively 
[2,11,40,43]. Keeping particles trapped in a magnetic field prevents undesirable 
aggregation and reduces the loss associated with particle transfers using batch incubation. 
Also, sample and reagent exposure times can be varied simply by altering flow rates to 
optimize signal under minimally required assay durations. This minimizes assay times 
while affording limits of detection competitive with assay formats requiring long 
incubations. This approach was used by Do et al. from the University of Cincinnati to 
design a new lab-on-a-chip facilitating an enzyme-labeled electrochemical immunoassay 
(ECIA) [11]. The chip uses a magnetic microarray as a bead separator and an 
interdigitated array (IDA) microelectrode as a biosensor. Results show IgG could be 
detected to 16.4 ng/mL in 35 minutes using 5 µl of reagent. 
 In another study magnetic nanoparticles were used as labels on microbeads to 
detect bound analyte by isomagnetophoretic focusing [2]. An external magnetic field 
causes particle movement to a denser or sparser field until its magnetic susceptibility is 
equal to the surrounding gradient. This is important because it allows small changes in 
concentration to be detected by utilizing a low concentration of gadolinium paramagnetic 
diethylenetriamine pentacetic acid (Gd-DTPA), used to create the magnetic susceptibility 
gradient. This low concentration allows a narrow dynamic range with high resolution. 
However, by employing a higher concentration of Gd-DTPA solution, a wider 
concentration range may be interrogated, making the assay flexible for diverse target 
compounds. Using this set-up rabbit IgG-biotin could be detected to a limit of 3.2 fg/mL. 
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The use of fluorescent microbeads allowed for a multiplexed assay with the detection of 
three analytes while maintaining pg/mL sensitivity and requiring 200 µL of sample. This 
represents improved sensitivity compared to commercially available ELISA, but required 
double the sample volume and similar assay duration. With the flexibility of tailoring the 
Gd-DTPA gradient, and using long incubations during sample preparation and 
specialized equipment to prepare and analyze samples, a low limit of detection was 
achieved for this assay. 
 Many of the fully on-chip immunoassays afford users rapid results and consume 
low volumes of sample [8,9,11]. Rapid analysis is allowed by manipulating the solid 
phase through reagents or by holding the solid surface in place while flow is used to 
direct sample to the assay surface, decreasing the depletion zone observed with diffusion-
mediated incubations. Large depletion zones, which reach a sensor-size dependent steady 
state during incubations dependent upon diffusion, can be combated by convective 
mixing or flow which accelerate mass transport and actively decrease the thickness of the 
depletion zone near a sensor surface [45]. This allows the assay time to be dependent 
upon the speed of the reaction itself as opposed to mass transport limitations. However, 
this rapid analysis is frequently accompanied by higher limits of detection. While non-
specific binding is not a large problem because the particles are in contact with sample 
and reagent for short time periods, the entire population of antigen may not be trapped 
causing an increase in limits of detection. In other cases long incubation times have 
allowed for sample analysis with high sensitivity, and the interrogation of multiple 
analytes [2].
 
Where optimal incubation times are employed these assays require less 
sample manipulation than their corresponding off-chip counterparts and have shown 
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equal, or greater, sensitivities. Similar to their off-chip counterparts many of these assays 
may be accomplished using a fluorescent microscope as the detection element. 
Nonetheless, due to the diversity of assay platforms, many formats require specialized 
equipment to perform. This, along with the need to fabricate chips on a large scale, could 
increase the initial cost and time investment in adaptations of the techniques to a large 
scale. The full on-chip assay structure holds promise both in terms of assay sensitivity 
and rapid analysis. However, in order to produce a truly optimized assay these 
considerations must be balanced to afford a test capable of interrogating any biological 
sample of interest, regardless of the targets’ physiological concentration. 
3.2.4 Other Techniques 
 Several studies have employed micro- or nanoparticles in creative ways that do 
not fit into one of the above categories. These include rapid analyses where particles are 
spiked directly into a sample for target quantification [3], protein-functionalized 
microparticles capable of electrostatic self-assembly [46,47], and fluorescent microbeads 
that employ simple detection methods [48].
 
These varied techniques hold individual 
advantages specific to their applications. Some have been tailored for the rapid analysis 
of target compounds, while others have been simplified to allow ease of use. The 
preeminent disadvantage associated with the assays described below is their vast 
differences from other microbead assays, requiring large adaptations in the average 
laboratory for widespread implementation.  
In the study by Ranzoni et al., a new technology based on magnetic nanoparticles 
in a pulsed magnetic field was investigated [3]. This method uses a small spike of 
nanoparticle probing reagent, pre-coated with monoclonal antibodies, which is directly 
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injected into a sample. The particles are free to move within the sample to capture antigen 
without the presence of a magnetic field. By introducing a pulsed magnetic field the 
particles are concentrated and allowed to form clusters mediated by biomarker-induced 
inter-particle binding. These clusters are then detected by applying magnetic rotation 
frequencies and using optical scattering to determine cluster size, which correlates with 
antigen concentration. 
Using this technique, after only one reagent addition step, an assay can be 
performed in a total time of 14 minutes. Using this scheme prostate specific antigen 
(PSA) was detected to a limit of 13.6 – 17 pg/mL in plasma. This format allows for the 
sensitive and rapid quantification of a single analyte, in a format greatly simplified 
compared to ELISA testing. The analysis of multiple compounds would depend on the 
specificity of antibodies, comparable to FMIA. It would also require detection to be 
altered so that clusters possessing different targets may be identified without the addition 
of sophisticated analysis equipment. 
 Another study based on the manipulations of magnetic microparticles was 
described by Afshar et al. in the development of a microfluidic magnetic actuation system 
that allows the 3D focusing of magnetic beads for agglutination assays [49]. The system 
was designed with a magnetic microtip, used as a field concentrator, to focus magnetic 
beads in a microchannel. A single lateral sheath flow positions and aligns individual 
beads in the center of the flow. This allows a small number of beads to be counted in an 
observation window by automated image reading. Having the individual beads 3-
dimensionally focused in the flow center allows reliable counting of single beads versus 
agglutinated bead doublets which allows biotinylated bovine serum albumin (bBSA) 
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concentrations to be determined. It was demonstrated that bBSA could be detected to 400 
pg/mL (6 pM) with the fully on-chip assay in about 20 minutes with the consumption of 2 
µl sample. This format, while rapid, would be difficult to multiplex due to the 
quantification of signal arising from the counting of aggregate numbers. 
As an alternative to the use of magnetic beads, the Gijs group contributed several 
immunoassay articles investigating electrostatically self-assembled micropatterns 
performed on-chip [46,47]. Electrostatic forces were used to mediate bead self-assembly 
in a channel formed by reversibly sealing PDMS onto an (aminopropyl)triethoxysilane 
(APTES) patterned glass substrate. As opposed to external magnets which create dense 
bead plugs on-chip, the fabrication of positively-charged APTES-patterns results in low 
fields where beads align. This allows the formation of self-assembled chains that are 
stable during both flow-based and static incubation steps.  Performing the immunoassay 
in stop-flow mode, where the channel is sequentially filled and incubated with sample 
and reagents afforded IgG was quantification to a lower limit of 15 ng/mL in 30 minutes 
using 560 nL of sample.  
A second contribution investigated the effect of continuous-flow versus stop-flow 
conditions for the assay [46]. The results show that mouse Antigen (m-Ag) could be 
detected under continuous flow to a limit of 250 pg/mL, representing roughly a 60-fold 
improvement over stop-flow limits and requiring only 10 minutes to perform. This 
procedure was performed using 1.3 µl. The advantage of reduced analysis time is 
afforded using continuous flow because diffusion associated depletion of analyte around 
the bead chains does not occur as observed under stop-flow conditions. This allows more 
analyte to be successfully captured onto beads in a short time span, analogous to analyte 
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capture in affinity chromatography utilized during protein purification. Additionally, high 
specificity antibodies allowed for two-analyte detection on a single chip. In both cases the 
rapid analysis and small sample size provide advantages as compared to ELISA without 
sacrificing the limit of detection. By decreasing the flow rate, thereby increasing analysis 
time, the second assay could potentially reach a more sensitive limit of detection. This 
would maintain its advantage of small sample requirements and rapid analysis while 
increasing its ability to compete with more sensitive analysis techniques.  
 Several studies employed simple polystyrene spheres in unique ways to produce 
fluorescent signals. In the study by Fu et al., a bead-trapping/releasing flow cell for a 
fluidic assay was developed [50]. This device integrated a pillar-array and pneumatic 
valve to provide flow injection/sequential injection analysis. Using the valve, beads could 
be manipulated in the device to perform the immunoassay in ten minutes with a detection 
limit of 0.80 ng/mL for 3,4,6-trichloropyridinol (TCP) using a competitive assay format 
and 15 µl of sample. This assay could later be altered to perform a noncompetitive assay, 
which would improve the sensitivity but increase the time required for analysis. Even 
with these alterations, the current detection method does not lend itself easily to 
multiplexing and would have to be altered to distinguish between signals arising from 
different compounds in order to quantify multiple antigens in parallel. 
A second example of polystyrene microsphere use is the cross-talk-free duplex 
FIA for the simultaneous detection of carcinoembryonic antigen (CEA) and neuron 
specific enolase (NSE) described by Cao et al [14]. A sandwich immunoassay was 
developed using multiple quantum dots as detection elements, which yield a tunable, 
symmetrical, and narrow emission band. Each color QD conjugate was capped by a 
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capture antibody, and polystyrene microspheres (PSM) brought antibodies proximal to 
the QD surface in a diffusion-driven incubation, allowing both antigens to be specifically 
identified simultaneously to a limit of 0.625 ng/mL, which is comparable to many 
methods using long incubation durations. The assay requires incubation times analogous 
to ELISA, but could be further multiplexed depending on the specificity of antibodies 
employed. 
Finally, employing intrinsically fluorescent beads in a unique way, a fluoro-
microbead guiding chip (FMGC)-based sandwich immunoassay for the quantification of 
biomarkers was investigated by Song et al [48]. The FMGC consists of four 
immunoassay regions, each containing five gold functional surfaces to support five 
identical tests performed simultaneously with the quantification of four separate analytes 
in parallel. The gold surfaces were conjugated to capture antibodies to create a sensing 
surface, where capture of both antigen and detection antibody was diffusion-driven. 
Using fluoro-microbeads conjugated to antibody and a fluorescent microscope, a 
sandwich immunoassay was performed and antigen concentrations determined directly 
by counting microbeads immobilized on the immunosensing regions. In an assay time of 
less than one hour cardiac troponin I (cTnI) could be quantified in a range from 0.1-100 
ng/mL. With the addition of agitation or convective mixing to increase sample capture 
and improve sensitivity, its time advantage over ELISA may be maintained. 
As illustrated in the sections above, the immunoassay applications achieved using 
both magnetic and non-magnetic particles as a solid support are diverse. These assays 
have been tailored to meet the needs particular to their use, which may be increased assay 
speed, sensitivity, or simplicity of operation. In general, assays that achieved rapid 
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analysis suffered from limitations in sensitivity. However, assays have not been produced 
which optimize the relationship between assay speed and ability to detect biomolecules 
with diverse physiological concentrations. Work done to improve this relationship may 
be the most promising avenue toward reaching a truly optimized micro-immunoassay, 
owing to the other advantages inherent to microparticle solid supports such as ease of 
manipulation, small sample size, and the straightforward coupling to advanced signal 
processing methods. 
3.3 Signal generation by flow conditions 
A second major area of interest in micro-immunoassay applications involves 
those based around the use of flow conditions to produce a quantifiable signal. In this 
section assays employing microcolumns [51,52] and immobilization on channel walls 
[53], where target quantification is achieved by the release and flow of a signal-
generating agent to a detector, will be discussed. This format has the advantage of 
allowing rapid quantification times with small sample requirements. Additionally, it is 
easily adapted to quantify different analytes. However, these assays are limited to a 
singleplex format and each antigen would require a unique column. 
 The Hage group from the University of Nebraska has contributed significantly to 
this area since 2008 [51,52]. One recent study introduced a reverse displacement 
immunoassay (RDIA) that generates signal by the analyte displacement of a label from a 
small immobilized analog column [52]. When a complex is formed between analyte and 
label, a displacement peak is created and the signal is measured allowing analyte 
quantification (Figure 3.3). Results show the lower limit of detection for RDIA to be 
around 67µg/mL (27-29 pmol) and the upper limit 400 µg/mL (160-200 pmol) for a 20 µl 
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sample of mouse IgG Fab1. The total assay analysis time is less than ten minutes, with 
signal generation occurring within 20-30 seconds after sample application to the column. 
This rapid analysis, which offers a pronounced time advantage over ELISA, is afforded 
because no pre-incubation of the sample with label is required. While this assay is limited 
to a singleplex format, it can be applied to any analyte where an appropriate label and 
immobilized analog are available or can be generated. Although sensitivity of the assay 
may be improved by using a larger sample volume, this format is not competitive with 
those employing incubation steps between sample and detecting agent. 
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Figure 3.3. Scheme for a reverse displacement Immunoassay. Reprinted with permission 
from [22] © American Chemical Society (2011). 
 
 A second contribution made by this group analyzed the binding and elution of 
target compounds from IAC/HPIAC (immunoaffinity chromatography/high performance 
immunoaffinity chromatography) columns in order to understand both association and 
dissociation efficiencies [51]. Using this format a variety of detection schemes can be 
used to obtain kinetic and binding information, including fluorescence, mass 
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spectrometry, and absorbance. The insight gained from this study can be valuable in the 
design of future solid-phase immunoassays. 
 A more sensitive flow based assay was described by Liu et al. who published on 
the development of a poly(methylmethacrylate) (PMMA) microfluidic chip coupled to 
electrochemical detection for the quantification of α-fetoprotein (AFP) [53]. AFP 
antibody is immobilized on the poly(ethyleneimine) (PEI)-derived PMMA surface. After 
antigen and horse radish peroxidase (HRP)-conjugated AFP antibody bind sequentially in 
the channel, a three-electrode electrical system at the microchip outlet records the 
reduction in the H2O2 current response. Results show a linear response between 1-500 
pg/mL with a 1 pg/mL detection limit requiring minimal use of sample in a time of 40 
minutes. Although it requires minimal sample and achieves sensitive quantification in 
under an hour, the assay is not easily adaptable to the analysis of multiple analytes in 
parallel. 
 Theoretical work to assist in predictions of device performance was conducted by 
Sinha et al [54]. A comprehensive model was created to characterize interactions during a 
flow-through immunoassay. Findings may help provide a rational basis for determining 
operating conditions in microfluidic IMS devices. 
 These immunoassays share the ability to achieve the rapid quantification of 
analytes using minimal sample volumes. This rapid analysis is made possible by the 
ability to perform the assay without sample pre-incubation steps. The sensitivity of these 
rapid tests is comparable to many immunoassays employing much longer incubation 
times [14,41,44], and are easily adaptable to quantify any target compound. However, 
  86 
since detection is dependent on the measurement of a displacement peak composed of 
label and antigen, multiplexing this assay format would be challenging. 
3.4 Use of a static solid support to trap antigen and generate signal 
The use of a solid support provides certain advantages, including the 
straightforward ability to multiplex and sensitive limits of detection. In this area of 
research many variations on this traditional “static well” format have evolved. This 
section discusses techniques that employ antibodies patterned on PDMS [6,7] or in 
capillary systems [15], as well as antibody microarrays [55], and novel techniques that 
employ static detection like the surround optical fiber immunoassay (SOFIA) [5] or 
oligonucleotide-linked immunosorbent assay (OLISA) [56].
 
These assays offer the 
advantage of easy and direct multiplexing, often accomplished by the patterning of 
capture antibodies on a static surface. Many of the assays also offer sensitive limits of 
detection, owing to long incubation times. The long incubations allow time for sample to 
interact with antibodies by diffusion, but put a limitation on the potential throughput or 
ability to track changes in protein levels over time using serial measurements. 
Since 2008 many groups have developed new technologies centered around the 
traditional static solid-phase immunoassay. The Delamarche group from Switzerland has 
made multiple contributions in this area [6,15]. In one study, the patterning of capture 
antibodies (cAbs) on PDMS in order to be compatible with capillary systems (CSs) was 
described [6]. Once cAbs are patterned, the PDMS block is placed on CSs with cAbs 
oriented perpendicularly to the reaction chambers which produces well-defined areas for 
analyte capture from solution. These small patterned areas allow one-step fluorescent 
imaging of all analytes, and the fast reaction is permitted by confining sample to a minute 
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space as it flows over capture zones. The capillaries allow multiple analytes to be 
detected from small samples (1 µL or less). This produces a “micro-mosaic assay” with 
the potential for 96 test sites if used with a chip having six independent reaction 
chambers. Results show that CRP could be detected to a sensitivity of 0.9 ng/mL in 11 
minutes using only 1 µl of sample. While already comparable in sensitivity to ELISA 
with a much smaller sample and shorter assay duration, the sensitivity of these assays 
may be further improved by coupling the detection to signal-amplification methods. 
In a second contribution the group described a one-step immunoassay using 
capillary systems [15]. The assay is based on the preloading of freeze-dried detection 
antibodies (dAbs) into the analyte flow path. After antibody reconstitution and analyte 
addition, fluorescence detection can be performed downstream on patterned capture 
antibodies. Results show that within ten minutes analyte concentrations with a lower limit 
of 3µg/mL could be detected. After 25 minutes of total assay time a decrease in the 
background noise-(resulting from the decay of unbound dAbs)- allowed concentrations 
down to 1 µg/mL to be observed. This single-step assay reduces handling overhead for 
the end-user. Although this assay possesses a higher limit of detection and an equal or 
longer assay time than the previous work, this study suggests that the positive aspects of 
CSs previously exploited could potentially be achieved in a one-step immunoassay. 
The fluorescent one-step immunoassay platform was further studied by Ruckstuhl 
et al [57]. In this contribution a system of polymer test tubes with fluorescence collection 
optics was utilized along with a compact fluorescence reader. The detection technology, 
based on supercritical angle fluorescence (SAF), allows for the real-time monitoring of 
surface reactions. Because the intensity of the signal decays exponentially with the 
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distance from the boundary, surface-selective detection is achieved providing a sensitive 
readout for immunoassays. In an assay time of only 13 mintues, IL-2 could be quantified 
with a linear response down to 4.5 pg/mL using a sample volume of 40 µl. This 
represents advantages compared to the traditional ELISA format, which requires four 
hours and 100 µL to give a limit of detection of 4 pg/mL, but presents an analogous 
limitation in terms of multiplexing. The assay, currently taking place in disposable test 
tubes, may be adapted to a well-plate format but will remain limited to the analysis of one 
compound per sample. 
Other static solid-phase assays produced based on the traditional format continue 
to employ 96 well micro-titer plates as incubation chambers. Chang et al. reported on the 
development of SOFIA, which uses 96 well plates for incubations, consuming volumes 
analogous to commercial ELISA methods [5]. Analysis takes place in a singleplex format 
using specially designed equipment. Samples are placed in a 100 µl microcapillary and 
excited in a detection unit by focusing temporally modulated light along the capillary’s 
axis. After light is focused into a single optical fiber and coupled to a low noise photo-
voltaic diode, detection takes place using phase sensitive detection employing a lock-in 
amplifier. The sensitivity was tested using Rhodamine Red and results show a 0.1 
attogram limit of detection. Prion proteins from varying species were also investigated 
and found to have a limit of detection >10 attograms from a sample volume of 100 µl and 
requiring long incubation times. While this assay offers superior sensitivity and the 
ability to multiplex, long incubation times and highly specialized equipment increase 
assay costs and limit sample throughput. 
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 Work done by Han et al. also made use of a 96 well plate to develop a creative 
variation on traditional ELSIA termed OLISA [56]. It is designed based on a detection 
antibody tethered to DNA through the incorporation of RNase H mediated signal 
amplification. Using a fluorescence platform, the limit of detection for OLISA was 
around 1 ng/mL using 100 µl of sample. This is comparable to the analogous ELISA, 
although slightly less sensitive. Detection antibodies employing different 
fluorophore/quencher pairs are employed that have independent spectral ranges for 
excitation and emission. This allows up to ten analytes to be interrogated in a single 
sample without signals arising from separate analytes interfering in the quantification of 
each compound. While this allows multiple analytes to be interrogated from a single 
sample, sensitivities are not improved relative to ELISA and incubation times, along with 
sample volumes, remain the same. Adaptations to the 96-well plate to allow nano-scale 
read volumes were achieved by the use of Siloam technology [58]. Incorporation of a 
spiral microchannel into each well of a microplate allows samples to be reduced to 5-10 
µL and the washing to be reduced while mirroring the standard ELISA steps. The 
sensitivity of this commercial format is in line with that for OLISA and ELISA (around 1 
pg/mL), but is accomplished in a time frame of 90 minutes and can accommodate 
multiple repeat samples to the same well to increase detection. 
 The static solid-support format has also been used to develop a fully automated 
ELISA on a portable disc-based format in work done by Lee et al [59]. In this unique 
alternative to typical disc systems, fluid transfer occurs through ferrowax microvalves 
created using low intensity laser light to melt paraffin wax embedded in iron oxide 
nanoparticles. The paraffin valves allow the full integration of the immunoassay on-disc 
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starting with a sample of whole blood. The assay is not limited in its number of steps as 
typically is seen with lab-on-a-disc systems where increasing spin speed is employed for 
sample transfers. With each disc having three identical units, multiple assays may be 
performed simultaneously in 30 minutes. The assay speed is afforded by disc rotation 
while sample is in the mixing chambers with reagents. This allows the assay to overcome 
time hurdles associated with diffusion-dependent incubations. Using 150 µl of whole 
blood, results show detection limits for anti-hepatitis B (anti-HBs) and hepatitis B antigen 
(HBsAg) of 8.6 mIU/ml and 0.51 ng/mL, respectively. This represents limits of detection 
comparable with ELISA using half the sample size and an assay time with one-fourth the 
duration. While this device is portable and disposable, assays are limited to the detection 
of three compounds simultaneously. This, coupled with the need to produce new devices 
for each assay may result in high costs associated with fabrication. This assay shares 
similar qualities to the commercially available Gyrolab, which is a completely integrated 
immunoassay system [60]. Here, 10 µL samples are loaded onto a special compact disk 
which, through centrifugal force, is pushed into nano-scale channels containing 
streptavidin-coated bead columns used to trap the immunocomplex. While quantification 
may take place in one hour, this format is limited to serial measurements and has high 
costs associated with specialized instrumentation and a single source of reagents. 
As an alternative to expensive and complicated fabrication processes associated 
with many static immunoassays, a low-cost micro-chip based fluorescent immunoassay 
was presented by Shao et al. for IgG detection [10]. The chip design is composed of four 
X-direction channels and one Y-direction channel to form four designated reaction zones 
(DRZ, Figure 3.4). Areas between the zones were used as negative controls, where no 
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obvious fluorescence was observed. Results show a limit of detection for IgG to be 5 
ng/mL from a 10 µl sample, but this method requires long incubation times. These 
incubation times (1 hour per step) were required because no agitation or mixing 
accompanied reaction steps, which were accomplished by diffusion after the initial 
channel filling. With times comparable to ELISA, this assay requires only one-tenth the 
sample volume to achieve analogous limits of detection. The same design could be used 
for the monitoring of multiple analytes with the possible integration of more DRZs 
without additional technical complexity. 
 
 
Figure 3.4. On-chip immunoassay protocol. Initially flowing coating antibody and 
blocking reagent through channel Y prepares the DRZs for the addition of analyte 
through the independent X channels. A reporting antibody can be delivered to each DRZ 
by addition through the Y channel, producing four independent DRZs, having negative 
controls present in the Y channel between reaction zones. The DRZs are prepared by (A) 
exposing channel Y to a coating antibody and (B) BSA as a blocking agent. (C) After 
sample addition through each X channel, (D) a reporting antibody can be delivered to 
each DRZ by addition through the Y channel. This produces four independent DRZs with 
negative controls present in the Y channel between reaction zones. DRZ: Designated 
reaction zones. 
 
Although detection took place on a static printed array, Lian et al. describe the use 
fluorescent nanoparticles (NP) to produce a NP-labeled microarray [55]. In order to 
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perform a multiplexed assay on the same slide, multiple blocks of capture antibodies 
were printed as subarrays. After incubation and wash steps occurring at room temperature 
as well as at 4°C for long time spans (two hours to overnight), select bioterrorism agents 
could be detected down to 10 pg/mL using 100 µl of sample over the entire array. The 
detection limits here represent roughly 100-fold improvements over fluorescent ELISA 
protocols used previously and require minimal sample use. However, equal or longer 
incubations are necessary which would limit assay throughput and the ability to make 
serial analyses. 
 While most static solid-support assays require long incubation times to complete, 
Li et al. reported on a pre-functionalized PDMS microfluidic chip in an effort to produce 
an ultrafast heterogeneous immunoassay [7]. Using an antigen-antibody reaction time of 
5 minutes, the study found that blocking time had very little effect on the signal-to-noise 
ratio observed. This implies that nonspecific adsorption is reduced by short 
immunoreaction times. Results show a limit of detection for IgG of 600 ng/mL in an 
overall assay time of 19 minutes, while requiring only 10 nl of sample. This assay also 
offered the ability to quantify 5 analytes in parallel on a single chip. This assay boasts the 
advantage of completing analysis six times faster than ELISA using one-tenth the sample 
volume. Since incubation steps are currently defined by diffusion, detection limits may be 
improved by the introduction of agitation during sample reactions. With the ability to 
more sensitively quantify many compounds in parallel using small sample volumes and 
short assay durations, this assay would be competitive with the most optimized formats 
currently employing mobile solid phases. 
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 With an emphasis on assay sensitivity as opposed to rapid quantification, Lee et 
al. presented a sensitive total internal reflection fluorescence microscopy (TIRFM) 
system for the detection of TNF-α on a nanoarray protein chip [17]. Using a homemade 
experimental system, TNF-α was successfully observed at a concentration of 0.13 fg/mL 
using a 50 µl sample. The total assay time took two hours to complete, following the 
preparation of capture protein probe and sample. The assay affords a comparable assay 
duration to ELISA, but employs half the sample. Although it offers a highly sensitive 
assay that could be reasonably adapted to quantify multiple analytes, the assay requires 
sophisticated and specialized equipment. 
While most static support immunoassay systems employ fluorescence detection, 
the Ju group investigated chemiluminescent immunoassay platforms for the near-
simultaneous detection of two analytes, CEA and AFP [61,62]. In the first study a 
modified glass tube with immobilized anti-CEA antibody was incubated with a mixture 
of the two antigens, their HRP-conjugated detection antibodies, and anti-AFP 
immobilized on paramagnetic particles [61]. After immunocomplexes were formed, AFP 
could be separated into an unmodified glass tube. Following separation, near-
simultaneous detection with the aid of an optical shutter could be performed. Results 
show detection limits for CEA and AFP of 0.6 and 0.89 ng/mL from 10 µL of sample, 
with negligible cross-reactivity, respectively. A later study, based on a system of series-
wound immunosensing channels (SWIC), was performed on the same target antigens 
[62]. With a procedure similar to the one reported previously, the immunoassay could be 
completed in 27 minutes using 15 µl of sample. Here, the limits of detection for CEA and 
AFP were reduced to 0.39 and 0.41 ng/mL, respectively. Both assays afford the 
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advantage of reduced assay duration and sample volume while maintaining comparable 
limits of detection to reference methods. 
 Many of the assays discussed in this section require relatively long incubation 
times and moderate sample volumes. These requirements are similar to those for micro-
cantilevers, which offer novel detection modes using elegant physics [63,64]. While 
simple to operate and capable of attaining clinically relevant sensitivities (0.1 ng/mL), 
these methods require long incubations and large sample volumes (100 -200 µL). 
Additionally, due to the detection platform they appear restricted in their ability to adapt 
to a multiplexed format, limiting their practical utility in diagnostic immunoassay 
applications. 
While many of the methods discussed here have long incubation requirements, in 
cases where incubation times may be reduced through agitation or mixing this format 
remains competitive with the on-chip assays utilizing magnetic solid supports. They offer 
the advantage of straightforward multiplexing and sensitive sample quantification, mostly 
without introducing complicated reaction processes or detection systems. While currently 
competitive with mobile solid-support formats these assays rely heavily on detection 
through static fluorescence measurements. This limits their ability to be coupled with 
advanced signal processing mechanisms and may restrict their capacity to quantify target 
compounds at the low end of the physiological range. 
3.5 Concluding Remarks 
 
Looking at the literature over this time span, a large number of publications 
focused on the use of a mobile solid phase, especially those utilizing magnetic micro- or 
nanoparticles. This emphasis evolved from the ease of manipulation through the 
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introduction of magnetic forces that allowed for simple wash steps to be performed 
during the assay. In designs executed entirely on-chip, it also allowed flow conditions to 
be used for sample and reagent introduction, which drastically cuts overall assay time 
requirements. While this group of assays have primarily been evaluated in a single-
analyte format, alterations allowing analysis of multiple compounds in parallel are 
straightforward and would not detract from sensitivity. In terms of attaining a fully 
optimized assay, fully on-chip immunoassays employing magnetic solid supports reduced 
sample size and time requirements while using simple detection methods and maintaining 
ease of use. The sensitivity achieved by methods with long incubation times could 
potentially be reached using convective mixing or slow flow rates to minimize the 
depletion-layer surrounding the solid surface, all while maintaining rapid analysis. To 
tailor assays for clinical use techniques must balance incubation durations and limits of 
detection. In addition, compatibility with the signal processing methods demonstrated to 
improve detection limits to reach superior sensitivity is ideal to and achieve a fully 
optimized micro-immunoassay [4,5,21].
 
 Another broad area of research is that using fluorescent microbeads as a solid 
support, predominantly in the area of FMIA, which has been used successfully to detect 
up to ten analytes simultaneously with clinically acceptable levels of sensitivity. This 
approach is obviously useful, as it provides information about multiple analytes in the 
same sample volume as one traditional assay and could theoretically be used to detect up 
to 100 compounds in a single run. However, its ultimate limitation is the specificity of 
antibodies used, and the cross-reactivity this produces between different targets. This 
could put a practical limitation on the number of compounds quantified simultaneously. 
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Adaptions to testing for different analytes, while entirely possible, will require intensive 
assay development to ensure that singleplex assays for each compound give equivalent 
results to the multiplex assay used diagnostically. Additionally, due to the diffusion-
mediated incubations, long assay durations are required to achieve acceptable limits of 
detection and this format is not readily capable of coupling to sophisticated signal 
processing methods. Nonetheless, in terms of practical immunoassay requirements these 
tests can achieve the required level of multiplex capabilities and offer reasonable limits of 
detection (ng/mL to pg/mL) for most analytes. 
 Finally, the micro-mosaic assays offer the advantage of easy multiplexing and 
simple fabrication. They also produce low limits of detection, although they require 
moderate sample volumes and long incubation times resulting from the diffusion-
mediated sample adsorption required using this format. Similarly, the flow-through 
assays allow simple sample analysis. These assays also produce rapid results using 
moderate sample volumes. However, unlike the micro-mosaic assays they do not lend 
themselves easily to multiplexing.  
3.6 Future Perspectives 
 
 While many of the assay formats described here were successful in improving 
upon one or more of the areas required for developing an optimized clinical test, none 
have been able to fully reach that mark. Today, the same issues challenging 
immunoassays development remain. These issues consist of finding the appropriate 
balance between rapid analysis and sensitivity using techniques capable of coupling to 
signal processing methods, which may enhance detection limits. New techniques, in 
addition to consuming limited quantities of sample, should be currently capable of, or 
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easily adaptable to, multiplexing without the requirement for highly specialized detection 
equipment. While various techniques have their specific advantages, a combination of 
aspects from multiple approaches appears to hold the greatest promise if a truly 
optimized assay is to be found.  
With an increased understanding of reaction principles and conditions leading to 
superior sensitivity, immunoassay techniques continue to improve and progress toward 
optimization. Additionally, the now more familiar process of microfabrication enables the 
realistic implementation of many on-chip methods through large scale photolithographic 
or injection mold production. In this arena techniques will benefit from simple chip 
designs to ensure technical reproducibility. More development on this front over the next 
few years is poised to provide immunoassays well-tailored to their specific needs, which 
may be rapid analysis of samples taken on-site, or the ability to detect minute fluctuations 
in biomarkers over time indicative of disease states.  
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CHAPTER 4 
OFF-CHIP MAGNETIC MICROBEAD IMMUNOASSAY FOR THE 
DETECTION OF MYOGLOBIN, CARDIAC TROPONIN, AND FATTY ACID 
BINDING PROTIEN 
4.1 Introduction 
 
Due to their high sensitivity, biosensors have become a popular diagnostic tool for 
both early and rapid disease detection. Rapid detection is particularly important in cases 
of acute myocardial infarction (AMI) where prompt diagnosis is crucial for patient 
survival. The biomarker targeted by the biosensor is of key importance and the 
characteristics an ideal cardiac marker have recently been defined [1].
 
These include both 
the rapid release of the biomarker into the blood for early detection and prolonged 
elevation for later assessment and confirmation, along with the quantitative assay 
possessing a high clinical sensitivity and specificity. The American College of 
Cardiology (ACC) and the American Heart Association (AHA) currently recognize a 
biomarker panel composed of myoglobin, cardiac troponins (cTnI), and creatine kinase 
MB (CK-MB) for the diagnosis of AMI [2,3]. However, because CK-MB has a low 
sensitivity for AMI within six hours after an incident and cTnI is better at detecting minor 
cardiac damage, it was not evaluated in this study [2]. Instead, heart-type fatty acid 
binding protein (H-FABP) was included due to its early release following cardiac injury 
and potential when used as part of a panel with cTnI [4-7].  
 Myoglobin is an oxygen-binding protein found in both cardiac and striated 
muscle, and is currently used as a routine biomarker for AMI [8,9].
 
Its early release into 
the blood (increasing 1-3 hours within the onset of myocardial necrosis), as well as 
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relatively high plasma reference concentration (34 µg/L) illustrate several of the qualities 
desired in an ideal cardiac marker [9].
 
However, because it may also indicate skeletal 
muscle damage, by itself myoglobin has shown a sensitivity of 75.9%, and a clinical 
specificity of only 25.0% for AMI diagnosis. In recent years H-FABP has also shown 
promise as an early cardiac injury marker in plasma [4,7,10,11].
 
Owing to its lower 
concentration in skeletal muscle compared to myoglobin, rapid release into circulation, 
and potential to predict patient prognosis, H-FABP has received considerable attention 
[5-7,12,13]. Still, due to its release in other medical conditions, H-FABP alone shows 
only a 64% sensitivity [5,14]. While no single marker has shown adequate diagnostic 
accuracy for AMI, a high sensitivity and specificity has been achieved using myoglobin 
and H-FABP as part of a biomarker panel along with cTnI [5,8,10,12,14-16].
 
Even using 
biomarker panels, there still exists a need for more sensitive assays capable of analyzing 
multiple markers in a short time enabling serial measurements to be practically evaluated 
in a clinical setting. This capability would be beneficial not only in the diagnosis of AMI, 
but for the early detection of many diseases which could greatly improve prognosis.  
 Over the last few years a great deal of research has been devoted to the 
development of micro-immunoassay platforms allowing for the sensitive quantitation of 
varied target biomarkers [17-25]. A particularly interesting subset of this research 
incorporates the use of magnetic micro- or nano-particles as the solid surface employed 
for primary antibody fixation and target trapping [26-34].
 
Use of magnetic particles 
permits easy sample manipulation and separation from interfering species, as well as 
straightforward coupling to signal amplification and signal processing. 
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 This work describes the development of a micro-immunoassay platform allowing 
for extremely sensitive quantitation. This system directly and indirectly addresses many 
the six metrics of an optimized immunoassay: increased sensitivity, reduced analysis 
time, reduced cost, lower sample volumes, ability to multiplex and operational simplicity 
[35]. The primary focus of this study is the improvement of quantitative sensitivity for 
the assay platform, and emphasis has been placed on optimizing this feature. However, 
additional metrics are addressed using this protocol, including the requirement for low 
sample volumes and potential to reduce the analysis time. While the studies here are 
performed on an AMI biomarker panel composed of myoglobin, cTnI and H-FABP, this 
format is easily adaptable to the detection of limitless targets and may be incorporated as 
a detection method into a micro-total analysis system (µTAS) for the parallel detection 
and quantification of biomarker panels. 
4.2 Experimental 
 
4.2.1 Myoglobin Detection Antibody Conjugation to Fluorescein-5-EX, Succinimidyl 
Ester 
 
Fifty micrograms (50 µL; 1 mg/mL) of polyclonal rabbit anti-human myoglobin 
reconstituted in DI H2O (LSBio, Seattle, Washington) was added to 50 µL of 1 M sodium 
bicarbonate in a 1.5 mL capped vial. One milligram of fluorescein-5-EX, succinimidyl 
ester (FEXS, Invitrogen) was dissolved in 0.1 mL dimethyl sulfoxide (DMSO) and added 
dropwise to the polyclonal antibody (Pab) solution at room temperature. This was reacted 
in darkness at room temperature for 3 hours on a stir plate (Corning) and then placed at 
4°C to continue the reaction overnight. The crude reaction mixture was added to a 
purification column with a 15,000 Dalton molecular weight cut-off (Invitrogen). The 
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fluorescently labeled antibody was separated on-column from unbound dye using 10 mM 
PBS with 0.15 M NaCl and 0.2 mM NaN3, pH 7.2 and collected in a single fraction. The 
purified FEXS-Pab solution was analyzed for absorbance measurements at 280 and 494 
nm (BioTeck Synergy HT Multi-Mode Microplate Reader). These measurements were 
used to determine the quantity of antibody present and extent of FEXS conjugation [36]. 
4.2.2 cTnI and H-FABP Detection Antibody Conjugation to NHS-Fluorescein 
 
250 μg (250 μL; 1 mg/mL) of polyclonal goat anti-human cTnI and 100 μg (100 
μL; 1 mg/mL) polyclonal rabbit anti-human FABP were used as purchased in PBS buffer 
(cTnI: 0.1% NaN3; FABP: 0.02% NaN3, 0.1% BSA), pH 7.2. NHS-Fluorescein (Thermo 
Scientific) was dissolved in DMSO to a concentration of 10 mg/mL and added dropwise 
to the Pab solutions at room temperature (24 μL and 40 μL, respectively). This was 
reacted in darkness at room temperature for two hours on a shaker (Southwest Science 
LabMini MiniMixer). The crude reaction mixtures were added to dialysis cups (Thermo 
Scientific) with a molecular weight cut-off of 3,500 Daltons. The labeled protein was 
dialyzed in 100 mM PBS with 0.02% NaN3 and 0.1% Tween 20, pH 7.2 overnight. The 
dialyzed NHS-Fluorescein-Pab solutions were analyzed for absorbance measurements 
utilizing the same method as for anti-human myoglobin Pab. 
4.2.3 Preparation of Capture Antibody and Particles 
 
Biotinylated anti-myoglobin Mab (bMab; 100 μL; 1.4 mg/mL; LSBio) was 
incubated with 3 μL of BioMag paramagnetic particles having an average diameter of 1.6 
μm and ranging in diameter from 1.0-2.0 μm (Quagen, Inc.). The total reaction volume 
was diluted to 300 μL with PBS at pH 7.2 containing 5% BSA, 0.1% Tween-20, and 
0.1% NaN3. This was incubated for 3 hours on a shaker (Southwest Science LabMini 
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MiniMixer) at room temperature and then stored at 4°C until used. Biotinylated anti-cTnI 
Mab (50 μL, 2 mg/mL, LSBio) and biotinylated anti-FABP Mab (45 μL, 2.33 mg/mL, 
LSBio) were prepared in the same way. 
4.2.4 Sandwich Immunoassays 
 
Purified human myoglobin (7.33 mg/mL) was purchased from MyBioSource, 
LLC (San Diego, California). Standards ranging in concentration from 0.62 fg/mL to 25 
ng/mL (36 aM to 1.5 nM) were created through serial dilution of the stock myoglobin. 
Following sample preparation 30 µL of each Mb standard was mixed with 30 µL of the 
bMab-BioMag colloid and incubated at room temperature on a shaker for 1 hour. 
Following the incubation, 4 µL of the detection polyclonal antibody-FEXS solution was 
added to each sample and incubated in the dark at room temperature for 1 hour with 
shaking. After the incubation, samples were washed 3 times using 60 µL of PBS buffer 
and then exchanged to a final volume of 30 µL. Three separate 10 μL droplets were 
analyzed for each sample, with a total of ten analyses performed for each concentration. 
Purified human cTnI (1.07 mg/mL) and H-FABP (2.2 mg/mL) were purchased from Life 
Diagnostics (West Chester, Pennsylvania). Standards ranging in concentration from 10 
fg/mL to 10 ng/mL (0.42 fM to 0.42 nM) for cTnI and from 1 fg/mL to 10 ng/mL (67 aM 
to 0.67 nM) for H-FABP through serial dilution of the initial stock solutions. Following 
sample preparation samples were prepared and analyzed in the same way as myoglobin.  
4.2.5 Data Collection 
 
Data were collected using an Olympus IX70 inverted microscope with a charge 
coupled device (CCD) camera connected to a computer capable of image-capture (Q-
Imaging, Surrey, BC). Capture settings for the CCD camera were optimized for the 
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observation of strong fluorescent signal clusters with minimal contribution from 
background pixels through studies utilizing biotinylated fluorescein (Sigma-Aldrich) as a 
positive control. Biotinylated fluorescein was chosen as a control due to the strong 
binding relationship between biotin and the streptavidin on the BioMag particles and a 
common fluorophore with the experimental immunoassays. Offset was adjusted to 
minimize background of a washed sample without reducing pixel intensity from signal, 
values between −1120 to 440 were tested. With the offset held constant at 100, gain 
values between 4.7 to 15.0 were explored to maximize the sensitivity of the assay without 
compromising the dynamic range. Optimal image quality was observed at an offset of 
100 and gain of 13.8. Once established, capture settings were held constant for all 
experiments performed on cardiac targets. 
Multiple 10 µL-sized droplets were analyzed for each sample concentration using 
a microscope slide having a small hydrophilic zone encompassed by a hydrophobic 
Teflon coating (Tekdon Inc., Myakka City, Florida). A cylindrical rare earth magnet (2.5 
cm diameter, 0.3 cm thick) placed 2 cm above the droplet was used to generate the 
magnetic field (Magcraft, Vienna, VA) and collect structures for ~30s. Supraparticle 
structures approximately 15 µm in length were observed. The magnet was secured to a 
DC motor by a 7 cm metal shaft allowing for rotation and controlled via a USB 4-motor 
stepper controller (Trossen Robotics). The controller was connected to the motor through 
a ribbon wire to protect it from fluids used during the experiment. The magnet was 
rotated at a constant velocity during assays (30 rpm), and illumination from a mercury 
lamp (Olympus) was passed through the appropriate filter cube and a LCPlanFl 40X/0.60 
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objective to excite the assay. Emitted fluorescence was collected using the QIACAM 
FAST cooled Mono 12-bit (QImaging) CCD camera and stored as video files. 
4.2.6 Data Analysis 
 
Video was analyzed using Image J (National Institute of Health, Bethesda, 
Maryland). The images (492 x 396) were captured at an exposure time of ~120 ms (gain, 
13.8; offset, 100) which translates to a rate of  ~12 frames/s. Fluorescence intensity 
measurements were collected by manually selecting all rotors (areas of interest, ROI) 
within a video frame and summing the fluorescence intensity. This was performed for ten 
randomized frames per video and the resulting intensities were averaged to attain a single 
average fluorescence intensity value for a given trial. Ten trials per sample concentration 
were averaged per experiment. 
4.3 Results and Discussion 
 
4.3.1 Assay Optimization and Protein Detection 
 
Three human cardiac biomarkers, myoglobin, cTnI, and H-FABP, were quantified 
using a singleplex immunoassay detection system. Proteins were detected by adjusting 
the hardware settings such that images with visible, yet unsaturated, signal clusters with 
minimal background contribution were captured. Using an exposure time of 120 ms, 
signals generated from low concentrations of proteins (down to 36 aM of myoglobin) 
were detected above the background intensity (Figure 4.1).  
Control experiments were performed at a zero antigen concentration, exposing 
paramagnetic particles with immobilized capture antibody to fluorescently-labeled 
detection antibody. Dark structures resulted, with minimal diffuse fluorescence 
suggesting that little or no nonspecific binding is present. The average fluorescence 
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intensity of the entire image was noted (including pixels from all areas, including diffuse 
fluorescence between rotors) since distinct signal clusters were not visible. This is a more 
stringent test for background quantification, since the noise from all pixels is included.  
At low sample concentrations, below 360 aM for myoglobin, the signal becomes 
highly variable and the uncertainty in the measurements was greater than 10%. When the 
uncertainty in a measurement falls below 10% the signal may not only be detected, but 
quantified with a reasonable level of certainty [37]. This distinction is important as it 
differentiates a qualitative positive result from the ability to distinguish when a biomarker 
is present in concentrations that correspond to diagnostic cut-off values. For the 
optimization of a clinical assay it is the quantitation limit that is of interest. 
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Figure 4.1 (A and B) Images showing fluorescence of high sensitivity immunoassays at 
the detection limit (below the limit of quantification) for 36 aM myoglobin (B) compared 
to background (A). (C and D) Surface plots illustrating the difference in fluorescence 
intensity between background (zero concentration, C) and signal clusters representing 
specific signal (36 aM myoglobin, D). While the signal clusters are not as distinct as 
those observed for higher target concentrations, this represents the lower limit detectable 
above zero concentration. 
 
4.3.2 Quantitation Limit 
 
Measurements of cardiac targets permitted the quantitation of myoglobin to a 
minimal concentration of 360 ± 2.5 aM with an observed detection limit of 36 ± 2.5 aM, 
and a linear standard curve from 360 aM to 14 fM (R
2
 = 0.996; Fig. 2A). H-FABP and 
cTnI were quantified to limits of 67 ± 3 fM and 42 ± 0.01 fM, with linear standard curves 
from 67 fM to 67 pM and 42 fM to 42 pM, respectively (R
2
 = 0.998; Fig. 2B and R
2
 = 1; 
Fig. 2C). The optimized collection of the video sets allowed for improvement in detection 
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over several orders of magnitude compared to previously collected myoglobin data, from 
50 pM to 36 aM (Table 4.1) [30]. The limits of quantitation observed in the present work 
compare favorably to the metrics of a fully optimized immunoassay, achieving detection 
on the same order of magnitude as fundamental limitations. At low numbers of 
molecules, quantification becomes impossible due to Poisson statistics [37].
 
While targets 
may be observed below this limit, they may not be quantified due to high levels of 
uncertainty in the measurements made.  
 Previous 
Studies30 
Commercial 
Techniques38,39 
Present 
Work 
Optimized 
Values 
Plasma 
Concentration40 
Myoglobin 50 pM
 
1.5 nM 360 ±2.5 
aM 
33 aM 2.5 nM 
H-FABP -- 6.7 pM 67 ± 3 
fM 
33 aM 110 pM 
cTnI -- 83 pM 42 ± 
0.01 fM 
33 aM 62.5 pM 
Table 4.1 Quantitation limits for immunoassay techniques. Optimized values represent 
the limit to immunoassay quantitation in a 10 μL sample volume. 
 
 Several differences exist in both the data acquisition and data analysis performed 
in this work that account for the observed improvement in quantitation ability compared 
to previous studies [30]. In terms of data acquisition, previous work noted differences in 
signal strength depending on their location in the field of view, increasing variation in 
both signal and noise. The changes to optics and acquisition conditions eliminated this 
issue, producing rotors with similar signal intensities independent of their location. 
Optimizing acquisition conditions through control studies with b-Fluorescein resulted in 
an increase in exposure time from 50 to 120 ms, as well as reductions in gain (from 2000 
to 13.8) and offset (from 2600 to 100) [30]. The increase in exposure time still allowed 
clear visualization of rotor rotation while reducing the impact on noise compared with a 
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shorter exposure. With a lowered gain, the amplification of the image collected by the 
CCD camera is reduced. Since both the signal and noise are reduced, this lowered value 
will improve the signal-to-noise ratio (S/N) and reduce the background intensity and 
noise while specific signal remains visible. By contrast, reducing the offset allows lower 
intensity values for both specific signal and background fluorescence to be captured. 
While this increases both the background intensity and noise as well as signal intensity 
and noise, this minimal value assures that clusters from low signal concentrations may be 
observed. By improving the signal-to-noise ratio of the captured video files lower 
intensity signals may be differentiated from background noise, improving assay 
sensitivity.  
Along with the changes made to data acquisition conditions, the process of data 
analysis has also been altered to increase the signal power obtained from each sample 
[30]. In previous work a small region of each image (150 x 120 pixels), containing 
roughly two of the 10-15 signal clusters present overall, was analyzed. Additionally, 
while signal clusters contributed to less than 30% of the region selected, the average pixel 
intensity was calculated for the entire selected area, including both signal and noise [41]. 
Signal processing studies performed on this data conclude that by calculating pixel 
intensity for the entire image selection, and by only two of the signal clusters contributing 
to target quantification, a large portion of the signal power is lost while the noise power is 
increased [41]. By manually segmenting data and selecting all rotors in each frame (492 x 
396 pixels) as was done in this work, both issues observed with previous analysis 
methods are solved. The overall noise power is reduced while signal power is increased 
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[41]. This, coupled to the increase in S/N through optimal data acquisition conditions, 
allowed for a five-fold improvement in assay sensitivity.  
In terms of the mass action equilibrium and detection, sensitivity is maximized by 
using an excess of both primary and secondary antibodies, and heavy labeling of 
secondary antibodies (average among all targets of 4 labels per antibody). Given that the 
paramagnetic particles have a binding capacity of 8.2 nmol/mL (manufacturer 
specifications), the binding capacity for the primary antibody preparation is 82 nM. Using 
fundamental relationships from basic immunology the equilibrium reaction between the 
protein and primary antibody can be described as 
 
𝐾𝑒𝑞 =  
[𝐴𝑔𝐴𝑏1]
[𝐴𝑔][𝐴𝑏1]
  (4.1) 
 
where [AgAb1] is the concentration of bound antigen, [Ag] is the concentration of 
antigen, [Ab1] is the concentration of primary antibody, and Keq is the equilibrium 
constant. Given a Keq of 10
9
 M
-1
, the equilibrium concentration of bound antigen for a 
myoglobin sample at a concentration of 3.6 fM is 0.3 pM, about one hundred times the 
concentration of target present. A similar calculation can be performed for the reaction of 
bound antigen with secondary antibody, giving an equilibrium concentration of [AgAb2] 
in the nM range. With these experimental conditions it can be determined that nearly all 
antigen is bound in the sandwich immunoassay, resulting in a linear response for the 
portion of the sigmoidal immunoassay curve examined.  
 At myoglobin concentrations below 360 aM, uncertainty is too high in the 
measurement achieve satisfactory quantitation. Although the lowest concentrations 
detected could not be quantified due to high variations in signal, the potential exists to 
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improve quantitative sensitivity through coupling to available signal processing 
approaches [41]. Using this approach, the detection limit of previously published data has 
been improved by a factor of 100. If the same factor of improvement and reduction in 
uncertainty for a given sample was realized for the data collected in this work, 
quantitation of the lowest sample data collected would be possible. 
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Figure 4.2 Standard curves showing fluorescence intensity data for the sandwich 
immunoassays performed on cardiac biomarker targets. a. Plot showing the quantitation 
of Myoglobin down to a minimal concentration of 360 aM. Inset shows the linear range 
to 14.7 fM. b. Plot showing the quantitation of h-FABP to a minimal concentration of 67 
fM with inset showing the linear range to 67 pM.  c. Plot showing the quantitation of 
cTnI to a minimal concentration of 42 fM with inset showing the linear range to 42 pM. 
 
Repeated experiments exhibit a similar result. Figure 3 shows the average 
fluorescence intensity of data collected from four separate experiments with independent 
dilutions of a myoglobin stock sample. Error bars show the standard deviation of each 
data set. Differences in overall fluorescence intensity were observed between 
experiments, due to aging of the mercury lamp used to illuminate samples. Even when 
differences in fluorescence intensity were observed between days, the same linear 
relationship was observed. 
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Figure 4.3 Standard curve showing the average fluorescence intensity versus 
concentration for the myoglobin sandwich immunoassay for four different experiments 
using the target protein. The inset shows the lower concentrations on the standard curve, 
error bars represent the standard deviation among data sets. Fluorescence intensity has 
been normalized to the background intensity (zero concentration) for each data set. 
 
4.3.3 Assay Evaluation 
 
As has been noted previously, in static immunoassays background fluorescence is 
a serious concern that limits the ability to differentiate specific signal from noise. Signal 
processing strategies offer the potential to improve detection limits through the 
identification of specific signal generating surfaces and reduction of background elements 
to reduce the variation observed in signal intensity for low concentration samples [41]. 
Surface localization is of use in image processing because it creates distinct signal objects 
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that are easier to detect and quantify compared to signal spread over the entire field of 
view. Creating these distinct signal objects allows for segmentation of collected images 
and the quantitation of fluorescent species bound in the immunoassay without the 
influence of diffuse background fluorescence.  
The potential to optimize quantitation capabilities also exists through the use of 
new signal input patterns. Lock-in amplification is a commonly employed method to 
recognize a specific input signal in the presence of noise [42]. This method allows an 
input signal modulated in amplitude to be matched to a reference signal with the same 
periodicity and amplified while background noise is not recognized and is effectively 
removed. It has been used in previous work to achieve detection limits in the pM range 
[30,32]. However, because the reference signal generated by lock-in amplification is a 
sine wave, its correlation with the input wave is imperfect and signal power is lost. This 
has been addressed in part by the development of a new signal processing method that 
maintains the input signal modulation but uses a new waveform as the reference signal 
[37]. While this approach was successful in improving quantitation, using autocorrelation 
analysis to recognize more complicated input patterns could improve the distinction 
between signal and noise and increase the slope of the regression line at low sample 
concentrations.  
Other immunoassay techniques have worked on improving quantitative sensitivity 
for protein targets [17,23-25,33,34]. Compared to those studies that were performed 
using traditional laboratory equipment [23-25,33,34], the assay investigated in this work 
achieved superior sensitivity (aM to fM range compared with typical nM sensitivity) 
using shorter incubation times. Incubation times could potentially be reduced further for 
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this assay as the dispersed magnetic microbead surface offers an advantage during 
analyte capture. Unlike static assay surfaces that are subject to depletion zones and 
relaiant on diffusion for target capture, the solid microbead surface is constantly in 
motion throughout incubations. Another study discussed the development of a microchip-
based immunoassay for cTnI detection [17]. Movement to the chip format allowed for 
shorter analysis times and easy adaptability to portable devices and multiplexed analysis. 
While offering an improvement over this work in terms of analysis time, the sensitivity 
achieved in this work was superior (fM compared with pM) using a comparable sample 
volume.  
 Many studies have reported on the improved sensitivity of cardiac diagnostic 
ability with the use of a biomarker panel as opposed to a single target [5,8,10,12,14-16]. 
One consequence of this is that parallel detection of targets from a single sample is 
desirable. Along with the potential to optimize this immunoassay platform for sensitive 
analyte quantitation, the use of magnetic microparticles offers the ability to move from 
the batch incubation assay conducted within this work to one performed on a microchip 
as part of a total sample analysis system. Easy manipulation of the magnetic solid surface 
through an applied magnetic field allows for the containment of surfaces functionalized 
for the capture of different targets in separate regions of the microchip. Following target 
isolation on chip through separation science techniques, individual species may be 
flushed into appropriate detection chambers and quantified. The linear range of this 
technique may also be extended through the dilution of samples investigated, or use of 
smaller sample volumes, allowing the assay to be tailored to meet detection needs as 
required for diagnostic or disease monitoring purposes. 
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4.4 Concluding Remarks 
 
Dispersed magnetic beads were utilized in a batch incubation format to conduct 
sandwich immunoassays on three cardiac biomarker targets. Following sample 
preparation 10 μL droplets were manipulated through variations in an applied magnetic 
field, and the periodic change in observed fluorescence was captured as a video file. 
Analysis of video utilizing ImageJ allowed the superior detection of myoglobin (360 
aM), H-FABP (67 fM) and cTnI (42 fM) compared to previous results.  
 Thus, a magnetic bead immunoassay platform was demonstrated utilizing simple 
batch incubation and a modified microscope slide. This platform has the potential to be 
incorporated into a full sample analysis chip as a quantification method for biomarker 
panels while maintaining sensitive detection capabilities, and offers the ability to couple 
results to more sophisticated signal processing approaches for the detection of low 
sample concentrations independently from background noise. In its current form this 
system directly addresses many of the six metrics of an optimized immunoassay. 
Incorporation of the assay into a μTAS could further these efforts by affording the ability 
to multiplex and further reduce analysis times while maintaining the high sensitivity, low 
sample volume, and operational simplicity achieved herein. Doing so has the potential to 
produce a platform optimized for the diagnosis of myocardial infarction in emergency 
rooms as previously defined: sensitivity allowing quantification of samples below the pM 
range using fingerprick blood and the ability to quantify 3 targets simultaneously in under 
30 minutes without the requirement for expensive, complicated or bulky instrumentation. 
Not only could these advances produce a testing platform tailored to emergency 
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diagnostics, but reaching immunoassay optimization of all six metrics would allow the 
application of this technique to other biological and medical issues. 
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CHAPTER 5 
THEORETICAL LIMITATIONS OF QUANTIFICATON FOR 
NONCOMPETITIVE IMMUNOASSAYS 
5.1 Introduction 
Immunoassays are invaluable tools for the detection and quantification of 
important biomolecules and many other chemical compounds at low concentrations. 
Antibodies bind to target structures with large binding constants, which enable selective 
detection at low analyte concentrations. Since immunoassays were first introduced, 
attempts to optimize the assay process have persistently focused on improving the limit 
of detection (LOD) [1,2]. This focus on low LOD’s has been stimulated largely by the 
desire for earlier therapeutic intervention through the detection of diagnostic markers at 
lower concentrations or from smaller volumes [3]. Over the years these efforts have 
resulted in the shift away from radioimmunoassays to enzyme-linked immunosorbent 
assays [4,5], and in the exploration of signal amplification approaches to improve 
detection of antibody-antigen binding [6-18].  
The LOD is an important figure of merit for determining an immunoassay’s 
quality and is frequently used to compare competing methods [19,20]. The term, LOD, is 
often used interchangeably in the immunoassay literature with the limit of quantification 
(LOQ), causing some confusion as to the reported capabilities of different assays [21-23]. 
As defined by Currie in 1968, the LOD corresponds to the presence of any detectable 
signal from the specific instrumental configuration that can be assigned to the target 
under study. The LOD is used as a demarcation of the presence or absence of an analyte 
(the Ld term in reference) and has high quantitative uncertainty at low sampling numbers 
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(reaching 100%), which undermines its use as an indicator of presence/absence. The 
LOQ is the level at which measurements have sufficient precision for quantitative 
determination [23]. The distinction between LOD and LOQ highlights that while single 
molecule immunoassays can detect the presence of one (or very few) putative signal 
generating molecules, detection at this level is highly qualitative. For immunoassays 
aimed at the quantification of minute amounts of proteins indicative of disease states, 
detection near the LOD is not adequate. Therefore, it is necessary to define the true LOQ 
for an immunoassay in terms of a statistical assessment and not instrumental factors. 
The LOD for most immunoassays has been limited primarily by the signal-to-
noise ratio provided by the instrument used to detect antibody-antigen binding or by 
nonspecific binding (NSB) [24,25]. With improving detection technology capable of 
routine single molecule detection, the instrumentation to detect antibody-antigen binding 
is no longer a fundamental factor that defines LOD’s for immunoassays. It is well known 
that NSB often limits the LOD for immunoassays [19,26-31];
 
however, if an 
immunoassay method is optimized to reduce NSB to insignificant levels, the LOD that 
can be obtained with an immunoassay are then limited by antibody-antigen binding and 
fundamental statistical limitations. 
Detection of a single molecule is an irresistible objective for analytical chemists. 
Recently, so-called ‘single molecule immunoassay’ techniques have been introduced [26-
28]. Much of this work demonstrates the detection of individual signals associated with 
distinct putative binding events, but detection limits do not approach single molecule for 
the antigen [26-28].
 
These techniques have relied on the use of chemically-linked 
fluorophores to secondary (or tertiary) antibodies with detection schemes able to sense a 
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single fluorphore (or activity of a single enzyme). The signals from the individual 
counting of presumed immune complexes are averaged, summed or provided other data-
processing mechanisms to generate an estimate of antigen concentration. These studies, 
while counting distinct signals assumed to be individual immune complexes, required the 
averaging of many individual signals to produce a quantitative measurement with a 
satisfactory coefficient of variation (<10%) [32,33]. The requirement for averaging many 
individual signals demonstrates that while singular complexes have been, in fact, detected 
using immunoassay techniques, the certainty with which they are detected is not 
sufficient for quantification of an analyte. Therefore, the true limits of quantification lie 
at higher levels than a single molecule. For any analytical immunoassay measurements 
approaching single antigen molecule detection, the LOD is ultimately bound by 
‘molecular’ shot noise – the absolute floor of the limit of detection, which is a statistical 
sampling effect that follows a Poisson distribution [34]. 
In this work, relationships based on the law of mass action are used to model the 
theoretical limit of quantification for immunoassays. Most commercial immunoassay 
methods currently use P4-P5 fittings (four or five parameter mathematical fittings of 
resulting sigmoidal curves with no connection to fundamental interactions) to model the 
sigmoidal immunoassay response curves for quantitative analysis because of the 
difficulty of implementing theoretical models based on the law of mass action with many 
parameters [35]. These P4-P5 fittings are useful for practical quantitative analysis with 
immunoassays, but they cannot be used to explore the fundamental limit of quantification 
for immunoassays. The focus of this work is the ultimate limitations of immunoassays, 
mostly centered on molecular shot noise. However, without comparing and contrasting 
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this limit with other effects, it cannot be put in proper context. The LOQ for 
immunoassays is considered using theoretical models based on the law of mass action for 
three situations: when the limit of quantification is defined by 1) instrumental limitations, 
2) non-specific binding—the most common case, and 3) conditions where statistical 
sampling theory is the only limit, so-called molecular shot noise. 
5.2 Theory 
 
5.2.1 Fundamental Relationships 
 
Using equations from basic immunology and describing reaction schemes 
according to the law of mass action, the first incubation in the sandwich-type 
immunoassay (Figure 5.1) can be described by 
𝐾1𝑒𝑞 =  
[𝐴𝑏1𝐴𝑔]
[𝐴𝑏1][𝐴𝑔]
                (5.1) 
 
where K1eq is the equilibrium association constant (antibody affinity, M
-1
) for the capture 
antibody, [Ag] is the concentration of free antigen (M), [Ab1] is the concentration of 
unbound capture antibody (M), and [Ab1Ag] is the concentration of the antibody-antigen 
complex formed during the reaction (M) [36]. Modeling the reaction this way requires 
several assumptions to be made: (i) the interaction of antigen and antibody can be 
described using a single equilibrium constant, (ii) binding of antibody to a solid surface 
(or fluorophore or enzyme) doesn’t affect binding characteristics, and (iii) wash steps 
separating bound and free antigen don’t disturb the equilibrium reached [36]. 
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Figure 5.1 Schematic of the sandwich immunoassay format. A) The primary antibody 
([Ab1]) is bound to a solid support forming a reaction capture area. B) The target analyte 
([Ag]) is incubated with the primary antibody and captured to the surface (forming 
[Ab1Ag] which is equivalent to [Ag2]). After washing to remove any unbound species in 
the sample volume, C) incubation with the secondary detection antibody ([Ab2]) and 
removal of the unbound antibody allows detection of a signal and quantification of the 
bound analyte ([Ab2Ag2]). 
 
 Given that [Ab1tot] is the total concentration of capture antibody, then 
 
[𝐴𝑏1] = [𝐴𝑏1𝑡𝑜𝑡] − [𝐴𝑏1𝐴𝑔]                                    (5.2) 
 
From Equation 5.2 we can write 
 
[𝐴𝑏1𝐴𝑔] = 𝐾1𝑒𝑞[𝐴𝑔]{[𝐴𝑏1𝑡𝑜𝑡] − [𝐴𝑏1𝐴𝑔]}            (5.3) 
 
which can be simplified to [36,37]:  
 
[𝐴𝑏1𝐴𝑔] =  
𝐾1𝑒𝑞[𝐴𝑏1𝑡𝑜𝑡][𝐴𝑔]
(1 + 𝐾1𝑒𝑞[𝐴𝑔])
  .                              (5.4) 
 
A plot of [Ab1Ag] with respect to log [Ag] is sigmoidal (Equation 5.4, Figure 5.2), with 
very low [Ag] concentrations producing linear changes in [Ab1Ag] (Figure 5.2 inset). The 
shape of the curves can be trivially understood by noting that 1 + 𝐾1𝑒𝑞[𝐴𝑔] ≅ 1 when 
  129 
[Ag] is small, thus making eq. 5.4 a linear relationship and when [Ag] is very large 
1 + 𝐾1𝑒𝑞[𝐴𝑔] ≅ 𝐾1𝑒𝑞[𝐴𝑔] and the relationship becomes concentration independent. 
 
Figure 5.2. Log plot showing the concentration of antigen (log[Ag]) bound ([Ab1Ag]) to 
primary antibody from a sample across approximately seventeen orders of magnitude 
(equation 5.4). This response is a typical sigmoidal-shaped response from the laws of 
mass action, which is commonly interpreted with four and five parameter sigmoidal 
fitting models (P4, P5) disconnected from core equilibrium relationships. Inset: 
Concentration of bound antigen ([Ab1Ag]) to primary antibody at low numbers of 
antigens ([Ag]), from single molecule to 600 molecules in 50 microliters (30 zeptomolar 
to 20 attomolar). Note that across these low concentrations the relationship is linear 
(inset).  
 
5.2.2 Second Equilibrium, Completion of the Sandwich Assay 
 
For the second step of the sandwich assay, where the detection antibody (labeled 
appropriately) is introduced, the final complex from step one [Ab1Ag] becomes the target 
antigen for step two. Therefore the bound antigen concentration [Ab1Ag] is set equal to 
the antigen concentration [Ag2] as the target of the second incubation. Maintaining the 
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assumptions outlined during the first incubation process, and going through the same 
algebraic strategy, from equation 5.4, the amount of antigen present in the second 
incubation ([Ag2]) is equal to the amount bound to the primary antibody in the first 
incubation ([AgAb1]). 
[𝐴𝑔𝐴𝑏1] =  
𝐾1𝑒𝑞[𝐴𝑏1𝑡𝑜𝑡][𝐴𝑔]
(1+ 𝐾1𝑒𝑞[𝐴𝑔])
 = [𝐴𝑔2]     5.5 
 
From basic immunology equations, the equilibrium constant for the second incubation 
(K2eq) is given in the same format as that for the first incubation (K1eq). 
 
𝐾2𝑒𝑞 =
[𝐴𝑔2𝐴𝑏2]
[𝐴𝑔2][𝐴𝑏2]
       5.6 
 
 
Given that 
 
𝐴𝑏2 = [𝐴𝑏2𝑇𝑂𝑇] − [𝐴𝑔2𝐴𝑏2]      5.7 
 
we can write 
 
[𝐴𝑔2𝐴𝑏2] =  𝐾2𝑒𝑞[𝐴𝑔2][𝐴𝑏2𝑇𝑂𝑇 − 𝐴𝑔2𝐴𝑏2]   5.8 
 
which simplifies to  
 
[𝐴𝑔2𝐴𝑏2] =  
𝐾2𝑒𝑞[𝐴𝑏2𝑇𝑂𝑇][𝐴𝑔2]
(1+𝐾2𝑒𝑞[𝐴𝑔2]
      5.9 
 
Substitution of equation 5.6 results in the concentration of the signal generating species 
[Ab2Ag2] (M) to be given by 
 
[𝐴𝑔2𝐴𝑏2] =  
𝐾2𝑒𝑞[𝐴𝑏2(𝑡𝑜𝑡)]
𝐾1𝑒𝑞[𝐴𝑏1𝑡𝑜𝑡][𝐴𝑔]
(1 + 𝐾1𝑒𝑞[𝐴𝑔])
(1 + 𝐾2𝑒𝑞
𝐾1𝑒𝑞[𝐴𝑏1𝑡𝑜𝑡][𝐴𝑔]
(1 + 𝐾1𝑒𝑞[𝐴𝑔])
)
              (5.10) 
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where K2eq is the equilibrium association constant (antibody affinity, M
-1
) for the 
detection antibody, and [Ab2tot] is the total concentration of the secondary antibody (M).  
5.2.3 Single Molecule Detection and Fundamental Sources of Noise 
 
Regardless of the detection modality, issues of signal-to-noise, bias and variance 
can be generalized for any system that has the appropriate conditions to sense the 
presence of a signal-generating species consistent with a single molecule. Each system 
will generate a characteristic bias, variance and sensitivity (amplification). To attain 
‘single molecule sensitivity’ (ISM), a signal strength more than to six times the standard 
deviation () of the noise (ISM>6noise) above the Ibl is considered to be unequivocal 
evidence of distinct signal above noise, generating a 99.73% probability that it 
statistically represents a positive result (a single molecule is present) if a normal 
distribution is assumed [38]. To generalize this assessment and examine the best case 
scenario, the only noise considered is Johnson-Nyquist; an unavoidable fundamental 
source of noise for all instrumentation [39-41]. Additional fundamental sources of noise 
(flicker, shot, etc.) can be added to this by summing bias (as expressed by intensity, I, 
(equal to Inoise)) and variance (variance is the square of the standard deviation (
2
), 
equal to 2noise). Other sources of instrumental bias and variance (dark current, 
environmental noise, etc.) can be similarly summed, the specific values depending on the 
details of the specific system. The baseline intensity (bias, Ibl), in the case of Johnson-
Nyquist noise, defines the variance, bl
2
, by  
𝜎𝑏𝑙
2 =  √2𝑞𝐼𝑏𝑙∆𝑓                                            (5.11) 
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Where q is the charge of an electron, and Δf is the bandwidth (in Hz). Variance also 
increases with signal intensity, Is, with the same function, but it is added separately: 
𝜎𝑠
2 =  √2𝑞𝐼𝑠∆𝑓.  
5.2.4 Instrumental Background and Noise 
 
There is a broad range of conditions where the relatively high instrument 
intensity, Ibl (and the resulting variance, 𝜎bl
2 ), or low amplification () defines the limit of 
detection. Either the amplification can be insufficient or the instrumental bias and 
variance may be too high. Whichever effect is the cause, the result is the same. Under 
these conditions the limit of detection is set at Is > 3bl, per standard analytical 
assessment.  
5.2.5 Non-Specific Binding 
 
Non-specific binding can influence the LOQ through one of two forms: those 
arising from the binding of antigen directly to the solid assay surface (and subsequently 
binding the signaling antibody) and signal antibody binding to the surface independent of 
the antigen. This source of noise will also have characteristic intensity (bias, INSB) and 
variance (2NSB) defined as in equation 5.11. In addition, for very low numbers of 
molecular interactions, this form of noise can also add molecular shot noise (a minor, rare 
situation—not considered further).  
The sum of the sources of noise and background (Esystem) in any system gives the 
relationship 
𝐸𝑠𝑦𝑠𝑡𝑒𝑚 =  𝐼𝑏𝑙 + 𝐼𝑁𝑆𝐵 + √𝜎𝑏𝑙
2 + 𝜎𝑁𝑆𝐵
2 + 𝜎𝑠2           (5.12) 
 
  133 
where 𝐼𝑏𝑙 and 𝜎𝑏𝑙
2  are empirically defined functions of the instrumentation used, and 𝐼𝑁𝑆𝐵, 
𝜎𝑁𝑆𝐵
2 , and 𝜎𝑠
2 are a function of the amplification and binding properties of a system.  
5.2.6 Molecular Shot Noise 
 
In an ideal case where instrument noise is minimized and NSB is eliminated, the 
LOQ is set by Poisson noise (molecular shot noise). This limit arises from the fact that 
biomolecules are discrete entities and their binding is of a quantum nature, which 
produces an unavoidable source of error in any detection system, a fundamental signal-
to-noise boundary for any assessment. This adds to the variance according to [34]: 
 
𝜎𝐴
𝑛𝐴
=
1
√𝑛𝐴
  .                                    (5.13) 
 
This source of error follows a Poisson statistical distribution for a small number of targets 
where σA is the standard deviation (variance is σA
2
) of the number of molecular 
signatures detected (nA). When NSB and extraneous sources of fluorescent signal are 
eliminated, the molecular signature is only from the actual number of antigen molecules 
detected. Improvement in the precision of sampling dilute targets requires the generation 
and averaging of multiple unique samples, since strongly fluorescent signals from non-
antigen specific events may significantly impact the background sampling noise [34]. 
This sampling statistical effect is different from statistical fluctuations in signal 
(variance), and represents an intrinsic limit on detection capabilities for a liquid-phase 
immunoassay (Figure 5.3). This source of error is beyond and separate from the 
instrumental sources of background (bias) and noise (variance). The sum of the error in 
any system may be described as:  
   𝐸𝑇𝑂𝑇 = 𝐸𝑀𝑆𝑁 +
𝐸𝑠𝑦𝑠𝑡𝑒𝑚
𝐼𝑇𝑂𝑇
                            (5.14) 
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where EMSN is error associated with molecular shot noise and ITOT is the total fluorescence 
intensity detected. Percent error (or uncertainty), Epercent, is defined: 
       𝐸𝑝𝑒𝑟𝑐𝑒𝑛𝑡 = 𝐸𝑇𝑂𝑇 ∗ 100 = (
1
√𝑁𝐴
+
𝐼𝑏𝑙+ √𝜎𝑠
2+𝜎𝑏𝑙
2
𝜉[𝐴𝑔]+𝐼𝑏𝑙+ √𝜎𝑠
2+𝜎𝑏𝑙
2
) ∗ 100  (5.15) 
 
5.3 Results 
 
The immunoassay signal response was calculated for assays detecting between 1 
and 6.7x10
4 
molecules (between 33 zM and 2.2 fM in a 50 µL sample volume). 
Equilibrium constants were fixed for both K1eq and K2eq at 1.0 x 10
9
 M
-1
 to model levels 
typical of monoclonal antibodies [43,44]. Calculations included elements for instrument 
bias (background) and variance (noise), non-specific binding, and molecular shot noise. 
These calculations were used to examine the LODs and LOQs for the three limiting 
conditions for an immunoassay. 
To understand the limits on quantification for immunoassay, three domains are 
identified, which allow for direct comparison with the ultimate MSN limits. Depending 
on which source of noise dominates, each imposes limitations on assay quantitation under 
differing conditions (Table 5.1). 
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Limiting Factor Criteria Assay Limit of 
Quantitation 
Type of Assay 
Instrument 
background noise 
𝐼𝑆𝑀
(6𝜎𝑏𝑙 + 𝐼𝑏𝑙)
< 1 
11,000 molecules 
(0.36 fM) 
Traditional laboratory 
assays 
Non-specific 
binding noise 
𝐼𝑁𝑆𝐵is present ~150 molecules 
and up (5 aM) 
Traditional laboratory 
assays 
Molecular shot 
noise 
𝐼𝑆𝑀 > 6𝜎𝑏𝑙 + 𝐼𝑏𝑙 ~131 molecules 
(3.7 aM) 
Optimized high-
sensitivity assay 
Table 5.1 shows the limitations of assays based on the type of noise that is responsible 
for limiting quantitation. When one source of noise is minimized or eliminated 
quantitation becomes more sensitive until reaching a finite statistical limitation bound by 
error (uncertainty) due to molecular shot noise. Concentrations are reported for a sample 
volume of 50 μL. 
 
Table 5.1, along with equation 5.14 (and equation 5.12), demonstrates that 
different factors can dominate the noise observed in assays depending on experimental 
conditions. If insensitive or noisy detection instrumentation is used, the background from 
these machines will dictate the minimum amount of sample that can successfully be 
quantified. If those limitations are overcome with the incorporation of sensitive detection 
equipment, assays are typically limited to quantitation in the nano- to picomolar range by 
NSB effects. NSB creates a minimal background signal that is detected under an assay 
format without sample present and limits the minimal quantitation that can take place. 
While it is observed that overall noise increases as signal size increases, the intensity of 
the noise compared to the intensity of the signal becomes proportionately smaller, 
resulting in a smaller coefficient of variation (CV) and a greater ability to quantitate the 
population of specific analytes present.  
 Since MSN limitations are observed under ideal assay conditions and represent a 
best case scenario, the impact of MSN on the LOQ is addressed first. Following this, 
influences from NSB and instrumental background, sources of uncertainty that must be 
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minimized or eliminated to observe the effects of MSN, are analyzed to illustrate further 
limitations on the LOQ that may be present in experimental immunoassays. 
When detection systems used are capable of single molecule recognition (ISM > 
(6noise + Ibl)) and NSB is eliminated, the effects of molecular shot noise are apparent 
(Figure 5.3). Plots were generated to explore conditions where assay quantification is 
limited only by molecular shot noise (Equation 5.13). Beyond defining the ultimate LOD 
and LOQ, operating in the regime required for single molecule sensitivity does not 
influence the rest of the classic sigmoidal curve, except that it may limit the dynamic 
range of the overall measurement due to instrumental linearity being exceeded by 
operating in a high amplification mode.  Plotting the percent error normalized to the first 
data point intensity (error bars = Epercent x total intensity (one molecule)) (Figure 5.3 inset) 
as error bars on the Total Intensity values gives an indication of the accuracy with which 
measurement can be made. Along with total intensity, the signal and instrument 
background and noise are plotted. While the detection limit is set to single molecule limit, 
the uncertainty (expressed as error) of the measurement still contributes finite error.  
Another method to examine the same calculations is to plot contributions to 
percent error (Epercent) for the different sources at low molecule counts (Figure 5.3, 
bottom). The signal intensity is linear with increasing concentration, whereas the error in 
the measurement grows dramatically at low molecular counts, dominated by molecular 
shot noise with some influence from residual instrumental variance. Under these 
conditions, the LOD is one molecule (30 zM) and LOQ is 131 molecules (3.7 aM). Note 
to effectively eliminate the instrumental influence, the amplification must be increased 
two-hundred-fold or instrument bias and variance must decrease by a thousand-fold.  
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Figure 5.3 Plots illustrating the impact of error from molecular shot noise and residual 
instrumentation effects on LOD and LOQ. Total Intensity (Equation 5.10 + Equation 
5.12), Signal Intensity (Equation 5.10) and Background and Noise Intensity (Equation 
5.12) were plotted. Variables set at Ibl=10, bl=2.38x10
-4
, and =(Ibl+6noise)=10. Error 
bars represent percent error. Top: large range of concentration of antigen to emphasize 
that most of the curve is not influenced by molecular shot noise (signal intensity and total 
intensity lines overlap). Inset: molecular shot noise generates significant error for small 
numbers of molecules, error bars are equivalent to the percent error associated with the 
measurement multiplied by the intensity of a single molecule and reach an acceptable 
%CV (below 10% error) at 131 molecules. Note instrumentation bias and variance 
contributes a minor, almost negligible, error. Bottom: Plot of the assay-specific signal 
intensity (Equation 5.10) the total intensity of the assay (Equation 5.10 + Equation 5.12) 
and the baseline intensity (Equation 5.12) (left-axis) versus the assay variance from 
molecular shot noise (Equation 5.13 * 100%) the total variance in signal intensity 
(Equation 5.15 * 100%) and the variance from the instrument (Equation 5.15 * 100% 
with MSN equal to 0; right axis). Darker background indicates increase error in the 
measurement. Total assay variation reaches a level of 10% error when there are fewer 
than ~131 molecules (approximately 3.7 attomolar in 50 μL) in a sample. 
 
0
20
40
60
80
100
120
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
0 50 100 150 200 250
P
er
ce
n
t 
Er
ro
r 
ln
te
n
si
ty
 (
ar
b
. u
n
it
s)
 
Number of Molecules 
Quantitation Limited by Molecular Shot Noise 
Total Intensity
Signal Intensity
Background and
Noise Intensity
% Error Total
% Error Molec.
Shot Noise
% Error from
instrument
10% Uncertainty 
  139 
While typical conditions were used for the investigation of MSN (detection 
system capable of single molecule detection, equilibrium constants of monoclonal 
antibodies held at 1.0 x 10
9
 M
-1 
for both K1eq and K2eq) to provide a representative 
analysis of immunoassay capabilities, antibody properties do influence the fundamental 
LOQ (Table 5.2). Increasing the equilibrium constant of one or both antibodies can 
improve the limit of quantitation to approximately 113 molecules. Increases in the 
equilibrium constant beyond that do not impact this fundamental limit strongly 
(increasing both K1eq and K2eq to 1.0 x 10
11 
M
-1 
only lowered the limit of quantitation to 
111 molecules). The effects of antibody properties are greater when antibodies with 
below average equilibrium constants are used. By using only one antibody with a Keq of 
1.0 x 10
8 
M
-1
 raised the LOQ to 277 molecules (9.2 aM in 50 μL). Based on the 
assumptions stated previously by modeling an immunoassay based on the laws of mass 
action, systems are considered to be at equilibrium [36].
 
An excess of both capture and 
detection antibody are used such that it is determined that all antigen in a system is bound 
and dissociation is not assumed to occur on the time scale of the experiment. If 
dissociation of the target compounds does occur after either wash step in a typical assay, 
the limit of quantitation would increase. Under optimal circumstances 131 molecules 
must be specifically detected to afford quantitation with a CV below an acceptable 
threshold (<10%). 
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K1eq K2eq LOQ (number of molecules) 
1X 1X 131 
10X 1X 113 
1X 10X 113 
10X 10X 112 
0.1X 1X 277 
1X 0.1X 277 
0.1X 0.1X 1371 
Table 5.2 shows the influence of antibody equilibrium constants on the limit of 
quantitation. Here, X is defined as 1.0 x 10
9 
M
-1
, representing the typical equilibrium 
constant of a monoclonal antibody [43,44]. The impact on the LOQ when this value is 
increased or decreased by a factor of 10 for one or both of the antibodies used in a 
sandwich immunoassay is demonstrated. 
 
When NSB has not been effectively eliminated from an immunoassay system, it 
can limit the LOD and LOQ if the bias and variance of the signal from the NSB exceeds 
the instrumental bias and variance. To examine this, amplification was placed at single 
molecule sensitivity (=10). NSB can be introduced into a system at any level, and here 
will be considered at levels between 30 zM and 0.33 fM (1 and 10,000 molecules in 50 
μL) being non-specifically adsorbed and detected (Figure 5.4). With a target 
concentration held constant at 1 fM, above the range where MSN and instrument 
background (capable of single molecule detection) influence impact quantitation, NSB 
was plotted between 30 zM and 0.33 fM. While it is observed that the intensity of the 
signal produced from NSB is much lower than the intensity of the specific signal, 10% 
uncertainty is reached with the addition of 83 aM (2500 molecules) non-specifically 
binding (Figure 5.4, top). This selection of sample concentration was an arbitrary value 
emphasizing that any and all NSB will decrease detection limits compared to single 
molecule detection, both in terms of false positive and increased molecular shot noise 
error. This influence can be similarly observed by comparing the influence of the number 
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of molecules NSB on the number of specific sample targets required to achieve 
quantitation (Figure 5.4, bottom). 
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Figure 5.4 Plot illustrating LOD and LOQ defined by non-specific binding properties. 
Variables set at Ibl=10, bl=2.38x10
-4
, and =(Ibl+6noise)=10 and modeled for a specific 
target concentration of 1 fM. The intensity (bias, INSB) and standard deviation (noise, 
NSB) were modeled for values between 0 and 10
4 
molecules NSB and included according 
to Equation 5.12. Top: The Signal Intensity (Equation 5.5), Total Intensity (Equation 5.10 
+ Equation 5.12), and NSB (𝐼𝑁𝑆𝐵) were plotted and compared to Percent Error (Equation 
5.10). Note the signal from NSB influences quantification far beyond the number 
adsorbed entities, reaching the LOQ at 2500 molecules (83 aM) non-specifically 
absorbed. Bottom: As the number of molecules non-specifically binding increases, the 
concentration of target molecules required to reach the LOQ increases.  
 
Historically, the LOD and LOQ were determined by the capabilities of the 
detection system, generating low amplification of signal or high instrument bias and 
variance (Figure 5.10). Reducing the amplification () or increasing the background (𝐼𝑏𝑙) 
of the instrument produced a similar impact on quantitation abilities. This relationship 
between signal amplification and background is modeled considering Johnson noise only 
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to examine the best case scenario as described previously where ISM > 6noise above Ibl 
and noise is modeled according to equation 5.11. The transition towards instrumentation 
capabilities being the limiting factor occurs when /(
𝐼𝑏𝑙
6
+bl) =/(
𝐼𝑏𝑙
6
+ √2𝑞𝐼𝑏𝑙∆𝑓
4 ) = 6. 
When the ratio is less than six, the signal from a signal molecule is no longer 
distinguishable above noise and the system is limited by instrumental considerations. For 
this data, the ratio was set at 1/1000th of the transition value (Ibl=10, bl=2.38x10
-4
, 
=(Ibl+6noise)/1000=0.01). Any value less than six can illustrate this point, but this value 
minimum that gave clear and instructive graphical information over a range of antigen 
concentrations. For these conditions, the LOD was ~1100 molecules (37 aM) and LOQ 
was 1.1x10
4
 molecules (0.36 fM).  
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Figure 5.5 Plot illustrating limited amplification or increased background bias and 
variance resulting in LOD and LOQ being defined by the characteristics of 
instrumentation. Total Intensity (Equation 5.10 + Equation 5.12), Total Background and 
Noise (Equation 5.12), and Signal Intensity (Equation 5.10) were plotted versus antigen 
concentration [Ag] (M). Plot shows signal intensity versus antigen concentration 
according to immunoassay system of equations. Variables set at Ibl=10, bl=2.38x10
-4
, 
and =(Ibl+6noise)/1000=0.01.  
 
5.4 Discussion 
 
It is commonly accepted that the sandwich-type immunoassay allows for the most 
sensitive detection among immunoassay formats [30].
 
With optimal instrumental 
detection capabilities, the theoretical quantification limit of the sandwich assay depends 
on the reaction binding constant, the percent of the reaction volume required for 
measurement, and the precision associated with the measurement made [16].
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consider in the distinction between the LOD and LOQ. The focus on the LOQ is to 
ensure that the relative error in a sample measurement remains less than a logical pre-
determined fraction of the total signal (<10%) [22,23,25,44]. 
Practically, the LOQ is affected by both constant and variable sources of noise 
which must be accounted for in determining finite immunoassay capabilities. The 
constant sources of noise, arising from detection elements, signal processing, molecular 
shot noise, thermal noise and Johnson noise will be present throughout any measurement 
at a defined intensity for a particular system. Variable noise arises predominantly from 
NSB, which can occur at each step in immunocomplex formation with differing effects. 
Although binding of the non-target species is less probable than the specific binding of an 
analyte, in the event that the target compound is present at a low concentration, or in a 
biological sample, non-specific binding will be a significant contributor to the overall 
signal [25].  
Plots based on the law of mass action were used here to illustrate three sets of 
conditions dictating the LOQ for immunoassays: a) molecular shot noise, b) non-specific 
binding, or c) the baseline signal intensity arising from measurement instrumentation. 
While the focus of this work is the determination of the LOQ based on the sources of 
uncertainty present in a system, and variation in signal response increases with increasing 
analyte concentrations [44], above the LOQ the signal-to-noise ratio (SNR) increases and 
the noise factor (
𝑡𝑜𝑡𝑎𝑙 𝑜𝑢𝑡𝑝𝑢𝑡 𝑛𝑜𝑖𝑠𝑒 𝑝𝑜𝑤𝑒𝑟
𝑜𝑢𝑡𝑝𝑢𝑡 𝑛𝑜𝑖𝑠𝑒 𝑝𝑜𝑤𝑒𝑟 𝑑𝑢𝑒 𝑡𝑜 𝑖𝑛𝑝𝑢𝑡 𝑠𝑜𝑢𝑟𝑐𝑒
) decreases [25]. These findings 
demonstrate that while there may be more total variation in signal at higher analyte 
concentrations, this variation represents a smaller percentage of the overall signal than 
fluctuations produced at low sample concentrations.  The mass action law was used in 
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this case to gain insight into fundamental limitations of immunoassay systems. While P4 
and P5 fitting models are useful in that they provide reasonable estimates of analyte 
concentration by back-fitting collected data without incorporating too many parameters, 
their estimates of error are less reliable than using the law of mass action and they do not 
allow the ultimate LOQ to be determined [1,35].
 
More recent models of detection statistics have relied on models built from 
Bayes’ theorem to define the LOD as both the probability that it exceeds a signal for a 
zero dose and its probability density [1,45]. While the accuracy of determining the LOQ 
is greatest using a dose-response curve based on the law of mass action, and this analysis 
allows the determination of fundamental limitations that may not be surpassed, models 
built from Bayes’ theorem provide more rigid requirements for the interpretation of data 
as a part of routine laboratory analysis compared with traditional P4 or P5 fittings [1]. 
These models not only use back-fitting, but also right-skewed probability densities to 
determine the extent of error both in blank calibration samples and those with target 
analyte present. 
When the signal from instrument background is minimized and non-specific 
binding is effectively eliminated, molecular shot noise is responsible for establishing the 
fundamental statistical LOQ for immunoassay. In this case uncertainty associated with 
sample heterogeneity at low analyte concentrations dictates the ultimate limit of 
quantification (Figure 3, Equation 10). The assay plots show that regardless of sample 
volume, in order to establish certainty in the quantification of an analyte, there must be a 
minimum of 131 molecules specifically detected. Because the error associated with 
molecular shot noise, coupled with a minimal variance from the instrument and baseline, 
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below this number of molecules corresponds to a coefficient of variation greater than 
10% the sample may only be potentially detected, not quantified. Establishing a 
fundamental limitation to the LOQ is important both in the design of immunoassay 
platforms and the evaluation of existing techniques. As detection instrumentation has 
improved to the point where sensing a single molecule is possible, many claims of single-
molecule immunoassays have been made [26-28]. However, despite using 
instrumentation capable of sensing individual signals, the actual limits of quantitation are 
much higher, falling in the aM range and reaching a minimum of 800 molecules 
quantified [28].
 
While claims of single molecule detection have not yet successfully 
approached the fundamental LOQ imposed by MSN, it is necessary to quantitatively 
establish this absolute limit and assess the impact of additional noise sources that may be 
present in an experimental immunoassay such that new assays may be appropriately 
designed to meet the quantitation requirements of specific target species. 
Beyond the limitations imposed by MSN, quantification can be impacted by 
uncertainty bias and variance introduced through non-specific binding. Non-specific 
binding must always be considered when discussing limit of quantitation for 
immunoassay. While MSN imposes a fundamental LOQ for immunoassays that cannot 
be improved, NSB is likely to occur to some extent in experimental immunoassay 
systems. It is particularly relevant in assays used for medical diagnostics, where desired 
targets are of relatively low concentration and present in a highly complicated sample. 
When present, NSB will impose a further limit on the minimal concentration quantified 
by a given system. This can be observed in that when even one molecule binds non-
specifically the LOQ increases from 4.3 to 5.0 aM (Figure 4, bottom). 
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When background noise from the instrument is higher than the signal intensity 
arising from molecular shot noise or non-specific binding, the limit of quantification is 
dependent only upon what can be effectively distinguished from this baseline signal. 
When the LOQ is dictated by the instrumentation, the effects of MSN are of minimal 
importance due to the higher numbers of target analyte required for a sample to be 
recognized above the background noise. For a given instrumental system this background 
noise is a constant source and cannot be altered by adjusting experimental parameters. 
However, with the use of a highly sensitive detection instrument capable of sensing the 
presence of a single molecule, background noise can be sufficiently lowered leading to 
quantitation bound by the limits of the assay itself. 
5.5 Concluding Remarks 
 
Due to the high specificity of the interaction between antibodies and antigens, 
immunoassays provide a valuable tool when sensitive detection is required. Often, these 
assays are used to determine the concentration of a particular biologically relevant target. 
When used as a quantitative tool, the limitations of immunoassays have a theoretical floor 
bound by molecular shot noise. While detection may still take place below this limit, it 
can only be considered qualitative since the uncertainty (error) associated with the 
measurement becomes too great (above 10%). While practical limitations, like non-
specific binding or baseline instrumental noise, may result in a higher LOQ for 
experiments, there cannot be quantitation with acceptable certainty if samples contain 
fewer than 131 detected antigen target molecules since signal outputs will be formed 
from rare events and be subject to statistical sampling effects. Therefore, true 
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quantification limits lie not at the single molecule level, but in the atto- to femtomolar, or 
poorer, range. 
 The models employed here to establish the fundamental qualitative ability for 
noncompetitive sandwich immunoassays can be employed to assess the ability of an 
experimental design to quantify targets under the parameters that will be used. This 
provides a valuable tool for predicting the utility of an assay for its intended application, 
as well as an aid in the assay design process.  
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CHAPTER 6 
IMMUNOASSAY TARGET SAMPLE PREPARATION USING DC GRADIENT 
INSULATOR DIELECTROPHORESIS 
6.1 Introduction 
 
Early illness intervention requires the capability of monitoring relatively small 
concentration changes in disease indicated species. Because it contains the most 
comprehensive depiction of the physiological state of an individual, blood, and in 
particular plasma, has become the primary sample fluid used in clinical diagnostics [1-3]. 
However, owing to a high dynamic range spanning over 10 orders of magnitude, as well 
as the presence of a few high abundance proteins (albumin, immunoglobulins, transferrin, 
haptoglobin, and lipoproteins), detection of species related to specific disease states is 
challenging [2-4]. Beyond the complexity of the plasma proteome, whole-blood samples 
also contain cells (platelets, red blood cells, and white blood cells) that may interfere with 
specific target detection if not removed [5].  
 Many clinical diagnostic methods rely on biological recognition, through the use 
of immunoassay techniques [6,7].
 
The specific interaction between the target molecule 
and antibody allows for quantitative testing to take place. However, in the use of whole-
blood or plasma one-step assays without prior sample simplification cross-reactivity 
limits the LOQ to the nM to μM range [8,9,10]. With the effective removal of 
contaminating species, highly sensitive quantitation of target analytes is possible [11-13].
 
Specific detection at this level is sufficient to quantify the low abundance proteins that 
are of interest in diagnostics [1,3].  
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Currently, centrifugation is most commonly used to eliminate cells from a blood 
sample [14,15].  Sample testing is primarily performed in centralized clinical laboratories 
and requires relatively large volumes of blood (mL) as well as long analysis times [16].
 
By moving from a centralized laboratory to portable micro-total analysis systems 
(μTAS), it is possible to incorporate a separations based strategy such that more 
information (both from blood cells and protein analysis) can be extracted from a minimal 
sample volume in a short analysis time. Achieving this minimally invasive, rapid 
diagnostic ability while maintaining high sensitivity requires sample preparation steps 
prior to detection. Separation techniques not only allow the removal of cross-reactive 
species for more sensitive quantitation, but provide the potential for multiplex detection. 
 Many experimental microfluidic techniques exist for the separation of blood cells 
from plasma. These technologies include manipulation and separation based on 
mechanical, inertial, hydrodynamic, optical, magnetic and electrical methods [14,17-20]. 
Particularly appealing among these techniques is the use of dielectrophoresis (DEP) 
because it allows the rapid and selective manipulation of neutral (as well as charged) 
bioparticles in a label-free system [17,21].
 
When species are introduced into a non-
homogeneous electric field they are exposed to a DEP force according to the relation 
[22]:
  
𝐹𝐷𝐸𝑃 = 2𝜋𝜀𝑚𝑅
3𝐶𝑀(𝛻𝐸2)  Eq. 6.1 
 
where εm is the permittivity of the medium the species is placed in, R is the radius of the 
particle, CM is the Clausius-Mossotti factor related to the permittivity of the particle 
compared to that of the medium and E is the amplitude of the electric field. While this 
equation includes some simplifications, assuming that the particle is homogeneous and 
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uncharged while the induced polarization once the field E is applied takes the form of a 
dipole moment, it is able to accurately predict the reaction of species to the DEP force. 
DEP has been used successfully to isolate yeast cells [23], prostate cancer cells [24],
 
ccf-
DNA [25], and red blood cells [26]. 
 Here, insulator-based DEP (iDEP) was performed in a microchannel with 
insulating sawtooth features along the channel sides to create an inhomogeneous electric 
field. The device used is the second-generation iteration of that described in previous 
work [26], and was employed to remove red blood cells from a sample containing heart-
type fatty-acid binding protein (H-FABP) or myoglobin to model the simplification of a 
blood sample prior to cardiac biomarker detection. Progressive changes to the distance 
between teeth (gate width) create increasing field strength along the length of the 
channel. When the magnitude of the DEP force is great enough to counter the effects of 
the electroosmotic flow (EOF) and electrophoresis (EP) forces driving analyte movement 
down the channel, species will be trapped. Effective trapping of the red blood cells 
without affecting protein movement through the channel suggests that this technique 
could be valuable as a first step in a μTAS system for the analysis of whole-blood where 
centrifugation is not practical due to the small scale of the system. The small sample 
volumes required by downstream detection methods are compatible in scale with the 
volume requirements needed for RBC removal by incorporating iDEP as an initial sample 
preparation step in a μTAS. This approach allows downstream analysis of proteins using 
sensitive immunoassay techniques without interference from abundant blood cells and 
with small sample volume requirements that allow complete analysis of limited samples 
or routine serial-monitoring of disease progression without becoming invasive. 
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6.2 Materials and Methods 
 
6.2.1 Microdevice Fabrication 
 
The sawtooth geometry of the microchannel has been previously described 
(Figure 6.1) [26].
 
In these experiments the channel length was 4 cm, with a uniform depth 
of 20 μm. The initial gate width was 73.3 μm and the final gate width was 25.3 μm. The 
device was fabricated using standard soft lithography techniques. Briefly, the channel 
was designed using Adobe Illustrator (Adobe Systems Inc., San Jose, CA) and printed 
onto a chrome-glass photomask (JD Photo-Tools LTD., Oldham, Lancashire, UK). A 
silicon wafter was made from the photomask using photolithography and dry etching 
techniques. From the silicon wafer, PDMS casts were made using a Sylgard 184 silicone 
elastomer kit (Dow Corning Corp., Midland, MI, USA).  Access holes were generated 
using a 3 mm Harris Uni-Core punch (Shunderson Communications Inc., Orleans, 
Ontario, Canada). Casts were stored at -20°C until use. Prior to device assembly, PDMS 
casts were washed with isopropanol, acetone, and 18 mΩ water, then sonicated for 30 
seconds (Aquasonic ultrasonic cleaner, VWR International, Radnor, PA, USA). 
Similarly, glass microscope slides (VWR International) were washed and sonicated for 
10 seconds. Slides and PDMS casts were dried using N2 gas and treated with a high level 
of O2 plasma for 60 seconds (Plasma Cleaner, Harrick Plasma, Ithaca, NY, USA) before 
contact sealing. Once sealed, the channel was rinsed with 115 mM sodium phosphate 
buffer at pH 7.4 and treated with 4 mg/mL BSA to reduce electroosmotic flow (EOF) and 
prevent nonspecific absorption prior to sample introduction.  
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6.2.2 Red Blood Cell and Protein Labeling 
 
 Fresh whole blood was obtained through fingerstick from a human donor and 
suspended in 1 mL of isotonic buffer with 1.8 mg/mL ethylenediaminetetraacetic acid 
(EDTA). The sample was immediately centrifuged and pelleted red blood cells (RBCs) 
were resuspended in buffer. After three wash steps to remove plasma, the RBC sample 
was stained as previously described [26]. The final cell pellet was resuspended in 115 
mM sodium phosphate buffer at pH 7.4 with a cell count at 111 cells/nL based on the 
presumed mean corpuscular volume (MCV) of 90 fL [27].  
 Purified human myoglobin (7.33 mg/mL) was purchased from MyBioSource and used as 
received. Purified human heart-type fatty acid binding protein (2.02 mg/mL) was 
purchased from Life Diagnostis and used as recieved. NHS-Rhodamine (Thermo 
Scientific) was dissolved in DMSO (Invitrogen) to a concentration of 10 mg/mL. Volume 
of NHS-Rhodamine was added dropwise to myoglobin and the sample was incubated in 
the dark at room temperature for 1 hour with shaking. Volume of NHS-Rhodamine was 
added to FABP and reacted in the same manner. Crude reaction mixtures were added to 
dialysis cups (Thermo Scientific) with a molecular weight cut-off of 3,500 Daltons. 
Samples were dialyzed in 100 mM PBS, pH 7.2 overnight. Proteins were diluted in the 
RBCs to ratios of 1:200 μL (MyO) and 3:200 μL (FABP) for analysis in the DEP device. 
6.2.3 Experimental 
 
Channels were filled with roughly 10 μL of a mixture of the fluorescently labeled 
protein and red blood cells and filled through capillary action. Flow was stopped by 
balancing the menisci at the entrance and exit of the channel through the addition of 
running buffer to the outlet reservoir. Platinum electrodes (diameter 0.25 mm) were 
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inserted into the access ports in the PDMS and potentials were applied to the channel 
using a LabSmith power supply (Series HV5448, LabSmith Inc., Livermore, CA, USA). 
Potentials ranging from 100 to 500 ΔV were applied globally to the device, resulting in 
an electric field strength of 25 to 125 V/cm.  
Data collection was achieved using an inverted microscope (Olympus IX70) 
illuminated by a mercury lamp. Light was passed through an Olympus DAPI, FITC, 
Texas Red triple band-pass cube (Olympus, Center Valley, PA) used for fluorescence 
microscopy. Video and still images were collected using a CCD camera (QImaging, Inc., 
Surrey, British Columbia, Canada) connected to image capture software (Streampix 5, 
NorPix, Montreal, Quebec, Canada). ImageJ (NIH, Bethesda, MD) was used for video 
analysis. Fluorescence intensity was measured just upstream of gates where capture of 
RBCs was observed. 
 
Figure 6.1 Schematic of the iDEP microchannel used. Devices were fabricated from a 
glass microscope slide and PDMS. 
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6.3 Results and Discussion 
 
Mixtures of red blood cells with either cardiac biomarker FABP or myoglobin 
were investigated using the iDEP sawtooth device. The behavior of both species was 
analyzed at the final set of gates, possessing a gate width of 25.3 μm, and at the end of 
the microchannel. The magnitude of the electric potential, ranging from 100 to 500 ΔV, 
was divided by the length of the channel (4 cm) to determine the local electric field 
strength applied (Eapp, V/cm).  
 
 
Figure 6.2 Observed capture of RBCs at gate 27 in the presence of H-FABP.  
Background fluorescence is due to H-FABP while the brightly fluorescent spheres are 
individual red blood cells. Capture was observed as a cluster of cells immediately 
upstream from a gate. Red selection shows the region used for fluorescence 
measurements. 
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 The dielectrophoretic behavior of RBCs was consistent with prior general 
observations in the sawtooth microchannel [26].
 
When fluid flow was balanced and 
potential was applied to the microchannel the bulk motion of particles was oriented 
toward the outlet reservoir (cathode) due to the combined forces of EP and EOF. Neither 
RBC or protein capture were observed at any voltage in regions of the channel having a 
gate width greater than 26.2 μm (size of second-to-last set of gates). In regions with a 
larger gate width all fluorescent material traveled toward the cathode. Capture was 
defined by the collection of RBCs immediately prior to a gate (Figure 6.2). As the gate 
widths become smaller in the microchannel the dielectrophoretic force experienced by 
the sample increases, reaching a local maxima at the entrance to the gate. Since the 
negative DEP force opposes the combined forces of EP and EOF, when the DEP force is 
equal or greater than the combined forces.   
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Figure 6.3 Quantitation of red blood cell capture by monitoring fluorescence intensity. 
Average percent fluorescence increase observed at gates 24 and 27 from 5 different 
devices and sample preparations of RBCs and FABP. Error bars show the standard 
deviation. Inset: Percent increase in fluorescence intensity observed at gate 27 after Eapp. 
Onset of capture is observed when Eapp = 300 V (75 V/cm). Capture is observed to a 
lesser extent at gate 24 with an Eapp = 300 V. Capture at gate 24 increases with higher 
Eapp. At all values of Eapp the fluorescence intensity of protein within the channel 
(background fluorescence in channel) is observed to remain unchanged.  
 
 The capture of RBCs occurred at 25.3 μm gates with an onset of Eapp = 300 V 
applied globally across the device. Capture was observed at 26.2 μm gates minimally at 
Eapp = 300 V, with greater material accumulation between Eapp = 400 and 500 V. The 
cardiac biomarker proteins were not observed to capture at any Eapp tested and instead 
were able to flow freely through the device. Below an Eapp value of 300 V no capture 
occurred even at extended time periods of applied voltage. Control studies without 
protein showed similar capture of RBCs without the diffuse fluorescence observed 
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throughout the channel in the presence of protein. With an applied voltage meeting the 
threshold required for RBC capture, material continued to collect during the time voltage 
was on in regions just prior to a gate. Extent of RBC capture was monitored by 
determining the local fluorescence intensity increase in regions with observed RBC 
collection. Repeated experiments show a similar behavior of the RBCs. Figure 6.3 shows 
the average fluorescence intensity for data collected from 5 different devices with 
separate preparations of RBCs and H-FABP. Error bars show the standard deviation of 
data sets.The extent of capture was dependent not only on the Eapp, but on the location 
within the channel (Figure 6.3 inset). RBCs were observed to collect at lower voltages 
and to a greater extent at the smallest gates in the channel before they were captured 
further upstream. For all values of Eapp tested, the fluorescence intensity resulting from 
H-FABP was unchanged. Myoglobin studies produced a similar trend (data not shown). 
Variables that could not be specifically controlled, such as staining efficiency of the 
RBCs, contribute to the variance observed between samples. Staining efficiency of the 
RBCs was determined by inspection of samples at relatively high magnification under 
both fluorescence and bright-field microscopy. In all cases staining efficiency was 
observed to be about 45%, but varied between 40% and 50% percent despite identical 
preparation protocols. 
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Figure 6.4 Depletion of RBCs in the exit channel beyond the final sawtooth gate. In each 
image Eapp is 400 V globally across the device (100 V/cm). 
 
Changes in fluorescence intensity were also measured in a small region directly 
following the final gate in the microchannel. Using an Eapp of 400 V to ensure complete 
capture of RBCs at the 25.3 μm gate, fluorescence was monitored at one minute 
increments to assess the depletion of RBCs in the sample that could be collected at from 
the exit reservoir (Figure 6.4). Both visual determination of RBCs present and 
fluorescence measurements in this region support that, once significant voltage is applied 
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across the channel, complete capture of RBCs occurs (Figure 6.5). This capture allows 
simplification of the initial sample, enabling easier quantitation of the protein target in the 
exit channel. 
 
Figure 6.5 A) Fluorescence measurements and B) RBC counts present in the exit channel 
after and Eapp of 100 V/cm. 
 
Extraction of protein samples was attempted from the exit channel using a 
hypodermic needle to remove fluid. Under the current configuration of the device, sample 
removal and quantitation is not practical due to issues in removing a great enough sample 
volume for off-chip manipulation and detection. While not demonstrated in this work, it 
is possible that the iDEP channel could be incorporated as the initial sample preparation 
step in next-generation μTAS for the separation and analysis of complex biological 
samples. Incorporation of further separation of eluted proteins using electrophoretic 
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manipulation, which has been demonstrated to be effective in the isolation of charged 
species [21], as well as on-chip detection through high-sensitivity immunoassay could 
allow multiplex detection of biomarkers.  
6.4 Concluding Remarks 
 
Using an iDEP microdevice with a sawtooth pattern insulated channel the 
effective removal of RBCs from solutions containing cardiac biomarkers H-FABP or 
myoglobin. Behavior of the RBCs was consistent with previous observations in an iDEP 
microchannel [26].
 
The results shown here indicate that RBCs can be successfully 
captured using DEP and removed from a sample containing protein species, which were 
unaffected by the electric potentials applied. Removal of blood cells from plasma 
samples is a necessary first step in sample preparation prior to quantitative detection in 
medical diagnostics. While centrifugation techniques are traditionally utilized to achieve 
cell removal, this method is not practical on a microscale level. Here, it is shown that 
iDEP can be used as an alternative initial step in sample simplification compatible with 
incorporation into a μTAS system for the quantitative detection of multiple biomarkers. 
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CHAPTER 7 
ISOLATION OF CARDIAC BIOMARKER PROTEINS USING 
ELECTROPHORETIC EXCLUSION 
7.1 Introduction 
 
In clinical diagnostics the parallel detection of biomarker proteins is of particular 
importance since no single marker has proven to have sufficient diagnostic accuracy for 
AMI, or a variety of other conditions in which early detection may improve prognosis [1-
3].
 
In the case of clinical diagnostics, plasma has become the primary sample fluid used 
because it contains the most complete version of the human proteome, including both 
classical plasma proteins as well as those present from tissue leakage [4-6].
 
While the 
protein content in plasma holds great diagnostic potential, protein concentrations in 
plasma span over 10 orders of magnitude and species of interest such as biomarkers are 
often present in very low concentrations [5-7].
 
Multiplex testing has been performed in 
many cases through batch incubation using monoclonal antibodies specific to each target 
species [8,9]. However,
 
when the quantification of species from a complex primary 
sample is required, the potential for cross-reactivity becomes a significant concern 
[10,11].
 
 
 In recent years, several microfluidic scale separation-based techniques have been 
employed as a sample pre-treatment step in the analysis of plasma [12-18].
 
These 
techniques include the use of physical barriers to filter the sample [12,13],
 
as well as 
electrophoretic separation methods [14-18].
 
Of particular interest among electrophoretic 
separation techniques are those that operate using counter-flow along with a gradient for 
the isolation and concentration of target species [16-18]. While counter-flow separations 
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have been achieved through pH or conductivity focusing, the use of an electric field 
gradient allows isolation and concentration to occur outside a separation channel.  
 The use of an electric field gradient as a counter to hydrodynamic flow, termed 
electrophoretic exclusion, was first used to isolate small molecules [18].
 
This technique 
enables the separation of species having different electrophoretic mobilities (μa). 
Assuming that hydrodynamic flow and buffer conditions remain constant throughout 
sample manipulation, the strength of an applied electric field may be altered to separate 
target species based on these differences. Exclusion of a target species from a channel is 
accomplished by maintaining a constant electric field across reservoirs connected to 
channels in a device and introducing a sharp electric field gradient in microchannels 
connecting these reservoirs. When the electrophoretic velocity of a target species (𝑣𝑎), 
according to: 
𝑣𝑎 =  𝜇𝑎𝐸                   7.1 
 
My work was performed as an extension of investigations performed in a microdevice 
demonstrating the first use of electrophoretic exclusion to separate small molecules on a 
microscale, as well as the use of a macroscale benchtop device for the manipulation of 
proteins [18, 19]. The development of a separations-based array previously allowed for 
the isolation of multiple small molecules and has been shown here to be effective in the 
exclusion and concentration three cardiac biomarker proteins [20]. The device contains 
three separation channels connected in parallel to form an array [12]. With electric field 
gradients applied at the entrance of channels connecting the reservoirs within the array, 
the magnitude of the electrophoretic velocity can be manipulated until it balances the 
hydrodynamic flow and prevents the entry of target species resulting in concentration 
  170 
within a reservoir. The ability to separate and concentrate these target molecules provides 
a foundation for the development of a micro-total analysis system (μTAS) offering 
parallel quantitation of biomarker panels from untreated whole blood samples. This 
method allows downstream analysis of proteins using sensitive immunoassay techniques 
without interference from abundant plasma proteins and with small sample volume 
requirements that allow complete analysis of limited samples or routine serial-monitoring 
of disease progression without becoming invasive. 
7.2 Materials and Methods 
 
7.2.1 Microdevice Fabrication   
 
A photograph of the device used for protein separation (top view) and a schematic 
of the array is shown (Figure 7.1A). The hybrid glass/PDMS array was used for all 
experiments. Each device contained a large entrance reservoir, three central reservoirs 
and three exit reservoirs connected by separation channels. The development of this 
device has been discussed previously [1,2], and is briefly discussed below. 
7.2.1.1 PDMS 
 
A single separation array consisted of an entrance reservoir connected to a three 
central and exit reservoirs through separation channels. The entrance reservoir was 19 
mm x 5 mm, all central and exit reservoirs were 5 mm x 5 mm and channels were 1 mm 
long and 100 μm wide with a uniform depth of 10 μm throughout the device. Masks were 
designed using Illustrator (Adobe, San Jose, CA, USA) and were printed on a 
transparency using a resolution of 65,000 dpi (Fine Line Imaging, Colorado Springs, CO, 
USA). Positive photoresist AZ 4620 was spun onto a silicon wafer and exposed at 500 
mJ/cm
2
 using an EVG
®
620 Automated UV-NIL, μ-CP System (EV Group, St. Florian 
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am Inn, Austria) using the transparency as a mask. The array was then fabricated using 
common soft lithography techniques. Using Sylgard 184 (Dow Corning, Midland, MI, 
USA) a 10:1 mass ratio of polymer and curing agent was prepared and poured onto the 
wafer at a thickness of roughly 5 mm. This was allowed to sit at room temperature for 15 
minutes and cured at 70°C for 60 min. The cured PDMS was then removed from the 
wafer and 3 mm diameter holes were punched in the entrance and exit reservoirs using a 
Harris Uni-Core punch (Shunderson Communications Inc., Orleans, Ontario, Canada). 
7.2.1.2 Electrode Fabrication 
 
Ti/Pt electrodes were plated on standard microscope slides (VWR International). 
A mask was designed using Adobe Illustrator and printed on transparency using a 
resolution of 8000 dpi (Fine Line Imaging, Colorado Springs, CO USA). Electrodes were 
plated 500 μm wide bracketing each reservoir on three sides to produce a flat potential 
within a reservoir and promote exclusion in channels connecting reservoirs. A schematic 
of the electrode design is shown (Figure 7.1B). Positive photoresist AZ 4330 was spun 
onto microscope slides and exposed at 150 mJ/cm
2
 with the EVG
®
620 Automated UV-
NIL, μ-CP System using the transparency mask. Electron beam evaporation was used to 
deposit two layers of metal on the glass microscope slides (PVD75, Kurt J. Lesker 
Company, Jefferson Hills, PA, USA). A 300 Ǻ layer of Ti was deposited onto the slides 
followed by 500 Ǻ of Pt. Electric leads were attached at the base of the slide using silver 
conductive epoxy for connection to an external power supply (Series HV5448, LabSmith 
Inc., Livermore, CA, USA) through a house-made voltage divider. 
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7.2.2 Protein Labeling and Sample Preparation 
 
Aspartic acid (Sigma-Aldrich, St. Louis, MO, USA) and DMSO (Mallinckrodt) 
were used as received. Aspartic acid buffer was prepared at a 5 mM concentration and pH 
of 2.95 using 18 MΩ Milli-Q water. Purified human myoglobin (7.51 mg/mL) , purified 
cTnI (1.07 mg/mL) and H-FABP (2.2 mg/mL) were purchased from Life Diagnostics. 
Myoglobin and H-FABP were used as received in PBS, cTnI was dialyzed to 100 mM 
PBS, pH 7.2 prior to use. NHS-Fluorescein and NHS-Rhodamine (Thermo Scientific) 
were dissolved in DMSO to concentrations of 10 mg/mL.  3.0 μL of NHS-Rhodamine 
was added to myoglobin and the sample was incubated in the dark at room temperature 
for 1 hour with shaking. NHS-Fluorescein was added to cTnI (1.5 μL) and H-FABP (3.0 
μL) and reacted in the same manner. The crude reaction mixtures were added to dialysis 
cups (Thermo Scientific) with a molecular weight cut-off of 3,500 Daltons. Samples were 
dialyzed in 100 mM PBS, pH 7.2 overnight. Proteins were diluted with aspartic acid 
buffer to concentrations of 0.33 mg/mL Myoglobin, 0.2 mg/mL cTnI and 0.22 mg/mL H-
FABP prior to analysis. 
7.2.3 Experimental 
 
The PDMS layer and glass slide with electrodes were bonded using oxygen 
plasma operated at high radio frequency (RF) for 60 s (Plasma Cleaner, Harrick Plasma). 
The array was filled with fluorescently labeled protein samples by pipetting the solution 
into the entrance reservoir. Channels were filled through capillary action and bulk flow 
was directed toward the exit reservoirs by the difference in height between the menisci of 
the entrance and exit reservoirs. A total of 21 μL of solution was added to each device. 
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Potentials were applied so that exclusion of individual proteins could be observed near 
the entrance to exit channel 2 and entrance channel 3. 
 Data collection used an inverted microscope with fluorescence capabilities (IX70, 
Olympus) using a 100 W high-pressure Hg lamp as the light source. Light was passed 
through a band-pass filter and 20X microscope objective to the array. Light emitted from 
the sample was collected through a long-pass dichroic mirror and band-pass filter to a 
CCD camera capable of image-capture (QICAM, Q imaging, Inc.).  ImageJ (NIH, 
Bethesda, MD) was used for video analysis. The fluorescence intensity was measured in 
the channel to monitor protein exclusion. 
 
  174 
 
Figure 7.1 Device used for exclusion of protein with schematic of electrode design. A) A 
photograph of the complete chip (glass/PDMS hybrid) with two arrays each containing 
three channels and a schematic of a single channel used for exclusion. B) Schematic 
showing electrode placement around the reservoirs, promoting exclusion within channels. 
 
7.3 Results and Discussion 
 
When the electrophoretic velocity of a target species is greater than or equal to the 
hydrodynamic counter flow, electrophoretic exclusion of that analyte is accomplished. If 
exclusion occurs at the entrance to a channel within the experimental array, that analyte 
may be separated from other species present in the starting sample. For electrophoretic 
exclusion to occur three factors must be present: hydrodynamic flow, species having an 
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electrophoretic mobility, and an applied electric field. With experimental conditions held 
constant, the hydrodynamic flow and electrophoretic mobility of investigated species are 
unchanged over the time period of data collection. This allows manipulation of the 
applied electric field strength such that individual species may be excluded from entering 
a channel. 
 The effects of electrophoretic exclusion on cTnI were investigated (Figure 7.2).
 
Briefly, an array is filled with a solution containing the sample of interest (either an 
individual protein or protein mixture) in aspartic acid buffer (pH 2.95). Initially, no 
electric field is applied to the array and sample is free to flow from the entrance reservoir 
towards the exit reservoirs, in the direction of hydrodynamic flow (Figure 7.2A). When 
an electric field is applied across a channel such that the electrophoretic velocity of the 
target protein is greater than or equal to the counter-flow, the species is prevented from 
entering a channel and is concentrated within a reservoir immediately upstream of that 
channel (Figure 7.2B). Once the electric field is removed, concentrated sample is again 
allowed to continue in the direction of hydrodynamic flow (Figure 7.2C). The complete 
exclusion of cTnI from the microchannel with an applied electric field of 65 V/cm 
demonstrates the potential of this technique to isolate and concentrate proteins from 
complex samples. cTnI was allowed to collect in the central reservoir over a time of 35 s.  
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Figure 7.2 Exclusion of cTnI from the entrance to exit channel two. Hydrodynamic flow 
is from top to bottom. A) Graphic illustrating where exclusion behavior is observed on 
the device. Fluorescence above the microchannel is due to protein, dark band observed in 
central reservoir 2 is the electrode. B) Before an electric field is applied the fluorescently 
labeled protein travels through the array in the direction of hydrodynamic flow.C) Once 
an electric field is introduced at 65 V/cm the protein is excluded in central reservoir two. 
D) After the field is released the protein may again travel with hydrodynamic flow 
towards the exit reservoir. 
 
When voltage was released the protein is concentrated compared to the original 
sample (approximately 3.5 fold). By concentrating samples prior to their quantification, 
greater sensitivities can be reached. This, in combination with the isolation of species 
afforded using electrophoretic exclusion, hold potential as a sample pre-treatment step in 
diagnostic assays requiring multiplex target quantification. 
 Similar behavior was observed for both myoglobin and H-FABP. Before electric 
fields were applied to the array, both proteins were allowed to flow freely toward the exit 
reservoirs. Once electric fields were applied at a channel entrance for 35 s, proteins were 
observed to collect in the reservoir immediately upstream of that channel. For all target 
species, once the electric field was removed samples were again able to enter the channel 
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and move toward the exit reservoirs in the direction of hydrodynamic flow. For studies 
monitoring individual proteins, the intensity of fluorescence was quantified within the 
channel. All cases were consistent with complete exclusion of the protein from the 
microchannel, whereas the electric potential required to achieve this exclusion differs 
among target species (Figure 7.3). In all cases it is observed that prior to the application 
of an electric field, the concentration of protein within the channel remains constant. 
Once potentials were applied to the channel (at t = 10 s) the protein is excluded in the 
upstream reservoir and prevented from entering the channel. This results in a decrease in 
fluorescence during the time the potential is applied. Following removal of the electric 
field (at t = 45 s) the protein is again allowed to enter the channel and an increase in 
fluorescence is observed. 
 Four data sets for each protein were analyzed in which the placement of the 
electrodes was consistent for allowing exclusion behavior to be observed within the 
channel. The electric field required to exclude each protein under these conditions 
remained consistent over time. For cTnI an average electric field of 62.5 ± 6.5 V/cm was 
required for exclusion. For myoglobin and H-FABP 143.8 ± 8.5 V/cm and 87.5 ± 6.5 
V/cm were required, respectively.  
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Figure 7.3 Bar graph showing required potential for complete exclusion of protein from a 
channel. Error bars represent standard deviation between protein preparations and 
devices, as well as the electric field strength required for protein exclusion. 
 
Alterations in the exclusion behavior (area of exclusion, speed of recovery) were 
observed with changes in electrode placement between days. The slight movement of 
electrodes and differences among protein samples account for the deviation in the 
exclusion potential required for each protein (Figure 7.3). However, even with this 
variation, the trend in exclusion behavior remained consistent, with cTnI requiring the 
lowest applied field for complete exclusion and myoglobin requiring the greatest.  
Different electric field strengths were applied to determine where the onset of 
complete exclusion occurred (Figure 7.4). The change in intensity over the length of the 
channel was calculated as the difference in fluorescence observed when the electric field 
was applied and immediately following the release of the electric field and return of 
protein. For cTnI, at field strengths below 55 V/cm, material is either not excluded at all, 
or incomplete exclusion from the channel is observed. With fields applied below 25 V/cm 
there is no evidence of exclusion (0 V/cm, 10 V/cm, 12 V/cm), and the characteristic 
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exclusion curve is no longer observed (inset). Evidence of incomplete exclusion is 
observed for moderate voltages (25 V/cm and 40 V/cm) showed only the partial 
exclusion of cTnI from the channel. Following the onset of complete exclusion (62.5 ± 
6.5 V/cm), greater voltages produced larger regions of exclusion (data not shown), but 
did not appear to further concentrate the species and required increasingly long time 
periods to visualize recovery. Experiments on the exclusion of myoglobin and H-FABP 
produced similar results (data not shown). 
 
Figure 7.4 Representative change in intensity values for varying electric field strengths 
over a time of 35 s applied potential for cTnI. 
 
Experiments were performed that demonstrated the ability of electrophoretic 
exclusion to separate cTnI (green) from myoglobin (red) within the array (Figure 7.5). 
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Based on the intensity measurements collected in-channel utilizing a blue filter cube, as 
well as color images obtained from imaging through an Olympus DAPI, FITC, Texas 
Red triple band-pass cube (Olympus, Center Valley, PA), the separation of species could 
be clearly visualized. Before the electric field was applied all species were free to flow 
through the system in the direction of hydrodynamic flow. After a 65 V/cm electric field 
was applied to the system for 35 s, cTnI was excluded from entering the channel while 
myoglobin was still able to continue in the direction of bulk flow (observed both visually 
in color images and through fluorescence intensity measurements filtered for the 
detection of the NHS-Fluorescein used to label cTnI). Following the release of potential 
cTnI was again allowed to enter the channel along with the myoglobin. 
 
Figure 7.5 Images showing the separation between cTnI labeled with NHS-Fluorescein 
(green) and Myoglobin labeled with NHS-Rhodamine (red). A) Illustration showing the 
location of protein separation. B) Channel before voltage is applied, C) separation after 
35 s of applied voltage (60 V/cm), and D) the channel after the applied voltage is 
removed. 
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The difference in electric potentials necessary to attain complete protein exclusion 
from a channel between the target species investigated suggests that a new design may be 
produced to exploit these differences and simultaneously isolate, concentrate, and 
quantify all three proteins within a single device. Separation of two proteins has been 
accomplished here, representing a first step in that process. Future designs include the 
incorporation of detection elements to the device such that isolated species may be 
quantified in a secondary step. A device utilizing voltage gates to separate detection 
chambers from a central separation channel with well-controlled flow and electric field 
elements can be designed to allow isolation and detection of desired species from 
complex samples. 
7.4 Concluding Remarks 
 
This work demonstrates for the first time the use of electrophoretic exclusion on a 
microdevice to manipulate and separate proteins. The exclusion of individual proteins, as 
well as the direct visualization of protein separation, are significant results. The ability to 
isolate and concentrate individual target species on a microdevice is an important first 
step in the development of a μTAS optimized for the quantitation of biomarker panels in 
clinical diagnostics. By combining the sample treatment step of electrophoretic exclusion 
with the sensitive and specific quantitation afforded through an immunoassay platform, 
there exists the potential to create a diagnostic platform that is fully optimized not only 
for sensitivity and low sample consumption, but for rapid analysis, multiplexed detection 
and operational simplicity. 
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CHAPTER 8 
THE DEVELOPMENT OF A MICROFLUIDIC DEVICE FOR USE IN 
PARALLEL IMMUNOASSAY QUANTITATION 
8.1 Introduction 
 
Previous chapters have addressed the need for a fully optimized immunoassay to 
aid in disease diagnostics and monitoring. Arising from the necessity to quantify multiple 
targets in parallel from a single complex sample, separation prior to analysis is an 
attractive option. As noted previously, electrophoretic exclusion, is a particularly 
appealing option since it allows for multiple capture zones to be oriented in series or 
parallel, may be dynamically controlled through adjustment of the applied electric field 
strength, and affords sample concentration prior to detection through immunoassay. 
 In addition to allowing multiplexed detection in parallel, sample treatment 
utilizing electrophoretic exclusion is rapid, can be performed on native species, and 
avoids the dispersive forces experienced by samples when separation occurs within a 
channel or column as opposed to at the channel entrance. This concentration of individual 
target samples is ideal prior to detection through immunoassay as it allows a single, small 
volume sample to be utilized for the extremely sensitive detection of several targets 
simultaneously. Concentration of the species relative to the original sample allows even 
greater improvement to the LOQ than improving on the technique of immunoassay alone, 
allowing its fundamental limitations of quantitation to be approached in a portable, 
simple to operate device. 
 Over the last decade, adaptations have been made to traditional immunoassay 
formats to allow their compatibility with emerging microfluidic devices. Microscale 
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devices have been utilized in diverse immunoassay designs for protein quantification 
including the use of magnetic and non-magnetic microparticles [1-6],
 
as well as the use of 
a static solid substrate using capillary systems [7,8],
 
modifications on ELISA techniques 
[9], and the incorporation of designated reaction zones [10].
 
Notable advantages allowed 
by the transition to detection on a microdevice include the ability to multiplex [1-5,10],
 
lowered analysis times [7-9],
 
 and minimal reagent consumption while maintaining 
sensitivities comparable to traditional immunoassay formats.
 
Minimizing the 
consumption of reagents is particularly important when sample volumes are limited, for 
example in the treatment of infants or during forensic testing. An additional asset of the 
microchip format is that allows devices that can often be made portable, allowing both 
bedside testing and use in remote locations [11-14].
 
 
Due to the previous success in the separation of proteins observed in a 
microfluidic device composed of glass and PDMS (Chapter 7), a modified design based 
on the concept of this array was designed, fabricated and tested. The use of PDMS is 
appealing because it is optically transparent and is compatible with the fluorescence 
detection method employed for the immunoassay described throughout this thesis [15].
 
Modifications were included such that quantitative detection could take place on-chip 
compared to the original array used in proteins separations. The rest of this chapter 
focuses on the development of a microfluidic device that could be used for the analysis of 
complex samples. It has been previously demonstrated that electrophoretic exclusion 
plays a potentially important role in the pre-treatment of complex samples prior to 
specific target quantification, and that the sensitive immunoassay described throughout 
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this work is well suited for incorporation as the detection method. However, a complete 
device combining these techniques has not been developed.  
Here, the preliminary device for sample separation, concentration and 
quantification is fabricated and tested. Experiments are performed using a mixture of 
myoglobin and cTnI to evaluate the proficiency of the device in performing separations 
along the primary separation channel (Figure 8.1). Additionally, experiments using a 
single target are done to assess the ability of the device to isolate and concentrate an 
individual species in one of the separation channel reservoirs prior to quantification. The 
capacity for quantification, in terms of protein manipulation into the quantitation 
reservoir following concentration, and binding of target species to the magnetic 
microbeads was also evaluated.  
8.2 Materials and Methods 
 
8.2.1 Design and Microdevice Fabrication 
 
Hybrid glass/PDMS devices were used for each experiment and each device 
contained a single analysis system. A photograph was recorded of the device (view from 
above) as well as a schematic of a single isolation channel (Figure 8.1). The fabrication 
of this device is analogous to the array design discussed in Chapter 7, where deviations 
are discussed below. 
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Figure 8.1. Microdevice for protein separation and quantitation by immunoassay. 
Photograph (left) of the complete microfluidic device with one separation channel and 
three isolation channels, and a schematic of a single (right) isolation channel explaining 
terminology used in the device. 
 
8.2.1.1 PDMS 
 
The separation channel was 41 mm in length. It contained five central reservoirs 
for isolation connected to two end reservoirs through a series of short channels. Each 
central reservoir was 5 mm x 5 mm, end reservoirs were 19 mm x 5 mm and channels 
were 1 mm by 100 μm having a uniform depth of 10 μm throughout the device. Each 
isolation channel consisted of one of the separation reservoirs connected to two end 
reservoirs and a quantitation reservoir through a series of short channels. Each isolation 
channel was 23 mm in length. The size and depth of reservoirs and channels was 
equivalent to those found in the central reservoirs/channels along the separation channel. 
Masks were designed in AutoCad (Autodesk, Inc., San Rafael, CA) and were printed on a 
transparency at a resolution of 10,160 dpi (Fine Line Imaging, Colorado Springs, CO, 
USA). Positive photoresist AZ 4620 was spun onto a silicon wafer and exposed at 750 
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mJ/cm
2 
using an EVG
®
620 Automated UV-NIL, μ-CP System (EV Group, St. Florian am 
Inn, Austria) using the transparency as a mask. The system was then fabricated using 
standard soft lithography techniques as discussed in Chapter 7. 
8.2.1.2 Electrodes 
 
Ti/Pt electrodes were plated on 75 x 50 mm microscope slides (Fisherbrand, 
Waltham, MA, USA) (Figure 8.2, right). A mask was designed in AutoCad (Autodesk, 
Inc., San Rafael, CA) and printed on a transparency with a resolution of 10,160 dpi (Fine 
Line Imaging, Colorado Springs, CO, USA). Electrodes were plated 500 μm wide 
bracketing each reservoir within the separation channel, along with the end reservoirs 
and quantitation reservoirs immediately adjacent to the separation channel. This was 
designed to produce flat potentials within reservoirs and promote exclusion at a channel 
entrance such that separation of proteins can occur and species may be concentrated and 
isolated within a reservoir. Electron beam evaporation was used to deposit metal onto the 
slide as previously discussed in Chapter 7. Electric leads were attached at the sides of the 
slide using silver conductive epoxy for connection to an external power supply (Series 
HV5448, LabSmith Inc., Livermore, CA, USA) through an in-house produced voltage 
divider (1:100). A schematic of the electrode and channel design is included (Figure 8.2). 
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Figure 8.2. Schematic designs of PDMS channel (left) and electrode (right) patterns. The 
PDMS pattern includes a separation channel where separation reservoirs contain posts to 
support the roof (white circles observed within reservoirs), a large entrance reservoir (far 
right) and an exit reservoir (far left). Perpendicular to the separation channel are three 
isolation channels. Each isolation channel consists of a backfill buffer reservoir (top), 
quantitation reservoir (below separation channel), and an exit reservoir (bottom). The 
electrodes are patterned to surround all reservoirs within the separation channel, as well 
as the backfill buffer reservoirs and quantitation reservoirs. 
 
8.2.2 Materials 
 
Myoglobin (Life Diagnostics), myoglobin antibody (Lifespan Biosciences, 
Seattle, WA, USA), cTnI (Life Diagnostics), cardiac troponin antibody (Lifespan 
Biosciences), NHS-rhodamine (ThermoFisher, Waltham, MA, USA), NHS-fluorescein 
(ThermoFisher), magnetic microparticles (Qiagen) and DMSO were used as received. 
PBS buffer was prepared to a 100 mM concentration at a pH of 7.2 with 0.2% NaN3 and 
0.2% Tween 20 using 18 MΩ Milli-Q water. Aspartic acid buffer was prepared to a 
concentration of 5 mM at a pH of 2.95 using 18 MΩ Milli-Q water. A 10 mg/mL stock 
solution of NHS-rhodamine was prepared in DMSO and 3.03 μL were added to 13.6 μL 
of a stock solution of 7.51 mg/mL myoglobin. The mixture was allowed to react at room 
temperature for 1 hour and dialyzed in PBS overnight to remove unconjugated dye prior 
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to experiments. The cTnI (1.07 mg/mL; 93.5 μL) was conjugated to 1.5 μL of 10 mg/mL 
fluorescein in the same way. Magnetic microparticles were diluted in PBS, coated with 
BSA and functionalized with antibodies before the day of experiments. Protein samples 
were diluted to concentrations of 0.33 mg/mL (myoglobin) and 0.20 mg/mL (cTnI) in 
aspartic acid buffer on the day of experiments. 
8.2.3 Experimental Setup 
 
The PDMS layer was bonded to the glass slide with the Ti/Pt electrodes using O2 
plasma (Plasma Cleaner, Harrick Plasma) operated at a high RF level for 60 s. The 
separation channel was filled with a protein sample by pipetting the solution into the 
entrance reservoir. The channel was filled by capillary action. The isolation channels 
were filled with buffer by pipetting directly into the quantitation reservoir, magnetic 
microparticles were added by pipetting directly into the quantitation reservoir and held in 
place with a flat, cylindrical rare-earth magnet. Bulk flow along the separation channel 
was induced by the difference in sample meniscus height between the entrance and exit 
reservoirs. A total of 21 μL of sample solution was pipetted into the separation channel. 
A total of 30 μL of buffer was pipetted into the isolation channels. Flow rates for all 
experiments were held at approximately 10 nL/min. Potential (60 V/cm) was applied 
using a LabSmith power supply (Series HV5448, LabSmith Inc., Livermore, CA, USA). 
Eight individual potentials were applied to the channel, one to each electrode pad along 
the separation channel as well as each isolation channel. A voltage divider was created in 
house from 100 kΩ, 120 kΩ, and 1 MΩ resistors as has been discussed elsewhere (Figure 
8.3) [16]. Each resistor was connected to a thin wire with a coiled end that would slip 
over the leads connected to the microscope slide. Output potentials were monitored using 
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a digital multimeter (Sperry Instruments, Menomonee Falls, WI, USA) throughout the 
course of the experiment. Output voltages from the voltage divider ranged from 0 to 16 
V, providing electric fields between 0 and 160 V/cm. 
 
 
Figure 8.3. Voltage divider (bottom) connected to the microscale analysis system (top). 
The voltage divider was created from 100 kΩ, 120 kΩ, and 1 MΩ resistors, and each 
resistor was connected to a thin wire with a coiled end. The coiled end could slip over the 
leads attached to the device and enabled the precise application of electric fields between 
0 and 160 V/cm. 
 
Experiments were monitored using an inverted microscope with darkfield and 
fluorescence abilities (IX70, Olympus, Center Valley, PA, USA) utilizing a 100 W Hg 
lamp as the light source. Light from the Hg lamp passed through a band-pass filter and a 
1.25X objective to the device during separations. A 40X objective was used during 
quantitation. During quantitation the rare-earth magnet was rotated to produce an 
alternating magnetic field and cause formation and rotation of rotors that served as the 
solid-surface for the immunoassay. The light emitted passed through a long-pass 
dichromatic mirror and a band-pass filter into the camera port on the microscope for 
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black and white images. These images were collected digitally using a QICAM CCD 
camera from Q Imaging, Inc. (Surrey, British Columbia, Canada) that was connected to a 
computer running Streampix (NorPix, Montreal, Quebec, Canada). Color images were 
collected from the eyepiece of the microscope using a mounted Nikon D5000 camera 
(Nikon, Melville, NY, USA). ImageJ (NIH, Bethesda, MD, USA) was used to determine 
the fluorescence intensity change in the channel reservoirs to assess the extent of 
concentration in the channel. 
All experiments in the system were performed at a pH of 2.95 in aspartic acid 
buffer to eliminate electroosmotic flow (EOF). Neutralization of proteins was required 
before binding for quantification, and was performed through the addition of Tris-buffer 
(pH 8) to the backfill buffer and quantitation reservoirs. 
8.3 Results and Discussion 
 
8.3.1 Device Design 
 
The separation channel/quantitation array design was based off the success of the 
initial array device in separating protein samples (Chapter 7). To allow for quantitation of 
proteins on chip, additional chamber interfaces were added. Instead of connection in 
parallel, five separation reservoirs were connected in series through short channels to an 
entrance and exit reservoir. Connected to three of the central separation reservoirs 
(reservoirs 1, 3 and 5) were perpendicular isolation channels composed of a single 
backfill buffer reservoir above the channel, and two reservoirs below the channel, a 
quantitation and exit reservoir. These reservoirs were physically open to the channel 
during separations and controlled using voltage gates. Separation reservoirs were 
connected in series along a single primary channel instead of in an array design for two 
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reasons; to improve the ability for concentration of each target in a single region of the 
device, and to enable the easy connection of quantitation reservoirs adjacent to the 
regions of protein concentration. Inclusion of the isolation channels provided, for the first 
time, the ability to manipulate and quantify species following their concentration and 
isolation through electrophoretic exclusion.  
8.3.2 Device Fabrication 
 
 Enlarged glass microscope slides (75 x 50 mm) were plated with electrodes to 
accommodate the size of the microfluidic system. A PDMS layer having reservoirs 
connected through channels was sealed to the glass slide. Due to the ability of the array 
described previously (Chapter 7), the same size reservoirs and channels were used in this 
design. Because electrode width was not an issue in the protein separations performed on 
the original array, allowed for the easier attachment of the copper leads to the electrodes, 
and aided in the manual alignment of the PDMS layer, the larger electrode width (500 
μm) was again used for this device. The impact of electrode alignment on the separation 
of both small molecules and proteins has been previously discussed [17].
 
 
8.3.3 Operation of the Microfluidic Device 
 
8.3.3.1 Detection of Species 
 
 Fluorescence detection was chosen to monitor both the exclusion and direct 
immunoassay quantitation as it was compatible with the singleplex immunoassay design 
and allowed highly sensitive detection to be maintained. It also allowed direct 
visualization of each step in the PDMS/glass hybrid device. Two species, cTnI and 
myoglobin were chosen for evaluation of the microdevice.  
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8.3.3.2 Experimental Design 
 
 As discussed in chapter 7, electrophoretic exclusion is achieved when the 
electrophoretic velocity (μaE) of a species is greater than or equal to the velocity of 
hydrodynamic flow through a channel. Balancing these forces prevents a target species 
from entering a channel and allows concentration of that target in the reservoir 
immediately upstream of the channel entrance. The microdevice prototype was designed 
with a total of six interfaces where exclusion could occur along the separation channel. 
Three of these separation reservoirs were directly connected to isolation channels, and 
were the intended locations of target protein concentration. The remaining separation 
reservoir/channel interfaces could be programmed to minimize the impact of NSB from 
potential interfering species in a complex biological sample. The entrance reservoir was 
used for the introduction of sample, while isolation channels were used for the 
introduction of neutralization and wash buffers. Electrodes plated around the reservoirs 
along the separation channel, as well as the backfill buffer and quantitation reservoirs in 
the isolation channel, were used as voltage gates to control where individual species were 
excluded and concentrated from the bulk solution. 
 Protein separation experiments were designed so that cTnI would be captured in 
separation reservoir 1, while myoglobin would continue to move with bulk flow along 
the channel and be captured in separation reservoir 3. A representative sequence of 
applied potentials is shown (Figure 8.4). 
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Figure 8.4 Representative values of applied potentials used for the separation of 
myoglobin and cTnI. With no voltage applied to the entrance reservoir or the first 
reservoir of the separation channel, both species were free to move in the direction of 
bulk flow. An applied voltage of 6 V (60 V/cm) was used for reservoirs 2 and 3 of the 
separation channel to prevent cTnI from entering separation channel reservoir 2 and to 
concentrate it in separation reservoir 1, but allow myoglobin to continue in the direction 
of bulk flow. 20 V was then applied to reservoir 4 of the separation channel to 
concentrate myoglobin in separation reservoir 3. High potential was applied to all 
backfill buffer and quantitation reservoirs to remove all protein from the isolation 
channels prior to separation and concentration. 
 
Exclusion of the proteins only occurred when an appropriate electric field was 
applied across a channel. In instances where there was no field (between entrance 
reservoir and separation reservoir 1, as well as between separation reservoirs 2 and 3), 
exclusion was not intended to occur. The progression of a separation experiment is shown 
in Figure 8.5. 
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Figure 8.5 Illustrative graphic showing the designed progression of a separation 
experiment between myoglobin and cTnI. A. Filling of the device before any electric 
potentials are applied. Green indicates the presence of cTnI labeled with NHS-
Fluorescein, red indicates the presence of myoglobin labeled with NHS-Rhodamine, 
saturation of color indicates higher concentration of protein. B. Concentration of cTnI in 
separation reservoir 1 and myoglobin in separation reservoir 3 after electric potential 
was applied to the electrodes. C. Removal of voltage from the quantitation reservoirs and 
addition of buffer to the backfill buffer reservoirs, forcing cTnI and myoglobin into the 
quantitation reservoirs. D. Observation of fluorescent supraparticle structures (dark red 
and green) following the addition of magnetic microparticles to the quantitation reservoir 
and application of a magnetic field. 
 
In the quantification experiments performed with cTnI as a target, following 
isolation and concentration in separation reservoir 1 using electrophoretic exclusion, the 
addition of a basic Tris buffer (pH 8) was used for neutralization. Neutralization allowed 
cTnI to bind to magnetic microbeads coated in capture antibodies within the quantitation 
reservoir. The addition of Tris buffer to the backfill buffer reservoirs also served to direct 
flow of the concentrated protein into the quantitation reservoir. In the quantitation 
reservoir, a direct immunoassay was performed analogous to that previously described 
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(Chapter 4), with the exception that convective mixing was used during the incubation as 
opposed to agitation in a micro-centrifuge tube. The fluorescence intensity of observed 
rotors was used to monitor protein bound to the surface. The designed progression of a 
quantitation experiment is demonstrated in Figure 8.6. 
 
Figure 8.6 Illustrative graphic showing the progression of a quantitation experiment 
using cTnI. A. Filling of the device before any electric potentials are applied. Green 
indicates the presence of cTnI labeled with NHS-Fluorescein, saturation of color 
indicates higher concentration of protein. B. Concentration of cTnI in separation 
reservoir 1 after electric potential was applied to the electrodes. C. Removal of voltage 
from the quantitation reservoir and addition of buffer to the backfill buffer reservoir, 
influencing the movement of cTnI into the quantitation reservoir. D. Observation of 
fluorescent supraparticle structures (dark green) following the addition of magnetic 
microparticles to the quantitation reservoir and application of a magnetic field. The red 
box illustrates the approximate location of the data collected for Figure 8.7. 
 
8.3.4 Results of cTnI and Myoglobin Separation Experiments 
 
The exclusion behaviors of cTnI and myoglobin were consistent with results 
attained from the array (Chapter 7). With flow directed from right to left across the 
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device an applied potential of 65 V/cm across the channel between separation reservoirs 
1 and 2 was used to achieve exclusion of cTnI (and concentration of cTnI in separation 
reservoir 1) while myoglobin was able to flow freely toward the exit reservoir (Figure 
8.7). Due to sample spreading in the isolation channels prior to voltage application, 
electric potentials of 160 V/cm were applied directly to the backfill buffer and 
quantitation reservoirs to remove all material during the time of exclusion. 
 
Figure 8.7 Images showing the separation of myoglobin (red) and cTnI (green). Flow is 
oriented from right to left across the device. The position of data capture is indicated by 
the red box in Figure 8.6. The dark band immediately to the right of the microchannel is 
the electrode. A) Channel before voltage is applied, B) separation after 35 s of applied 
voltage (65 V/cm), and C) the channel after the applied voltage is removed. 
 
During the time voltage is applied, cTnI is excluded from entering downstream 
channel reservoirs and is concentrated in separation reservoir 1. The extent of cTnI 
concentration was monitored using a blue filter cube to selectively observe the 
fluorescence caused by the NHS-fluorescein used to label the protein. Repeated trials 
show consistent results using different preparations of protein and devices over five 
experiments. With an applied electric field of 65 V/cm within the separation channel and 
fields of 160 V/cm applied to all reservoirs in the isolation channel, cTnI was observed to 
concentrate 4- fold with 35 s of applied voltage. Maintaining the applied electric field for 
longer time periods increased the protein concentration further. It is observed that after 60 
s the fluorescence intensity in the reservoir reaches the maximal pixel intensity that may 
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be captured using the CCD-camera, representing a 7-fold, or greater, increase in 
concentration. 
8.3.5 Results of cTnI Quantification Experiments 
 
 Following the concentration of cTnI in separation reservoir 1, material was forced 
into the quantitation reservoir by adding Tris buffer, pH 8.0 to the buffer backfill 
reservoir. Control of material in this way was modeled after the pinched sample injection 
methods used in microfluidic devices [18-21]. Magnetic microparticles bound to the 
cardiac troponin capture antibody were pipetted directly into the quantitation reservoir 
and manipulated to achieve convective mixing and promote protein capture (Figure 8.8). 
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Figure 8.8 Images showing the concentration, manipulation, and quantification of cTnI. 
A) Separation reservoir 1 before voltage is applied B) separation reservoir 1 after 60 s of 
an applied electric field (note that bubbles formed left and right, limiting the solution to 
the irregularly shaped center portion, concentration enhancement still occurs)  C) 
quantitation reservoir 1 after buffer has been added to the backfill buffer reservoir D) 
protein bound by the cTnI capture antibody attached to the magnetic microparticles in the 
presence of a magnetic field. 
 
The concentration of cTnI can be clearly observed in reservoir 1 of the separation 
channel, as evidenced by the increase in fluorescence intensity within the reservoir from 
6,600 to 45,000, approximately a 6.7-fold increase (Figure 8.8 A and B), even in the 
presence of bubbling (dark zones left and right) due to local electrolysis (Figure 8.8B). 
Following the removal of electric potential to quantitation reservoir 1, and the addition of 
Tris buffer to backfill buffer reservoir, material is observed to enter the quantitation 
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reservoir. However, flow into the reservoir is slow, and incomplete over the time course 
of the experiment (Figure 8.8 C). By increasing the magnification from 1.25 to 20X, the 
magnetic chains in the quantitation reservoir, analogous to those seen in the singleplex 
immunoassay (Chapter 4) could be observed (Figure 8.8 D).  
While some of the cTnI bound to the rotors, based on the fluorescence observed 
on the chains, there is still a high background fluorescence intensity that indicates not all 
material is binding. This could be caused by interference in binding sites from the NHS-
Fluorescein used to label the cTnI, or the incomplete neutralization of the protein 
resulting in denatured protein not binding to the rotors.  
8.3.6 Assessment of the Initial Design 
 
8.3.6.1 Observed Challenges Preventing Optimal Function 
 
Similar to the previous array this device was able to achieve separation and 
concentration of proteins. However, to prevent the leakage of material into the isolation 
channels during separation it was necessary to add floating electrodes directly into the 
quantitation and backfill buffer reservoirs to ensure the exclusion of material. These 
floating electrodes were created by inserting platinum wire leads connected to the voltage 
source directly into the access holes punched in both the quantitation and backfill buffer 
reservoirs. Floating electrodes were necessary for several reasons. First, the electrodes 
plated around the quantitation reservoirs are connected to those utilized for the 
separation reservoirs and may not be articulated independently. Additionally, due to the 
close proximity of electrodes surrounding the backfill buffer reservoirs and the reservoirs 
within the separation channel, bubble formation occurred to a greater extent than 
observed in the previous separation-based array.  
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An additional issue caused by the current device design is that not all of the target 
material is concentrated within the desired reservoir of the separation channel. Some of 
the material remained in the entrance reservoir, or in the case of myoglobin, in 
separation reservoirs upstream of separation reservoir 3, where exclusion and 
concentration took place. Several alterations could be made in the fabrication of a next 
generation device in order to eliminate these issues and allow the rapid separation, 
concentration, and quantification of biomarker panels. 
8.3.6.2 Proposed Alterations to Electrode Design 
 
In the initial device used for the separation of proteins, electrode width was not an 
issue. The larger width of electrodes (500 μm) facilitated the alignment of the PDMS 
layer and attachment of the copper leads to the electrodes. For these reasons the electrode 
width was maintained in the design of the current microdevice. However, due to the 
issues observed both in the ability to articulate isolation channel reservoirs 
independently, bubble formation within the separation channel, alterations to the 
electrode design should be made in a future device. While it is advisable to maintain the 
width of the electrodes around the reservoirs in the separation channel to conserve the 
advantages noted previously, removing electrodes from the isolation channels would 
improve the ease of use for the device. Incorporating a physical barrier to prevent sample 
leakage into these reservoirs would aid in the ease of operation, as well as ensure a 
greater level of purity for the sample detected in each quantitation reservoir. 
8.3.6.3 Incorporation of Physical Valves 
 
 Incorporation of physical valves as a control element within a microfluidic device 
can aid in the improvement of overall performance [22]. Valves can be designed such 
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that they are compatible with soft lithography techniques [22-25], and help to improve 
throughput, sensitivity and the dynamic range capabilities of the device [22]. 
Incorporation of PDMS valves is an attractive alternative to the use of voltage gates 
because they are easy to fabricate, maintain a low device fabrication cost, and may easily 
be scaled to fit the dimensions of system [22]. While voltage gates are also easy to 
incorporate into a device, the ability to physically control the filling of isolation channels 
using a physical barrier would improve the overall ease of use for the device and increase 
the sensitivity of detection by ensuring fewer contaminants reach isolated quantitation 
reservoirs. 
8.3.6.4 Sample Introduction to the Microdevice 
 
 Presently, a solution of buffer containing the sample is directly added to the 
entrance reservoir and used to fill the separation channel. Buffer alone is pipetted into 
isolation channels, however, as no physical barrier exists at the time of device filling, the 
sample is free to flow throughout the device until an electric potential is applied. By 
instead filling the entire device with buffer and using a microscale peristaltic pumping 
system to introduce sample at a known flow rate, electric potentials could be applied 
prior to sample introduction. It would also allow the valves protecting the isolation 
channels to be shut and prevent sample leakage prior to isolation and analysis. 
Incorporation of a pump would force samples through the device at a higher rate, 
enabling all protein to move through the separation channel and be isolated in the 
appropriate reservoir such that even very low concentrations of target species may be 
quantified from complex samples.  
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8.4 Concluding Remarks 
 
 This chapter described the design, fabrication, and evaluation of a microfluidic 
device. The device was intended for the quantification of a biomarker panel from a 
complex sample. It was demonstrated that it is possible to isolate and concentrate target 
proteins in reservoirs along the separation channel. Results suggest that creation of a 
fully optimized device for clinical diagnostics is possible, and this work represents a first 
step in that direction. Alterations to the electrode layout and sample introduction 
methods, as well as the incorporation of physical valves, could improve the ease of use, 
speed, and quantitative ability of the device. By addressing each of these issues 
systematically, a future design could allow the full optimization of a clinical diagnostic 
platform allowing the rapid and sensitive quantification of biomarker panels using 
immunoassay detection in a microscale device. 
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CHAPTER 9 
CONCLUDING REMARKS 
9.1 Fundamental Limitations of Quantification for Immunoassay 
 
The sandwich immunoassay is generally considered the most sensitive 
immunoassay detection platform and has been a fundamental tool for the sensitive 
detection of proteins for several decades. While several studies have recently claimed 
single-molecule sensitivity capabilities, all have failed to reach that mark. There exists a 
fundamental statistical limitation to quantification abilities for immunoassay regardless of 
sample volume, imposed by molecular shot noise. The development of the theory 
addressing ultimate quantitation capability has been previously discussed (Chapter 5). 
Also demonstrated are the other potential influences on the LOQ of experimental 
immunoassay; NSB and the instrumental background. Ultimate limitations of 
quantification lie around 131 molecules in a sample (3.7 aM in 50 μL).  
9.2 Current Commercial and Experimental Capabilities for Bioanalysis 
 
 Many experimental and commercial methods for bioanalysis have been explored 
in recent years. These methods have improved upon abilities of an immunoassay 
technique according to one, or more, of the six metrics described for a fully optimized 
assay; high sensitivity, rapid analysis, cost effective, simple to operate, use of low sample 
volumes, and the ability to multiplex for parallel detection. While the field has seen 
general improvements over the last several years, with various assays reaching aM 
sensitivity, analysis times under a minute, the ability for multiplexed detection, sample 
volumes around 10 μL, and minimal sample manipulations with the movement to 
microchip platforms, no single assay has attained complete optimization in all aspects. 
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9.3 Immunoassay Quantitation of Individual Targets 
 
 Although separation and detection of multiple targets in a total analysis system 
was defined as the ultimate goal, the immunoassay and protein separation studies 
presented in this dissertation focused mainly on the sensitive detection of individual 
targets. Earlier work described the use of a microscale batch incubation immunoassay 
technique sensitively quantify myoglobin, cTnI, and H-FABP individually (Chapter 4). 
Microchip experiments demonstrated the ability of dielectrophoresis to provide sample 
preparation, as well as electrophoretic exclusion to separate individual targets (Chapters 6 
and 7). These results indicated that the use of electrophoretic exclusion in a separations 
based device would be useful to isolate targets prior to quantitation using a sandwich 
immunoassay. 
9.4 Potential for Multiplex Immunoassay Utilizing a Microscale Total Analysis 
System 
 
In addition to the off-chip immunoassay quantitation of individual targets, as well 
as quantitation of the enrichment of those proteins within an electrophoretic separation 
array, studies utilizing multiple proteins in the device suggest that electrophoretic 
exclusion is capable of separating proteins (Chapter 7). A microscale analysis system was 
designed and tested (Chapter 8) based on the parameters used for the separations based 
array. Studies indicate that proteins may be manipulated within the channel using 
electrophoretic exclusion, allowing both the separation and concentration of target 
species. Further refinement of the system, including incorporation of physical valves to 
prevent sample leakage into quantification reservoirs prior to analysis, holds the potential 
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for the development of a system optimized for clinical diagnostics utilizing immunoassay 
quantitation techniques. 
9.5 Future Directions 
 
Rapid analysis of complex biological samples requires the use of sample 
simplification techniques in combination with sensitive and selective quantitation of 
specific targets. Immunoassay techniques are attractive for incorporation into total 
analysis systems because they afford the sensitive detection of target molecules through 
the specific interaction between antibody and antigen. In terms of sensitivity, techniques 
exist that are nearing the fundamental limitations of the technique, and significant 
improvements in this area are unlikely to be realized. However, many challenges remain 
before an assay fully optimized for clinical diagnostics will exist. These challenges can 
be addressed through the incorporation of immunoassay detection methods into 
microscale total analysis systems, allowing the separation and concentration of target 
species through electrophoretic exclusion prior to detection. This can afford both the 
ability for multiplexed detection, as well as low sample consumption per analyte 
investigated. Incubations that rely on convective mixing can combat the long assay times 
required of traditional, static assays. 
 In altering the system in which an immunoassay is incorporated many of the 
obstacles remaining in the early, multiplexed detection of biomarker panels can be 
eliminated. It is feasible to envision a μTAS system in which an untreated complex 
sample can be separated as it is introduced and target species may be isolated and 
concentrated along an initial separations channel. Following rapid separation and 
concentration, immunoassay detection methods may be employed for rapid quantitation 
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without necessitating additional sample handling steps. These modifications could allow 
for near real-time blood testing to take place both in remote settings as well as clinically, 
achieving rapid diagnostic and disease intervention abilities. 
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Technique Applications Sensitivity Analysis 
Time 
Equipment/Fabrication 
Requirements 
Single/Poly/ 
Multiplex 
Ref
eren
ces 
Non-magnetic 
particle assay 
      
FMIA Protein/ drug/ 
small 
molecule 
quantification 
pg - 
ng/mL 
70min-
4 hours 
Luminex beads; flow 
cytometer; Luminex 
X-map technology 
Multiplex 12, 
13, 
20, 
23-
30 
FIA Protein 
quantification 
~0.1 
ng/mL 
1-3 
hour 
Fluorescent 
microscope; chip 
fabrication 
Singleplex/ 
Polyplex 
14, 
48, 
50 
AlphaLISA Protein/ toxin 
detection 
~0.007 
ng/mL 
1(+) 
hour 
EnVision reader; 
AlphaScreen beads 
Singleplex 32, 
33 
BD Biosciences Cytokine 
quantification 
3 pg/mL 3(+) 
hours 
BD FACS array bio-
analyzer; CBA kit 
Multiplex 31 
Off-chip 
incubation 
magnetic bead 
assay  
      
FIA Protein/ 
antibody 
quantification 
~11.5 
pg/mL 
1-3 
hours 
Microchip fabrication; 
fluorescent 
microscope 
Singleplex 4, 
21, 
36, 
39, 
101 
Electrochemical 
Detection 
Antibody 
quantification 
0.19 
ng/mL 
~3 
hours 
Electrochemical 
sensor; microchip 
fabrication 
Singleplex 41 
Chemiluminescent 
Detection 
Protein 
quantification 
0.61 
ng/mL 
~2 
hours 
Microchip fabrication Singleplex 34 
On-chip 
magnetic bead 
assay 
      
Manipulation of 
particles 
DNA, 
antibody, 
small 
molecule 
quantification 
~250 
ng/mL – 
0.1 
µg/mL 
10 min 
– 2.5 
hours 
Fluorescence 
microscope; 
microchip fabrication 
Singleplex 8, 
9, 
44 
Manipulation of 
reagents 
Protein/ 
antibody 
quantification 
3.2 fg/mL 
– 16.4 
ng/mL 
35min 
– 3 
hours 
Microchip fabrication; 
electrochemical 
detector; 
isomagnetophoretic 
detector 
Singleplex/ 
Multiplex 
2, 
11, 
40, 
43 
Flow-based assay       
RDIA Protein 
quantification 
67 µg/mL <10 
min 
Analog column; 
fluorescence detector 
Singleplex 51, 
52 
Electrochemical 
Detection 
Protein 
quantification 
1 pg/mL 40 min Three-electrode 
electrical system; 
microchip fabrication 
Singleplex 53 
Static solid-
support assay 
      
  239 
Capillary systems 
(CSs) 
Protein 
quantification 
0.9 
ng/mL – 
3 µg/mL 
11 – 25 
min 
Microchip fabrication; 
fluorescence detector 
Multiplex 6, 
15 
Supercritical 
angle fluorescence 
Cytokine 
quantification 
4 pg/mL 13 min Microchip fabrication; 
fluorescence detector 
Singleplex 57 
SOFIA Dye/protein 
quantification 
~10 
ag/mL 
~3 
hours 
Lock-in amplifier; 
optical fibers; photo-
voltaic diode 
Singleplex 5 
OLISA Protein 
quantification 
1 ng/mL ~3 
hours 
Fluorescence detector; 
detection antibodies 
with differing 
fluorophore/quencher 
pairs 
Multiplex 56 
Portable disk 
automated ELISA 
Protein/ 
antibody 
quantification 
0.51 
ng/mL 
30 min Micro-disc fabrication Polyplex 59 
Gyrolab Protein/ 
antibody 
quantification 
5 ng/mL ~1 hour Fluorescent detector; 
Gyrolab Bioaffy CDs 
Singleplex 60 
DRZ chip Protein 
quantification 
5 ng/mL ~3 
hours 
Fluorescence detector; 
microchip fabrication 
Polyplex 10 
NP-labeled array Small 
molecule/ 
protein 
quantification 
10 pg/mL 3(+) 
hours 
Fluorescence detector; 
microchip fabrication 
Multiplex 55 
TIRFM system Cytokine 
quantification 
0.13 
fg/mL 
2 hours Microscope; 
microchip fabrication 
Singleplex 17 
SWIC system Protein 
quantification 
0.6-0.89 
ng/mL 
~27 
minutes 
Chemiluminescence 
detector; optical 
shutter; microchip 
fabrication 
Polyplex 62 
Microcantelievers Small 
molecule 
quantification 
0.1 – 1 
ng/mL 
1(+) 
hour 
Photon sensitive 
detector; flow cell; 
beam splitter 
Singleplex 19, 
20 
Table 3.1. Provided here is a summary of the techniques described for emerging micro-
immunoassays. While this table provides an overview of technologies in the field, they 
represent average values for each category of assay which give only a gross 
approximation for the capabilities of each immunoassay technique
  
